Post-translational modification of chemokines : implications for their biological function by Thompson, Sarah
 POST-TRANSLATIONAL MODIFICATION OF 
CHEMOKINES: IMPLICATIONS FOR THEIR 
BIOLOGICAL FUNCTION 
SARAH THOMPSON 
 
A thesis submitted in partial fulfilment of the requirements for the degree 
of Doctor of Philosophy 
 
Institute of Cellular Medicine, Newcastle University, UK 
 
September 2018 
  
  
 
 
 
i 
 
ABSTRACT 
Chemokines mediate a targeted immune response by orchestrating the migration 
of leukocytes to sites of injury. CXCL8 is a neutrophil-recruiting chemokine implicated in 
the pathology of many diseases. Ischaemia-reperfusion Injury (IRI) induces oxidative 
stress, and the reactive nitrogen species (RNS) peroxynitrite (ONOO-). Our group has 
shown that post-translational nitration of chemokines by peroxynitrite can 
affect function and detectability. These modified chemokines (if non-functional) could 
pose a natural mechanism for the regulation of inflammation.  
I have shown that nitration of CXCL8 by peroxynitrite reduces its ability to induce 
neutrophil migration in chemotaxis assays in vitro and murine intraperitoneal 
chemotaxis assays in vivo, through inhibition of both G-protein coupled receptor (GPCR) 
signalling and glycosaminoglycan (GAG) binding. I have used N-loop mutant and nitrated 
mutant versions of CXCL8 (Y13F) and CXCL1 (L15Y) to assess the importance of 
tyrosine residues in nitration. In both cases nitration impairs chemokine function.   
In collaboration with Bio-Rad, I have developed a novel antibody which has shown 
specificity for nitrated CXCL8 over wild type CXCL8 in initial validation studies, and a 
detection limit of 1-10ng/ml. This antibody has facilitated the detection of naturally 
occurring nitrated CXCL8 in a bronchoalveolar lavage sample from a pneumonia patient. 
Pending further optimisation, this antibody could be incorporated into an ELISA assay to 
measure nitrated CXCL8 in biological fluids. 
I have demonstrated that CXCL8 and 3-nitrotyrosine (a marker of ONOO- activity) 
production can be differentially upregulated in response to different stressing agents in 
breast cancer and cardiovascular cell lines in vitro.  This indicates that the potential for 
CXCL8 to be nitrated naturally is likely to vary between health and disease states, and 
also between specific tissues and types of stress.  
Characterising the expression and function of wild type and nitrated chemokines could 
lead to the development of techniques measuring these molecules as biomarkers to 
indicate the severity of IRI, or their use as anti-inflammatory therapies.  
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1 INTRODUCTION 
1.1 BACKGROUND TO THIS STUDY 
Chemokines regulate states of health and disease by orchestrating the migration of 
leukocytes to sites of inflammation or injury. This study looks at how chemokine 
function is regulated, focusing on post-translational nitration of the chemokine CXCL8 in 
particular.  
1.2 CHEMOKINES 
Chemokines are small positively charged chemoattractant cytokines that have 
developed as part of the immune system to direct the migration of leukocytes towards 
areas of inflammation or damage. Leukocytes will migrate along a chemokine gradient 
from areas of low chemokine concentration to areas of high chemokine concentration. 
This gradient is achieved by the dynamic immobilisation of chemokines on 
glycosaminoglycans (GAGs) present on the surfaces of cells and within the extracellular 
matrix. Chemokines interact with leukocytes through binding to their G-protein coupled 
receptors (GPCRs). Chemokines can be grouped into four major subfamilies depending 
upon the location and arrangement of the N-terminal cysteine residues; C, CC, CXC and 
CX3C. The chemokine system is complex, with multiple chemokines binding the same 
receptor and the multiple receptors being activated by the same chemokine. The system 
is non-redundant, however, partly due to its complex regulation.  
1.2.1 Chemokine Structure 
Most chemokines share a common basic structure with some variations. Shown in 
Figure 1-1 is the basic structure with four cysteines, although it is worth noting that 
some chemokines have two or six cysteines. The first and third cysteines form a 
disulphide bridge, as do the second and fourth, and is it these disulphide bonds that give 
the chemokines a globular 3D shape, and arrange the N-terminus as a loop, the centre as 
3 anti-parallel β-sheets, and the C-terminus as an α-helix 1.  
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Figure 1-1. Diagrammatic representation of the structure of a typical chemokine. A flexible 
N-terminus is connected by the N loop to 3 anti-parallel β-sheets in the centre of the molecule, 
which ends in an α-helix in the C-terminus. This structure is achieved by the formation of 
disulphide bonds between cysteine1 – cysteine3 and cysteine2 – cysteine4. 
1.2.2 G-protein Coupled Receptor Signalling 
Chemokines mediate their effects through binding to GPCRs present on the surfaces of 
leukocytes. These receptors all share a similar fold structure: an extra-cellular N-
terminal domain, seven transmembrane-spanning segments, three extracellular loops, 
three cytoloops, and a C-terminal segment, as shown in Figure 1-2. Disulphide bonds 
form between two cysteine residues in extracellular loops 1 and 2, and between cysteine 
residues in the N-terminal domain and exoloop 3. The α-helix and β-strands function as 
a scaffold, and could be exchanged between different chemokines without impairing 
function 2. Receptor binding occurs between the chemokine N-loop and receptor N-
domain residues, and between the chemokine N-terminal and receptor extracellular 
loop residues 2. The receptors are classified as C, CC and CXC as the chemokines are, but 
with the “L” for ligand replaced by “R” for receptor. 
The chemokine system is complex, and although some receptor-ligand interactions are 
specific, such as CCL20-CCR6, often multiple chemokines bind the same receptor 
(CCL3/4/5/7/8 all bind CCR1) and one chemokine can bind multiple receptors (CCL7 
can bind CCR1/2/3/5) as shown below in Table 1. Despite this promiscuity, the system 
is non-redundant, although its complexity and ability to compensate could be the reason 
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that many therapeutics designed to target a single chemokine or receptor have largely 
been unsuccessful. 
Binding of chemokine ligands to their receptors leads to a signalling cascade involving 
Gαi/o, Gαs, Gαq/11 or Gα12/13, which ultimately leads to calcium flux and cell migration 
(chemotaxis) 3. Chemokines can also signal through other pathways involving β-arrestin 
(though this is dependent on the ligand and cell type involved) 4. Chemokine-GPCR 
signalling can be involved in many homeostatic processes.  For example, B and T cell 
migration to, and organisation within, the lymphoid organs during maturation in the 
case of CCL25-CCR9 and CCL19/CCl21-CCR7 signalling 5,6. CXCL12-CXCR4 signalling 
mediates the migration of haematopoietic precursor cells to the bone marrow during 
embryogenesis, as well as the development of organs such as the heart and brain in mice 
7,8. Chemokines can also regulate angiogenesis, both physiological ad pathological, as 
occurs during chronic inflammation. CXCL1/5/8/12, CCL1/2/11 and CXC3CL1 are pro-
angiogenic in vitro, whereas CXCL4/9/10, and CCL21 are anti-angiogenic in vitro 6. 
In addition to homeostatic roles and as mentioned previously, chemokines also mediate 
inflammation by signalling through GPCRs to recruit leukocytes to sites of injury or 
insult in a range of diseases. Increased levels of CX3CL1-CX3CR1and CCL1-CCR8 
signaling have been implicated in the pathology of atopic dermatitis  9. CXCR4 and CCR5 
are known co-receptors that, along with CD4, facilitate infection by the HIV virus in 
humans 10.  CXCL4/9/10/11 signaling promotes tumour invasiveness in CXCR3-
expressing cells in prostate cancer, lymphoma and leukaemia, and this signalling system 
has also been linked to inflammatory arthritis, diabetes, organ transplant rejection and 
systemic sclerosis 11. Alterations to receptor-ligand interactions can also alter normal 
signalling and cause disease, for example mutations in CXCR4 lead to neutrophil 
retention in the bone marrow causing WHIM syndrome 12, and a polymorphism in the 
CX3CR1 gene has been linked to atherosclerosis 13. 
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Figure 1-2. Diagrammatic representation of the structure of a typical chemokine receptor. 
Shown are the 7 trans-membrane spanning loops of the receptor, its orientation within the cell 
membrane, and association with a G-protein through which it signals. 
1.2.3 Atypical Chemokine Receptors 
As well as their typical GPCRs, chemokines can also bind atypical chemokine receptors 
1-4 (ACKRs 1-4) 14. As shown Table 1, the same variations in ligand-receptor binding 
specificity apply to ACKRs as they do to GPCRs, for example, ACKR2 can bind to 12 
different CC chemokines. Chemokine binding affinity for ACKRs also varies, for example, 
CXCL12 has a stronger affinity for ACKR3 than for its typical GPCR CXCR4 15. 
Upon ligand binding, these receptors do not induce downstream signalling due to their 
inability to couple to G-proteins, but instead act as chemokine scavengers and are 
thought to modulate the immune response 16,17. Indeed, ACKR1 expressed on the surface 
of erythrocytes is thought to act as a “buffer” of inflammatory chemokines in the 
circulation, preventing large fluctuations in free chemokine concentration. If 
chemokines are cleared from the blood by other methods ACKR1-bound chemokines can 
be released back into the circulation to compensate for this, and if there are high 
chemokine concentrations in the circulation, then scavenging of these chemokines by 
ACKR1 will ensure that excessive circulating chemokine concentrations do not result in 
leukocyte desensitisation and chemokine receptor downregulation 15,18. ACKR-mediated 
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activation of the β-arrestin pathway can lead to chemokine-receptor complex 
internalisation and dissociation within endosomes, followed by intracellular 
degradation of the chemokines in lysosomes 15. The ACKR can then be translocated back 
to the cell surface to scavenge more chemokine ligand. In the case of polarised cells, 
binding to ACKR1 (but not ACKR2 or ACKR3) can also lead to the transport of 
chemokines to the opposite side of the cell monolayer 15,17. 
ACKRs can form homodimers and heterodimers to mediate their own biological 
function, as well as that of typical chemokine receptors. For example, ACKR3 
homodimers can heterodimerise with CXCR4, which modulates the signalling of CXCL12 
through it 19. 
ACKRs play many roles in physiological processes, such as blood clotting in mice 20, in 
parasitic infections such as malaria where ACKR1 acts as a cell entry factor for the 
parasite Plasmodium vivax 21, and in diseases like cancer where ACKR2 is reported to 
have anti-tumour functions 22 and ACKR3 is reported to promote tumour survival and 
metastasis 15. This broad range of functions can be carried out through binding to 
chemokines as well as other molecules, and ACKRs are clearly key regulators of 
chemokine biology.  
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Family 
& Name 
Other Names Typical 
Receptors 
Atypical 
Receptors 
 
Main Immune function 
C 
XCL1 SCM-1α, Lymphotactin A XCR1  
Cross-presentation by CD8+ DCs 
XCL2 SCM-1β, Lymphotactin B XCR1  
 
CC 
CCL1 1-309 CCR8/11 ACKR1 
Th2 cell and Treg cell trafficking 
CCL2 MCP-1 CCR2/4 ACKR1/2 Inflammatory monocyte 
trafficking 
CCL3 MIP-1α CCR1/4/5 ACKR2 
Macrophage and NK cell 
migration, T cell-DC interations 
CCL4 MIP-1β CCR1/5/8 ACKR2 
CCL5 RANTES CCR1/3/4/5 ACKR1/2 
CCL7 MCP-3 CCR1/2/3/4 ACKR1/2 
Monocyte mobilisation 
CCL8 MCP-2 CCR1/2/3/5/
11 
ACKR2 
Th2 response 
CCL9/10 MIP-1γ CCR1  
Mediates hepatobiliary excretion 
CCL11 Eotaxin CCR3 ACKR1/2 Eosinophil and basophil 
migration 
CCL12 MCP-5 CCR2  Monocyte/macrophage 
chemoattractant 
CCL13 MCP-4 CCR1/2/3/11 ACKR1/2 
Th2 response 
CCL14 
 
HCC-1 CCR1 ACKR1/2  
CCL15 HCC-2 CCR1/3   
CCL16 HCC4-LEC CCR1   
CCL17 TARC CCR4 ACKR1/2 Th2 responses, Th2 cell 
migration, Treg cell homing, 
homing to the lungs and skin  
 
CCL18 PARC, DCCK1 Unknown  Th2 responses, AAM marker, 
homing to the skin 
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CCL19 ELC, Exodus-3, MIP-3β 
 
CCR7 ACKR4 T cell and DC homing to lymph 
nodes 
CCL20 LARC, Exodus-1, MIP-3α CCR6  Th17 responses, B cell and DC 
homing to 
gut-associated lymphoid tissue 
 
CCL21 SLC, 6Ckine, Exodus-6 CCR7 ACKR4 T cell and DC homing to lymph 
nodes 
CCL22 MDC CCR4 ACKR2 Th2 response, Th2 and Treg cell 
migration 
CCL23 MPIF-1, Ckβ8 CCR1   
CCL24 Eotaxin-2, MPFIF-2, Ckβ6 CCR3  Eosinophil and basophil 
migration 
CCL25 TECK CCR9 ACKR4 T cell homing to gut, thymocyte 
migration 
CCL26 Eotaxin-3, MIP-4α CCR3  Eosinophil and basophil 
migration 
CCL27 CTAC, ILC CCR2/3/10  
T cell homing to skin 
CCL28 MEC CCR3/10  T cell and IgA plasma cell homing 
to skin 
 
CXC 
CXCL1 Gro-α CXCR1/2 ACKR1 
Neutrophil trafficking CXCL2 Gro-β, MIP-2α CXCR2 ACKR1 
CXCL3 Gro-γ, MIP-2β CXCR2 ACKR1 
CXCL4 PF-4 CXCR3  
Pro-coagulant 
CXCL5 ENA-78 CXCR2 ACKR1 
Neutrophil trafficking 
CXCL6 GCP-2 CXCR1/2 ACKR1 
CXCL7 NAP-2 CXCR2  
CXCL8 Interleukin 8, NAP-1 CXCR1/2 ACKR1 
CXCL9 MIG CXCR3  
Th1 and CD8 T cell trafficking, 
NK cell trafficking 
CXCL10 IP10 CXCR3  
CXCL11 I-TAC CXCR3 ACKR1/3 
CXCL12 SDF-1 CXCR4 ACKR3 
Bone marrow homing 
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CXCL13 BCA-1 CXCR5  
B cell and Tfh cell positioning 
CXCL14 BRAK, Bolekine Unknown  
Macrophage homing to the skin 
CXCL15 Lungkine Unknown  Neutrophil recruitment to the 
lung 
CXCL16 SRPSOX CXCR6  NK Cell and ILC migration and 
survival 
CXCL17 DMC, VCC1 CXCR8  Monocyte/dendritic cell 
chemoattractant 
CX3C 
CX3CL1 Fractalkine, Neurotaxin CX3CR1  NK cell, monocyte and T cell 
migration 
Table 1-1. Members of the chemokine families, their receptors and primary functions 
within the immune system. This list was adapted from Griffith, Sokol and Luster (2014) 23 and 
other sources 24-26. Abbreviations: DC = dendritic cell, ILC = innate lymphoid cell, NK = natural 
killer cell, Tfh = T follicular helper cell, Th = T helper cell, Treg = regulatory T cell. 
 
1.2.4 Glycosaminoglycan Binding 
GAGs are linear polysaccharides (consisting of repeating disaccharides that can range in 
length from one unit to over a hundred units), the majority of which are bound to a core 
protein through covalent interactions, therefore forming a glycoprotein 27. N-linked 
glycosylation accompanies protein synthesis in the endoplasmic reticulum and refers to 
glycoproteins where the interaction between the sugar residues and the core protein 
occurs at the amide nitrogen group within asparagine. O-linked glycosylation occurs 
through the step-wise addition of sugar residues to the core protein post-translationally, 
where the interactions occur at the oxygen on serine/threonine side chains 28,29. GAGs 
can be classified into five groups; heparin/heparan sulphate, chondroitin sulphate, 
dermatan sulphate, keratin sulphate and hyaluronic acid, the latter being a non-
sulphated GAG which forms non-covalent attachments to proteins 30. The structures of 
these GAGs are shown below in Figure 1-3. The highly acidic and negatively charged O-
linked GAGs such as chondroitin sulphate, dermatan sulphate, heparin or heparan 
sulphate bind to basic residues in chemokines (usually lysine, arginine and histidine, 
which can be arranged in the form of a BBXB or (B)BXX(X/B)BXXB(B) motif) through 
electrostatic and hydrogen bonds 29,31,32.. 
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GAGs such as heparan sulphate are present on the surface of endothelial cells and within 
the extracellular matrix (ECM), where they bind and immobilise chemokines 
dynamically. It is thought that transient binding of chemokines between GAGs and 
GPCRs creates an equilibrium of free/GAG bound/GPCR bound chemokine 
monomers/dimers localised to the site of injury 27,33,34. This state of equilibrium is 
highest in concentration at the site of injury, and becomes more diffuse further away, 
thereby creating a “trail of breadcrumbs” effect to direct leukocyte migration 35,36. 
Immobilisation of chemokines on GAGs also assists their presentation to leukocytes in 
tissues 37,38, and prevents their degradation 39,40. The interactions between chemokines, 
GAGs and chemokine receptors are shown diagrammatically in Figure1-4, using a 
neutrophil, CXCL8 and CXCR1/CXCR2 as a simplified example system. 
GAG binding has been shown to be essential for chemotactic function in vivo, as 
chemokine mutants with a retained ability to bind GPCRs, but an impaired ability to bind 
GAGs were unable to induce leukocyte migration 32. GAG heterogeneity is an important 
contributing factor to the fine-tuning and regulation of chemokine functionality, as the 
exact composition of GAGs and thus selective affinity for certain chemokines depends on 
cell type and location 41. This heterogeneity occurs at many levels, from differences in 
GAGs expressed by different tissues (and the ability of cells to modulate their GAG 
expression in response to stimuli), amounts of soluble versus matrix-bound GAGs within 
the vicinity, the polysaccharide chain lengths of these GAGs, and their varying patterns 
of sulphation all contribute to chemokine binding specificity 27,29,36,42,43. Generally, 
however, longer GAGs have higher affinity for chemokines (due to their length enabling 
them to interact with multiple GAG-binding epitopes present within chemokine 
oligomers), and as most chemokines are basic they tend to have higher affinities for 
GAGs with high sulphate content such as heparan sulphate, although the distribution of 
sulphate groups also affects affinity 27. 
CXCL4/11 and CCL5/21 have high affinities for GAGs, while CCL2 and CXCL8 have 
intermediate affinity and CCL3/4 have low affinity. Different chemokine oligomers have 
varying affinities for GAGs 44, and GAG binding is known to stabilize chemokine 
oligomers, therefore oligomerisation and GAG-binding are described as mutually re-
enforcing processes27. CXCL11, CXCL12, CCL2 and CCL5 all showed a decreased binding 
affinity for 2-O-desulphated heparin in comparison to wild type heparin, but CXCL4 
showed equal affinity for both 44. Naturally, the interactions between free and bound 
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chemokine monomers/dimers/oligomers with soluble and immobilised GAGs will in 
turn affect the ability of the chemokines within this localised area to interact with their 
respective GPCRs in what is a greatly complex and dynamic situation.   
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Figure 1-3. The structures of glycosaminoglycans (GAGs). Heparin/heparan sulphate, 
dermatan sulphate, keratin sulphate and chondroitin sulphate are connected to a 
transmembrane protein within the extracellular matrix (ECM) by a serine residue (O-linked 
GAGs are shown as examples). Hyaluronic acid is not linked to a protein core. Abbreviations: Xyl 
= xylose, Gal = galactose, GlucA = D-glucuronic acid, GlucNac = N-acetylglucosamine, GalNac = N-
acetylgalactosamine, IdurA = iduronic acid. This figure was adapted from 45. 
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Figure 1-4. Chemokine function is mediated through glycosaminoglycan (GAG) and G-
protein coupled receptor (GPCR) binding. Diagrammatic representation of the dynamic 
interaction and on/off binding of chemokines with both GAGs present on endothelial cells (via 
the chemokine C-terminal region), and with the GPCR present on the leukocyte surface (via the 
chemokine N-terminal region).   
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1.2.5 Chemokine Multimerisation and Structural Function 
Many chemokines exist as multimers both at high concentrations in vitro and during 
interactions with GAGs at sites of inflammation in vivo 32,46. The affinity that a given 
chemokine has for its GPCR and for GAGs is largely affected by its oligomerisation state 
as mentioned previously, although it is generally accepted that all chemokines are active 
as monomers in terms of GPCR activation 47. This has been demonstrated for 
CCL2/3/4/5 48-50 and CXCL1/7/8/10 51,5253. In the case of CC chemokines, dimers are 
unable to bind to GPCRs due to essential GPCR-binding residues being located within the 
dimer interface (thus they are not accessible to the GPCR) 54, however dimerised CXC 
chemokines are still able to bind to their GPCRs, albeit with affinities different than 
those of their monomeric forms 46,55. CXC-type dimers are globular in structure, and are 
formed by interactions between the β1 strands in the two monomers, whereas CC-type 
dimers are more elongated in nature, and are formed by interactions between the two 
short N-terminal β-strands in the two monomers 56. 
Some chemokines primarily exist as monomers such as CCL7, whereas others form 
tetramers such as CXCL4, and polymers such as CCL5 27. CCL7 is still able to bind to GAGs 
with high affinity despite its inability to oligomerise, (CCL7 lacks a conserved proline 
residue necessary for the dimerization of CC chemokines), due to its high numbers of 
GAG-binding epitopes, in contrast to chemokines such as CCL2, which has fewer GAG-
binding epitopes but readily oligomerises 27,57. Oligomerisation-deficient CXCL4 and 
CCL5 mutants showed reduced binding to heparin and heparan sulphate in surface 
plasmon resonance experiments than their wild type counterparts, which where able to 
oligomerise upon the immobilised GAGs 44. 
As well as forming homodomers and multimers, chemokines can also form 
heterodimers, as has been shown for CCL3-CCL4, CCL2-CCL8 58, CXCL4-CXCL8 59 and 
CXCL4-CCL5 in vitro and in vivo 60,61, and as with homodimerisation, heterodimerisation 
modulates the biological activity of chemokines. Interactions with GAGS have been 
shown to promote the formation of, and stabilise chemokine hetero-oligomerisation as 
well as homo-oligomerisation .62,63 
Monomers, dimers and multimers exist in a dynamic equilibrium, although the relative 
amounts of these different structural forms depends upon the chemokine in question 
(some form strong and stable oligomers whereas others have weaker interactions and 
14 
 
exist as monomers/dimers), the tissue microenvironment i.e. GPCRs/GAGs present, as 
well as the chemical environment i.e. pH, ionic strength and buffer type 56. 
In addition to chemokine multimerisation, GPCRs themselves can also multimerise both 
with other GPCRs and non-chemokine receptors, which also alters signalling. 
Homodimers have been detected in the cases of CCR2/5, CXCR1/2/4 and ACKR1, and 
heterodimers have been detected in the cases of CCR2-CCR5, CXCR1-CXCR2, CXCR4-
CCR2, CXCR4-CXCR7, CXCR4-CCR5 and ACKR1-CCR5 64. Inflammation induces 
oligomerisation of CCR7, which facilitates an oligomer-specific Src kinase signalling 
pathway leading to enhances chemotaxis 65.   
1.2.6 Regulation of Chemokine Function 
Regulating the function of chemokines is essential in order to create adequate but not 
excessive inflammation after injury, to facilitate optimum healing. As eluded to above, 
this regulation is complex and involves many aspects of chemokine biology, including 
the actual production of chemokines (affected by epigenetic modifications), the 
concentration and therefore oligomeric state of the chemokine (i.e. 
monomers/dimers/oligomers (both hetero and homo), as this will affect chemokine 
affinity for GAG and GPCR binding), tissue microenvironment, 
length/composition/sulphation patterns of GAGs, and receptor signalling bias 30,66. For 
example, CCL19 and CCL21 both signal through CCR7, but CCL19 is known to exist 
mainly as a soluble unbound monomer whereas CCL21 binds with high affinity to GAGs 
unless cleaved, but shows enhanced CCR7 signalling when heterodimerised with 
CXCL13 44,56,67. CCL3 and CCL5 are both ligands of CCR1 and CCR5, and homo-
oligomerisation of both has been linked to GAG binding, however these chemokines 
differ in their affinities for GAGs, with CCL3 having a low and CCL5 having a high affinity 
44,56,68. In addition, and as mentioned above, CCL3 heterodimerises with CCL4, and CCL5 
heterodimerises with CXCL4 56. Another novel aspect of chemokine biology that can 
regulate function is post-translational modification, such as nitration, citrullination, 
phosphorylation and glycosylation. This project will focus on post-translational nitration 
of CXCL8 as a model CXC chemokine. 
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1.3 POST-TRANSLATIONAL MODIFICATION OF CHEMOKINES 
Post-translational modification is emerging as a critical aspect of chemokine biology in 
terms of regulating function. The modifications themselves, as well as their causes and 
subsequent effects on biological activity vary and must be studied on an individual basis. 
Post-translational modifications have been shown to affect chemokine function in terms 
of GAG and receptor binding abilities which in turn affects their ability to induce 
migration of leukocytes, as well as their detectability by antibodies raised against their 
wild type un-modified counterparts. This project will focus on nitration, although other 
types of post-translational modification are discussed briefly. 
1.3.1 Truncation and Cleavage 
Enzymatic modifications of chemokines can involve cleavage by a range of enzymes 
including matrix metalloproteinases (MMPs), CD26 and cathepsin G. The expression of 
MMPs is closely linked to inflammation, with MMP-8 being released by neutrophils, and 
MMP-12 by macrophages. These enzymes (and others) can cleave chemokines, as well 
as mediate tissue remodelling and ECM degradation 69.  
In some cases, cleavage of chemokines by MMPs can enhance function, with the resulting 
molecule being more chemotactically active. This is the case for the cleavage of CXCL5 by 
MMP-8, and CXCL8 by MMP-1/MMP-8/MMP-9 70-72. In other cases however, cleavage 
can abrogate function, such as the N-terminal cleavage of CXCL8 by MMP-12 (due to 
disruption of the ELR motif which is essential for function), or the C-terminal cleavage of 
CXCL9/CXCL10 by MMP-8/MMP-9 (likely due to disrupted GAG 
binding/oligomerisation) 73,74. Enzymatic cleavage of chemokines to reduce function is 
also used as a method of immune evasion by bacteria including Streptococcus pyogenes. 
The bacterial enzyme Streptococcus pyogenes cell envelope proteinase (SpyCEP) cleaves 
chemokines such as CXCL8 at the C-terminus, which prevents the chemokines from 
inducing neutrophil recruitment and thus allows the bacteria to disseminate 75. 
1.3.2 Citrullination 
Enzymes can also mediate single residue modifications such as the citrullination of 
arginine residues by peptidylarginine deaminase (PAD) enzymes 76. Citrullination 
results in a 1Da increase in mass per residue affected, and in a loss of the basic charge of 
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the arginine residue, which is therefore likely to impact negatively on its ability to form 
hydrogen bonds and participate in ionic interactions. This in turn compromises 
chemokine structure and function. This is thought to be one reason that citrullination of 
all chemokines tested to date, including CXCL10, CXCL11, CXCL12 and CXCL8 76-78, 
reduces chemotactic ability and could therefore be described as an “anti-inflammatory” 
post-translational modification.  
1.4 POST-TRANSLATIONAL NITRATION BY PEROXYNITRITE 
The reactive species peroxynitrite (ONOO-) is produced from the spontaneous reaction 
of nitric oxide (NO) and the superoxide anion (O2-), which will be discussed later in more 
detail. Peroxynitrite has a very short half-life of around 10ms at physiological pH, during 
which it will modify any proteins within a 20μm range of its production 79. Peroxynitrite 
has been shown to nitrate both free and protein-bound tyrosine residues to form 3- 
nitrotyrosine (3NT), alter tryptophan via oxidation, nitration and nitrosation at many 
positions on the core phenol ring, and oxidise thiol groups present in cysteine and 
methionine residues to form sulfoxide groups 80-82. Peroxynitrite can also modify 
histidine to create a histidyl radical, and lysine to produce N6-(Carboxymethyl)lysine 
83,84.  Some examples of these modifications are shown diagrammatically in Figure 1-5. 
3NT has been shown to be a detectable footprint of nitrative stress and peroxynitrite 
activity (due to peroxynitrite itself having such a short half-life) 85, and has been 
documented in plasma samples from many human diseases 81.  
17 
 
 
Figure 1-5. Peroxynitrite (ONOO-)-mediated modifications of amino acids. Peroxynitrite-
mediated nitration (red) of tyrosine to form 3-nitrotyrosine, tryptophan to form (e.g.) 6-
nitrotryptophan, and cysteine to form nitroslyated cysteine. Peroxynitrite-mediated oxidation 
(blue) on tryptophan to form dihydroxytryptophan, on thiol groups of methionine and cysteine 
to form sulfoxide groups which can then form disulphide bonds. Lysine can also be modified by 
peroxynitrite to form N(Carboxymethyl)lysine, and histidine can be converted to a histidyl 
radical (not shown). 
1.4.1 Nitration, Ischaemia-Reperfusion Injury and Oxidative Stress 
Organ transplantation is a model scenario in which to study the nitration of chemokines 
and other proteins, due to the ischaemia-reperfusion injury (IRI) which occurs when the 
donor organ is isolated from circulation and is then reperfused upon transplantation 
into the recipient. IRI is associated with delayed graft function and rejection in kidney 
transplantation 86 and graft dysfunction in liver, lung and heart transplantation 87-89 .  IRI 
features in a number of other conditions including acute coronary syndrome/acute 
heart failure after cardiopulmonary bypass in the heart, acute kidney injury as a result of 
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vascular surgery, acute lung injury as a result of thoracic surgery, and stroke in the brain 
86. 
During the ischaemic phase of IRI, the shift from aerobic to anaerobic metabolism (due 
to a lack of oxygen), leads to the depletion of adenosine triphosphate (ATP) and calcium 
overload within cells, which in turn results in mitochondrial damage involving the 
opening of the mitochondrial permeability transition pore (mPTP) during reperfusion, 
the generation of reactive oxygen and nitrogen species (ROS and RNS respectively) 
86,90,91, and ultimately cell death. The most common ROS/RNS are, non-radicals such as 
hypochlorous acid (HClO) and hydrogen peroxide (H2O2), and radicals (a molecule 
containing a spin-unpaired electron in the outer shell) including the superoxide anion, 
peroxynitrite and the hydroxyl anion (OH-) 92,93. It is the imbalance between the 
formation and release of these reactive substances, and anti-oxidative mechanisms such 
as scavengers, which prevent excessive stress and damage 90,94,95, that causes the 
oxidative stress that is a key feature of IRI. 
As reactive species themselves, the precursors of peroxynitrite; NO and O2-, are both 
known to be increased during oxidative stress and inflammation 96-98. NO is produced by 
a range of enzymes, including endothelial NO synthase (eNOS), neural NO synthase 
(nNOS) and inducible NO synthase (iNOS), which are widely expressed by many cell 
types including endothelial cells and cardiomyocytes 99-101. NO acts as a vasodilator and 
inhibitor of platelet aggregation and is therefore beneficial at low concentrations 102. O2- 
is produced by many enzymes including nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase, which is present within the mitochondria of all cells, and xanthine 
oxidase (XOD), which is also widely expressed by polymorphonuclear cells, endothelial 
and epithelial cells 103. It is also released during the neutrophil oxidative burst. Both NO 
and O2- can be detrimental if present in excess either as themselves, or through the 
formation of secondary molecules. NO itself can inhibit enzymes that have transition 
metal components or produce free radical intermediates as part of their catalytic cycles, 
such as cytochrome P450 81. NO can form nitrous anhydride, (N2O3) when autooxidised, 
which mediates DNA and protein damage 99,104. Two superoxide molecules can undergo 
spontaneous dismutation to form H2O2 105, and as aforementioned, NO and O2- can react 
together to produce peroxynitrite 81,106,107.  A simplified version of this complex pathway 
is shown diagrammatically below in Figure 1-6. Upregulation of XOD, NADPH and NOS 
enzymes occurs during IRI as, therefore, will the production of peroxynitrite 86. 
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Peroxynitrite elicits many damaging effects, including DNA strand breaks, lipid 
peroxidation and increasing MMP2 activity 108. Peroxynitrite is also responsible for the 
activation of poly (ADP-ribose) polymerase (PARP) which alters metabolism and 
increases energy consumption, thereby depleting intracellular ATP stores leading to cell 
dysfunction and death 81,109,110. In addition, peroxynitrite can inhibit natural anti-
oxidative mechanisms such as the superoxide dismutase enzyme (SOD) and 
glutaredoxin, which leads to positive feedback loops of intracellular oxidant generation, 
and therefore exacerbation of injury 98,111. Peroxynitrite has therefore unsurprisingly 
been implicated in the pathology of many diseases 112 as well as in organ 
transplantation.  These include neutrophil –induced myocardial IRI 113, cardiac allograft 
rejection post-transplant 114, kidney diseases such as acute tubular necrosis 115, 
osteoarthritis 116, interstitial lung disease 117, type II diabetes mellitus and Fabry disease 
118. 
As production of both peroxynitrite and chemokines are upregulated during periods of 
oxidative stress, nitration of chemokines would therefore be more likely to occur during 
oxidative stress and inflammation. 
 
Figure 1-6. Diagrammatic representation of the formation of peroxynitrite (ONOO-). 
Shown are the sources and production of nitric oxide (NO) by nitric oxide synthase enzymes 
(NOS), the superoxide anion (O2-) by nicotinamide adenine dinucleotide phosphate oxidase 
(NADPH) /xanthine oxidase (XOD), and the reaction of the two to form peroxynitrite. 
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1.4.2 Functional Consequences of Chemokine Nitration 
Nitration of chemokines is a non-silent modification, which affects biological function. 
Nitration of CCL2 and CCL5 by incubation with peroxynitrite has been shown to reduce 
their ability to induce monocyte and eosinophil chemotaxis respectively 119, whereas 
nitration of CCL2 by tumour-derived reactive nitrogen species (RNS) was shown to 
impair CD8+ T cell, but not myeloid cell, recruitment. This is thought to be due to 
nitration partially reducing the ability of CCL2 to bind to its GPCR CCR2, as this receptor 
is present at much lower concentrations on the surface of CD8+ T cells than on myeloid 
cells, which express far greater amounts 120. Nitrated CCL2 has also been shown to have 
impaired binding to both heparin and heparan sulphate in comparison to wild type CCL2 
121, so the reduction in migratory capacity in this case is likely due to a combination of 
impaired GPCR and GAG binding. CXCL12 was unable to induce lymphocyte chemotaxis 
in vitro or in vivo when nitrated, despite the fact that this modification does not affect the 
ability of CXCL12 to bind GAGs. It was, however, found that while nitration does not 
inhibit the binding of CXCL12 to its GPCR CXCR4, it does prevent the chemokine from 
inducing downstream signalling once bound 122. In the case of CXCL12 therefore, the 
inability to induce migration is a likely a result of nitration impairing GPCR activation 
solely. Incubation with peroxynitrite also impaired the ability of CCL3 to recruit 
neutrophils and monocytes 123 and of CCL11 to recruit eosinophils 124.  
In some cases, as for CCL2 and CXCL12, nitration has also been shown to prevent the 
detection of chemokines by antibodies raised against their wild type un-modified 
counterparts. This is presumably due to epitope modification by the added NO2 
group(s), which prevents the antibody from recognising the modified chemokine 95,120. 
This therefore limits the biological relevance of chemokines as biomarkers if only wild 
type chemokine is detectable in samples. The number of different modified versions of 
chemokines present within biological samples, and the ratios they are present in, could 
be a more accurate profile of the inflammatory situation, and could prove to be a more 
accurate indicator of health/disease than just measuring unmodified chemokines alone. 
1.4.3 Functional Consequences of Protein Nitration 
Any proteins present within the vicinity of peroxynitrite production (besides 
chemokines) are also susceptible to nitration. Nitration of tyrosine residues may alter 
protein signal transduction in vivo through interference with tyrosine phosphorylation, 
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which is an important aspect of many signalling cascades 125.  Nitration of proteins is 
thought to be the main cause of pathology in acute and chronic alcoholic fatty liver 
injury models, due to the nitration altering their functionality 126-128. Nitration of 
Complex I (NADH ubiquinone oxidoreductase) and Complex V (ATP synthase) decreases 
protein function leading to decreased energy production, nitration of SOD1, SOD2, and 
glutathione peroxidase (GPX) decreases their antioxidant abilities 128. Nitration of some 
liver proteins is also thought, but not confirmed, to contribute to pathology by 
increasing their functions, such as nitration of heat shock protein 90 (HSP90) leading to 
its conversion to a toxic product, and nitration of protein phosphatase type 2A (PP2A) 
leading to increased vascular permeability 128. Nitration of glutathione S-transferase 1 
(GST-1), however, increases the protein’s antioxidant functionality, and is an example of 
protein nitration increasing function in a beneficial manner 128. Peroxynitrite-mediated 
nitration of specific proteins in particular have been correlated with various other 
diseases, such as Apolipoprotein A1/ Glyceraldehy 3-phosphate dehydrogenase 
(GAPDH) in cardiovascular disease, Apolipoprotein B100 in atherosclerosis, creatine 
kinase in myocardial infarction, and Tau protein in Alzheimer’s disease 129. 
Nitration of proteins also has the potential to be immunogenic, as suggested by the 
increased levels of anti-3NT antibodies detected in the plasma of patients with acute 
lung injury 130, the serum of patients with systemic lupus erythematosus (SLE), and the 
synovial fluid of arthritis patients 129. 
1.4.4 Protein Denitration 
The denitration of proteins has been observed in many experimental settings in vitro, 
although its exact mechanisms in vivo are yet to be determined 125. Nitratase activity has 
been detected in rat heart and brain homogenates 131, isolated platelets 132, isolated 
mitochondria133 and activated macrophages 134, and is usually determined by an inverse 
correlation between 3-nitrotyrosine-positive proteins and free nitrate groups 135. This 
likely means that nitration is alterable, and the proportions of nitrated and denitrated 
proteins, including chemokines, could be actively regulated to fine-tune protein 
signalling and function. 
22 
 
1.5 CXCL8 
This project will study CXCL8 as a model CXC chemokine. CXCL8 is a potent neutrophil 
chemoattractant protein released by many cell types (both leukocytic and non-
leukocytic) in response to a wide range of stimuli including cytokines, microbial 
products and hypoxia 1,136. CXCL8 has also been shown to act on other cell types such as 
lymphocytes and fibroblasts, and is known to promote leukocyte degranulation 137 and 
angiogenesis 138. CXCL8 is therefore implicated in both acute and chronic inflammation 
139. The primary amino acid sequence of CXCL8 is shown in Figure 1-7A, as well as the 
3D structures of monomeric CXCL8 (Figure 1-7B), and dimeric CXCL8 (Figure 1-7B) with 
some key amino acids highlighted. The biological significance of some of these 
highlighted amino acid residues are described in more detail in Figure 1-8. 
While mice do not express the CXCL8 gene, they do express MIP2 and KC, which are 
known functional homologues of CXCL8 and signal through the same receptor, both 
inducing neutrophil chemotaxis 139,140. KC and MIP2 share 43% and 53% amino acid 
sequence homology with CXCL8 respectively (protein BLAST) 140. Despite the 
differences in their sequences, conserved regions between the three chemokines include 
the ERL motif, which is necessary for GPCR binding, and key basic residues at positions 
20, 60, 64, 67 and 68 which are involved in GAG binding 140. It is likely due to these 
similarities in key functional regions that human CXCL8 can be administered in murine 
in vivo models and successfully induce the recruitment of murine neutrophils 46,55,140.
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1.5.1 CXCL8 and GCPR Signalling 
CXCL8 signals via both CXCR1 and CXCR2 present on the surface of neutrophils, with a 
higher affinity for CXCR1. Distinct parts of the CXCL8 3D structure are responsible for 
activating the different receptors; the N-loop is responsible for CXCR1 activation, 
whereas the N-terminus is responsible for CXCR2 activation 141.  The ELR motif of CXCL8 
is known to be necessary but not sufficient for receptor binding and activation 142-145, 
and other residues such as tyrosine 13 (Y13) 142,146-148 and leucine 49 (L49) 142 are also 
known to be important for GPCR signalling as shown in Figure 1-8. Disulphide residues 
present within CXCL8 have been shown to be important in receptor binding, as 
modifying (without deleting) these disulphides results in reduced receptor binding 
affinities –demonstrating that they do mediate function in the folded protein 2. After 
ligand binding, the receptor becomes phosphorylated, and the CXCL8 receptor-ligand 
complex is rapidly internalised and recycled back to the cell surface 149. CXCR2 is 
internalised more rapidly than CXCR1, but its recycling back to the cell surface occurs 
more slowly 150. 
A range of signalling pathways can be activated downstream of CXCL8 binding, including 
PI3K, MAPK, PKC and FAK, and CXCL8 is known to activate transcription factors such as 
AP-1, HIF-1, STAT3 and NFκB 150. CXCR1 has been shown to mediate both the 
neutrophil’s cytotoxic microbicidal effects and facilitate the oxidative burst, as both of 
these functions are impaired when cells are stimulated with CXCL8 in the presence of 
CXCR1, (but not CXCR2) blocking antibodies 151-153.  
Chemotaxis in response to large quantities of CXCL8 (i.e. in an inflammatory situation) 
has been shown to be mediated largely by CXCR1, as blocking CXCR1 (particularly the N-
terminus) either abolished 154 or reduced 155 chemotactic function. Other studies have 
suggested that CXCR2 does in fact also play a role in neutrophil chemotaxis, however 
this is generally in induction of chemotaxis in response to picomolar concentrations of 
CXCL8 156,157. Both receptors are reported to mediate granule enzyme release 152. 
CXCL8 can also bind the atypical chemokine receptor ACKR1 which is present on the 
surface of erythrocytes and facilitates the clearance of CXCL8, therefore preventing its 
ability to induce migration of neutrophils and thus reducing inflammation 77. 
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1.5.2 CXCL8 and GAG Binding 
The dimeric form of CXCL8 is the higher affinity GAG ligand, but binds the receptor with 
a lower affinity than the monomer – possibly negatively regulating receptor function 2. 
H18, K20, R60, K64, K67 and R68 are core GAG-binding residues (red in Figure 1-8) 
present in GAG binding sites of both the monomer and dimer. K15, R47, K23 and K54 are 
secondary GAG-binding residues located around the core residues (dark blue in Figure 
1-8) 158,159. K64A, K67A and R68A CXCL8 mutants showed reduced ability to bind to 
GAGs such as heparin and heparan sulphate, and a reduced ability to induce chemotaxis 
151.  
1.5.3 CXCL8 Multimerisation and Function 
Unbound CXCL8 is detectable in serum/blood samples, and is known to be present at 
low concentrations (pg/ml) during normal conditions, and to increase during 
inflammation. What is not reliably measurable is the concentration of bound CXCL8 
immobilised on GPCRs or GAGs. As CXCL8 concentrations increase both temporally and 
spatially during inflammation, it is likely that CXCL8 is actually present as a dynamic mix 
of monomers/dimers/multimers that varies in composition over time and space 160. This 
is supported by data showing that at high concentrations in both solution and 
crystallised state, CXCL8 has been detected as a homodimer 161, however at lower 
concentrations in the nanomolar range (assumed to be more physiologically relevant), 
CXCL8 exists as a monomer 162.  
Studying CXCL8 monomers/dimers has been attempted in a number of studies using 
disulphide-linked dimers and induced monomers. Monomeric CXCL8 is known to be 
active in terms of mediating GPCR signalling; a “forced monomer” analogue of CXCL8 
(created by methylating L25) was shown to be functional in terms of GPCR binding and 
neutrophil activation, and was 10 to 100-fold more active than an R26C non-dissociating 
dimer mutant 52,160,163. This data is supported by a later study conducted by Leong et al., 
who found that a range of disulphide-linked CXCL8 variants could bing CXCR1 and 
CXCR2, but with lower affinities than wild type CXCL8 164, and a study showing a 
different monomeric CXCL8 analogue (a V27P/E29P mutant) was as active as wild type 
CXCL8 in functional studies 165. Another study, however, showed that a different 
disulphide-linked CXCL8 dimer was as equally active as wild type CXCL8 in terms of 
inducing calcium release in neutrophils 166. These discrepancies could be due to the 
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disulphides being introduced at different positions in the different studies. The 
consequences of artificially introducing disulphides to create dimers is not fully 
understood, although data shows that the R26C disulphide-linked dimer is similar to the 
wild type CXCL8 dimer in terms of dimer interface and NMR-analysed 3D structure 47. 
More recent studies have shown that in a mix of CXCL8 monomers and dimers only the 
monomer preferentially binds to CXCR1, and binding of CXCL8 to CXCR1 has been 
shown to cause dimer dissociation 163,167,168. The observed attenuation of neutrophil 
recruitment observed at very high CXCL8 concentrations could be attributed to the 
chemokine dimerising and therefore having a reduced affinity for GPCRs at these 
concentrations 47. 
Monomeric and dimeric CXCL8 also regulate GPCR function differently. For CXCR1 
monomeric CXCL8 shows greater activity in terms of mediating receptor 
phosphorylation, desensetisation and β–arrestin-mediated internalisation, whereas for 
CXCR2 monomeric and dimeric CXCL8 show similar activity in regulating these 
functions 160. The differences in binding affinities between the CXCL8 monomer and 
dimer can likely be attributed to differences in the C-terminal helical residues, which are 
unstructured in the monomer and structured in the dimer and altered binding 
properties of the N-loop residues 47,169,170. The latter is likely due to a general reduction 
in flexibility observed in the dimer, as the N-terminal and N-loop regions that mediate 
GPCR binding are located away from the dimer interface 47. CXCL8 has also been shown 
to form a heterodimer with CXCL4, which enhances the signalling capabilities of both 
chemokines 59. 
As it has been shown that heparin-bound CXCL8 monomers and dimers are unable to 
bind to CXCR1/CXCR2 34, it is hypothesised that CXCL8 exists as a dynamic “cloud” of 
bound (to GPCRs or GAGs) and free CXCL8 monomers/dimers/multimers (both homo 
and hetero), which fine-tunes the immune response,. The ratio of these components 
within the “cloud” will be affected by chemokine concentration, GPCR expression and 
homo/heterodimerisation, GAG composition/length/sulphation patterns as well as the 
chemical microenvironment described previously. Simplistically, while both CXCL8 
monomers and dimers bind GAGS and GPCRs, due to different affinities it is likely that 
the dimer preferentially exists in GAG-bound form, and the monomer in the free/GPCR-
bound form 34. The dynamic conversion of free CXCL8 monomers to dimers and vice 
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versa means that that the overall CXCL8 “cloud” composition is also dynamic and in 
constant flux 34.  
1.5.4 Post-Translational Modifications of CXCL8 
Several N-terminal processed forms of CXCL8 are produced by proteolytic cleavage after 
secretion from peripheral blood monocytes, leukocytes and endothelial cells. In general, 
CXCL8 (amino acids 6-77) is the most common form 2,171. As mentioned previously, 
cleavage of CXCL8 by MMP-1/MMP-8/MMP-9 increases the chemotactic ability of 
CXCL8, whereas cleavage by MMP-12 abrogates function. Citrullination of CXCL8 has 
been shown to reduce its ability to induce neutrophil migration into the mouse 
peritoneum in vivo, impair its ability to bind heparin, and also prevents its enzymatic 
cleavage into more active forms 76. Citrullinated CXCL8 was shown to have an enhanced 
ability to induce neutrophil mobilisation from the bone marrow into the circulation, 
where the chemokine itself also persists as citrullination prevents it from binding to 
ACKR1 and thus protects it from erythrocyte scavenging 172.  This is likely one 
explanation for the lack of recruitment to the mouse peritoneum seen, as both the 
neutrophils and the chemokine will remain in the circulation due to impaired GAG 
binding of the latter. Naturally occurring citrullination could occur as a mechanism by 
which the numbers of blood neutrophils are kept constant at a time of injury or 
inflammation when many are recruited out of the blood and into tissues 172.  
Peroxynitrite is also known to activate the NF-κβ pathway leading to CXCL8 production 
and neutrophil recruitment 100. Production of CXCL8 in the same vicinity as 
peroxynitrite means nitration of CXCL8 is also highly likely to occur. A study conducted 
by Sato et al, has shown that incubation of CXCL8 with peroxynitrite inhibits its ability to 
recruit neutrophils in vitro 173. As tyrosine residues are targets of peroxynitrite-
mediated modification (to form 3-nitrotyrosine), and the sole tyrosine residue at 
position 13 within CXCL8 has a functional role in GPCR signalling, it is likely that 
nitration of CXCL8 could affect is ability to signal through CXCR1/CXCR2. CXCL8’s GAG-
binding capacity could also be affected by peroxynitrite, through the modification of 
lysine residues that are essential for CXCL8-GAG interactions. This project aims to 
characterise how nitration affects CXCL8’s biological activity and detectability. 
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1.5.5 Targeting CXCL8 Therapeutically 
Targeting the function of CXCL8 is an attractive therapeutic concept, and has been 
researched in a number of studies. Regulating chemokine function could be achieved 
through targeting many different aspects of chemokine biology, including GPCR 
signalling (through inhibitors/antagonists/blocking antibodies), the chemokine itself 
(through antibodies), and GAG binding (through competitors/synthetic non-GAG 
binding mutants). 
1.5.5.1 Targeting CXCL8 Production 
Treatment of primary blood neutrophils with sirolimus (Rapamycin) and its derivative 
everolimus, which are selective mTOR inhibitors, decreased the ability of the cells to 
produce CXCL8 and VEGF, and could therefore possibly inhibit excessive neutrophil 
recruitment in in vivo transplant cases 174.  
Neutralizing monoclonal antibodies raised against CXCL8 have successfully decreased 
necrosis in rabbit myocardial IRI 175,  and  rat intestinal IRI 176. Peptides synthesised 
from chemokine receptor sequences have been shown to bind and inhibit chemokines 
including CXCL8 177,178. 
1.5.5.2 Targeting of GPCRs 
In mouse studies, genetically targeting CXCR2 through gene knockout out (CXCR2-/-), 
reduced (but did not abrogate) neutrophil migration into the mouse peritoneum in 
response to a thioglycollate injection 179, and reduced neutrophil migration in a murine 
urinary tract infection model which resulted in pyelonephritis 180. This suggests that 
while CXCR2 is largely responsible for neutrophil migration in mice, another mechanism 
must exist to compensate for its loss. In a mouse cardiac allograft rejection model, hearts 
transplanted into a CXCR2-/- recipient mouse showed reduced leukocyte infiltration and 
expression of pro-inflammatory cytokines 181, and CXCR2-/- mice showed smaller infarct 
sizes and fewer infiltrating immune cells than wild type mice in a myocardial infarction 
model 182. SB656933 is a compound designed to specifically inhibit CXCR2 signalling 
that is currently in phase I clinical trials to treat chronic obstructive pulmonary disease 
183. Danirixin is another CXCR2-specific antagonist, which was shown to inhibit LPS-
induced neutrophil migration to rat lungs in vivo 184. 
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Several small peptides derived from the CXCR1 binding portions of CXCL8 (residues 8-
21) have also been shown to reduce the adhesion of THP-1 cells (a monocyte-like cell 
line) to HMEC-1 cells in vitro by binding to CXCR1 and thus preventing the interactions 
between CXCR1 and CXCL8 185. 
Reparixin is a small molecular weight non-competitive allosteric CXCR1 and CXCR2 
inhibitor, which has been shown to be highly effective in decreasing CXCL8-mediated 
neutrophil chemotaxis in several IRI models. It is now currently in phase II clinical trials 
for primary and delayed graft function treatment, in lung and kidney transplant patients 
183. Reparixin has also been shown to improve survival of pancreatic islet allografts in 
both mice and humans 186, as well as reduce damage in post-ischemic rat intestine 187 , 
brain 188 , liver 189 and kidney transplant 190.Targeting the CXCL8/CXCR1/CXCR2 axis is 
an area of focus in many other disease states including type 1 diabetes 191, neurological 
damage post-stroke 192, arthritis 193,194, and cancers 195. 
1.5.5.3 Targeting GAG Binding  
The interactions between CXCL8 and GAGs can be targeted to modulate inflammation. 
This occurs naturally, as the anti-inflammatory TNF-stimulated gene/protein-6 (TSG-6) 
causes a reduction in neutrophil recruitment by directly interacting with the GAG-
binding domain of CXCL8. This prevents the formation of haptotactic CXCL8 gradients 
on GAGs and, by extension, neutrophil recruitment and inflammation 151.  
Small, synthesised chemokine peptides have been used to compete with wild type 
chemokines for binding on GAGs. A CXCL9 C-terminal peptide has been shown to bind 
heparin and heparan sulphate (as well as other GAGs), thus competing with a range of 
chemokines, including CXCL8, resulting in a reduction in neutrophil migration 196. These 
small peptides, or variants of them, could in theory exist naturally as a result of 
chemokine cleavage by proteinases as mentioned previously. 
Heparin and other GAG mimetics have been administered in mouse models of arthritis, 
traumatic brain injury, and LPS treatment, and were shown to reduce inflammation by 
the same principle of disrupting pre-formed chemokine gradients 197-199. Although this 
beneficial effect was found to be dependent upon dosage and administration time 200, 
and would likely affect a large range of heparin-binding  proteins rather than 
chemokines or a single chemokine specifically.  
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Non-GAG-binding mutants of many chemokines have also been created with the idea 
that these mutants could be administered to occupy receptor-binding sites on 
leukocytes, where they would prevent GAG-associated chemokines from binding and 
thereby reduce leukocyte recruitment. This was shown to be the case for CCL5, CCL7 
and CXCL12 201,202, but not for CXCL11 203. For CXCL8 non-GAG binding mutants could 
prevent migration of neutrophils to the peritoneum but not the lung 55,140. This 
emphasises the need to study each chemokine on an individual basis and avoid 
generalisation.
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Figure 1-7. Different structural regions within the peptide sequence of CXCL8.  A) The full-length chemokine (1-77 amino acids) is 
shown, as well as the more common and active form (6-77 amino acids), which is produced due to cleavage of the first 5 amino acids 
(AVLPR). Loop regions within the chemokine are shown in purple, β strands in green, β sheets in orange, helices in blue, the turn in red, 
and blue brackets indicate disulphide bonds. B) Monomeric 3D structure of CXCL8 (PyMOL), with tyrosine 13 (Y13) highlighted in 
magenta C) Dimeric 3D structure of CXCL8 (PyMOL). GPCR binding residues are highlighted in green, core GAG binding residues in red, 
secondary GAG binding residues in dark blue, and tyrosine 13 (Y13) in magenta. 
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Figure 1-8. Functional roles of some key residues within the peptide sequence of CXCL8.
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1.6 NEUTROPHILS 
Neutrophils, or polymorphonuclear leukocytes (PMN) are essential components of the 
innate immune system. They are produced in the bone marrow, where they mature in 
response to a combination of cytokines, then they emigrate into the circulation as the 
most abundant leukocyte present in human blood, from which they are recruited rapidly 
to sites of inflammation 204. Neutrophils are undoubtedly a major component of acute 
inflammatory responses, but evidence is now suggesting they play complex roles beyond 
pathogen elimination, that can affect the adaptive immune system and chronic 
inflammation 205.  
CXCL8 is the most potent neutrophil chemoattractant and activator 136,206, and upon 
binding to Gi-coupled receptor on the neutrophil surface (CXCR1/CXCR2), elicits calcium 
flux and MMP-9 release. MMP-9, as mentioned previously, can cleave CXCL8 to its more 
active form, thereby creating a positive feedback loop of CXCL8-dependant neutrophil 
recruitment 1. Activation of neutrophils by chemokines or bacterial products can also 
extend their lifespan beyond the usual 8 hours (under normal conditions), to ensure an 
adequate immune response within the site of inflammation, although this can 
inadvertently lead to the damage of healthy host cells 207.  
1.6.1 Chemotaxis and Transmigration 
This study will focus on neutrophil migration along chemotactic gradients of CXCL8 
specifically (through its binding to CXCR1/CXCR2 GPCRs expressed on the surface of 
neutrophils) however it should be noted that there is a complex interplay between many 
chemoattractant molecules and their receptors that contributes to neutrophil 
chemotaxis and biological function. These include endogenously released molecules 
such as leukotriene B4, platelet activating factor, and complement-derived C5a and C3a, 
other chemokines such as CXCL1/2/3/5/6/7/12 and CCL3/5/6/7/9 or bacterial 
chemoattractants during infection, such as N-Formyl-Methionyl-Leucyl-Phenylalanine 
(fMLP) (through binding to FPR1), which is presented by GAGs on the surface of 
endothelial cells 208,209. Neutrophil migration from the bone marrow into the circulation, 
the circulation into tissue, and then to the inflammatory site within the tissue, is tightly 
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regulated by temporal and spatial cascades consisting of complex mixes of many of these 
signalling molecules simultaneously 209. 
Initial interactions between the neutrophil and the endothelial cells involves the 
activated endothelial cells translocating Wiebel-Palade bodies storing P-selectin/E-
selectin to their surface membrane where these selectins are then expressed, and can 
interact with selectin ligands (such as P-selectin glycoprotein ligand-1 (PSGL-1)), which 
are expressed by neutrophils. This creates tethering and slow rolling of the neutrophil 
along the endothelial cell layer. Neutrophils will then upregulate the expression and 
clustering of β2-integrins (such as the CD11a/CD18 and CD11b/CD18 complexes), 
which will interact with integrin ligands (adhesion molecules ICAM-1, VCAM-1 and 
PECAM-1) on the endothelial cells. This facilitates the arrest and firm adhesion of the 
neutrophil on the endothelium and allows ICAM-1-CD11b/CD18-mediated crawling to 
occur. This crawling then leads to the transmigration of the neutrophil from the 
circulation into the tissue. This can occur transcellularly (i.e. though an endothelial cell 
itself), or more preferentially paracellularly (i.e. between endothelial cells) through 
interactions with PECAM-1, which is expressed at intercellular endothelial junctions. 
The neutrophil must then cross the basement membrane, aided by MMPs and other 
proteinases, before passing between pericytes and travelling further along the 
chemotactic gradient to the precise location of injury or inflammation 210,211. This 
process is summarised in Figure 1-9 below. 
34 
 
 
Figure 1-9. Neutrophil trans-migration into tissue from the circulation. Neutrophil 
tethering and slow rolling is mediated by interactions between selectins (P-selection/E-selectin) 
expressed by endothelial cells and selection ligands (PSGL-1) present on neutrophils. Arrest and 
firm adhesion, and crawling of the neutrophil is then mediated by its upregulation of integrin 
complexes (CD11a/CD18 and CD11b/CD18), which interact with integrin ligands (ICAM-1, 
VCAM-1, PECAM-1) on the endothelial cells. The neutrophil can then extravasate by paracellular 
or transcellular migration into the tissue. 
1.6.2 Degranulation 
Neutrophils mediate their anti-pathogenic functions by the release of a range of anti-
microbial proteins and enzymes into membrane-bound phagosomes where 
bacteria/pathogens have been engulfed 204. Neutrophils can also release substances 
stored in pre-formed granules (or synthesised in response to stimuli) through 
exocytosis in a process called degranulation, which is regulated by a range of signalling 
molecules within neutrophils including guanosine triphosphatases (GTPases), β-
arrestins, src kinases and phospholipids 204, this process is summarised 
diagrammatically in Figure 1-10. Four types of granules have been identified in 
neutrophils. Primary (or azurophilic) granules contain elastase, myeloperoxidase 
(MPO), defensins, heparanase, collagenase, alkaline phosphatase, lactoferrin and a range 
of lysozymes amongst others 212. Secondary and tertiary granules both contain 
lactoferrin and MMP-9, but can be distinguished from each other by their densities when 
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centrifuged in gradient media 213. The fourth type of granules are secretory vesicles, 
which are known to contain human plasma 204. 
1.6.3 Oxidative Burst 
The neutrophil oxidative burst is an essential aspect of the neutrophil’s anti-microbial 
function and involves the rapid production of ROS. This is mediated by the NADPH 
oxidase enzyme, which as described above, converts oxygen to the super oxide anion O2- 
214 . This superoxide anion radical can then go on to from other ROS such as H2O2, the 
hydroxyl radical (OH-), and HClO 215. The enzyme MPO, which is released from primary 
granules during degranulation also contributes to the ROS produced. MPO oxidises 
halides to form hypohalous acids such as HClO mentioned above, and hypochlorite (OCl-
), as well as other classic peroxidase substrates through reactions with H2O2 216.  
When neutrophils are inactive/quiescent, these multiprotein oxidase complexes are 
segregated into cytosolic and membrane compartments, but upon activation of the cells, 
these complexes translocate and assemble at the cell surface membranes to facilitate 
this oxidative burst, in a manner dependent on protein kinase C (PKC) 215,217 . 
The way in which the ROS produced during the neutrophil oxidative burst damages 
invading microorganisms is unclear. Both H2O2 and O2- can oxidize 4FE-4S clusters 
present in many proteins, and also damage any enzymes containing iron as a non-redox 
co-factor through Fenton’s chemistry. H2O2 can also react with cysteine residues, and 
OH- can damage many biological molecules including DNA 218 . 
Many of these secreted substances, while being anti-pathogenic, do not distinguish 
between self and non-self and can damage normal healthy tissue cells 204. They include 
O2-, H2O2, and HClO– which is a strong oxidising agent and can alter the balance between 
proteases and anti-proteases, thereby contributing further to cellular damage and 
dysfunction 219-221. Thus neutrophils are essential components of IRI and oxidative 
stress due to their close proximity to endothelial cells and tissue epithelial cells which 
they can damage during tissue infiltration, and other leukocytes which they may 
influence/polarise 105,222-233.  
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Figure 1-10. Neutrophil degranulation and oxidative burst. The binding of CXCL8 to its 
receptors CXCR1/CXCR2 on the surface of the neutrophil induces transduction of the signal 
through G-proteins. This can lead to either the coupling of β-arrestin to both the receptor and 
primary/secondary granules leading to their translocation and exocytosis, or can lead to 
signalling through IP3 resulting in an increase in intracellular calcium and the subsequent 
mobilisation of primary/secondary/tertiary granules or secretory vesicles. The neutrophil 
oxidative burst, which comprises of the production of reactive oxygen species (ROS) including 
OH-, HClO, OCl- and H2O2 by NADPH oxidase and MPO is also shown. Abbreviations: aa = amino 
acids, ER = endoplasmic reticulum, IP3 = inositol 1, 4, 5-triphosphate, MMP-9 = matrix 
metalloprotease-9, MPO = myeloperoxidase, NADPH = nicotinamide adenine dinucleotide 
phosphate oxidase. 
 
1.6.4 Neutrophil Extracellular Traps (NETs) 
Neutrophil activation by CXCL8, microbes, bacteria, viruses, yeast or parasites can also 
can also induce a novel anti-pathogenic function known as neutrophil extracellular 
traps, or NETs 234. These NETs comprise of anti-microbial granules concentrated in a 
web of extracellular fibres composed of deoxyribonucleic acid (DNA) and histones 204,219. 
Three models for the production of NETS, or NETosis, have been described. Suicidal 
NETosis involves activation of the cell, decondensation of chromatin, and ROS-mediated 
loss of the nuclear membrane, then formation of NETs through the translocation of 
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elastase and MPO from granules to the nucleus. Vital NETosis occurs through cell 
activation via toll-like receptors (TLRs) or the complement receptor for C3, occurs 
independently of ROS, and the loss of DNA does not affect the neutrophil lifespan. The 
final model is a variation of vital NETosis that occurs in response to neutrophil 
stimulation by C5a or LPS, is ROS-dependant, and involves the release of mitochondrial 
DNA as opposed to nuclear DNA. The NETs are then released from the cells through lysis 
or membrane pores 234. 
NETosis has been implicated in the pathology of a range of diseases including systemic 
lupus erythematosus 235, rheumatoid arthritis 236,237, type 1 diabetes mellitus 238 and 
ulcerative colitis 239 amongst others.  
1.6.5 Resolution of Inflammation 
Neutrophils can also contribute to the resolution of inflammation. Ageing neutrophils 
express higher levels of CXCR4, which traffics them back to the bone marrow for 
clearance, and also inhibits the release of further neutrophils out of the bone marrow 
and into the circulation. Neutrophils can also be cleared in the intestinal tract, and 
within the liver circulation by Kupffer cells (resident macrophages) in a process 
involving a balance of IL-17, IL23 and C-GSF. Upon apoptosis, neutrophils enhance their 
own clearance and phagocytic destruction by macrophages through self-opsonisation 
with molecules such as phosphatidylserine and altered lipids 240, and inhibit the 
recruitment of more neutrophils by releasing lactoferrin and annexin A1 241. 
Phagocytosis of these dying neutrophils by macrophages stimulates them to release 
TGF-β, IL-10 and resolvins, all of which act to promote fibrosis and reduce inflammation 
242,243. 
Neutrophil activity is a double-edged sword; infections occur if the neutrophil response 
is deficient or absent as in neutropoenic conditions, but excessive recruitment or 
degranulation is also detrimental, as is the case in conditions such as asthma, septic 
shock and inflammatory arthritis 204, therefore the function of CXCL8 in recruiting these 
cells must be tightly regulated. We aim to study how post-translational nitration of 
CXCL8 affects neutrophil function. 
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1.7 THE ROLE OF CXCL8 AND NEUTROPHILS IN INFLAMMATION AND 
DISEASE 
Increases in CXCL8 expression, both circulating and localised to specific tissue, have 
been reported and implicated in the pathophysiology of many diseases. CXCL8’s primary 
function is the recruitment of neutrophils to sites of damage and inflammation, thereby 
facilitating neutrophil involvement in multiple pathologies. 
1.7.1 Respiratory Diseases 
CXCL8 secreted by airway smooth muscle cells has been shown to drive steroid-
resistant neutrophilic airway inflammation in asthma patients 244 and cystic fibrosis 
patients 245. CXCL8 production has been linked to the inflammation driving chronic 
obstructive pulmonary disease 246, and cigarette smoke was shown to stimulate CXCL8 
production by neutrophils 247. The levels of CXCL8 detectible in bronchoalveolar lavage 
samples from patients suffering from acute respiratory distress syndrome as a result of 
tuberculosis also directly correlated with disease severity 248. 
1.7.2 Neurological Diseases 
CXCL8 is implicated in the pathology of neuroinflammation and neurodegeneration 
within the central nervous system. CXCL8 expression is increased in HIV-1 positive 
patient serum, plasma, cerebrospinal fluid and brain lysates in comparison to controls 
249-252. Sources of the CXCL8 produced during HIV infection include astrocytes, microglia 
and human brain microvascular endothelial cells 253. Actrocytes, microglia and neurons 
also produce CXCL8 in response to amyloid-β, hence CXCL8’s elevated expression in 
Alzheimer’s disease 254,255. CXCL8 has also been detected in the cerebrospinal fluid and 
serum from multiple sclerosis patients during periods of relapse 256.  
In all cases, CXCL8 mediates the recruitment of neutrophils and monocytes across the 
blood-brain barrier, where they potentiate inflammation. 
1.7.3 Organ Transplantation 
Serum levels of CXCL8 have been shown to be elevated in cardiac transplant patients 5 
minutes post-reperfusion in comparison to those of elective cardiac surgery patients 257. 
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This CXCL8 is thought to be produced by cardiac endothelial cells due to the extended 
period of hypothermic ischaemia experienced during transplant surgery.  
1.7.4 Cancers 
CXCL8 is often implicated in the pathogenesis of many cancers. It has been shown to be a 
major chemoattractant for myeloid-derived suppressor cells (MDSCs) 258,259, and N2-like 
immunosuppressive tumour-associated neutrophils 260 , which migrate into the tumour 
environment and inhibit T-cell anti-tumour responses . CXCL8 also induces granulocytic 
neutrophil-like GrMDSCs to release NETs, which are implicated in thrombus formation 
and metastasis 261,262. CXCL8 derived from tumour-associated macrophages has been 
linked to progression and metastasis in papillary thyroid carcinoma 263 and endometrial 
carcinoma 264 . 
Increased expression of CXCL8 has been linked to worse prognosis and outcomes in 
cases of hepatocellulcar carcinoma (due to its activation of AKT/mTOR/STAT3 
pathways which lead to disease progression and metastasis) 265, and in colorectal cancer 
(due to its promotion of angiogenesis and inhibition of anoikis/apoptosis) 266. Similar 
patterns have been observed in lung cancer, prostate cancer, renal cell carcinoma, 
pancreatic cancer, gastric cancer, ovarian cancer and lymphomas 267 . 
1.8 HYPOTHESIS 
As the production of peroxynitrite and its precursor molecules increase during 
inflammation, and as most of the studies performed to date have shown that nitration of 
chemokines impairs their ability to recruit leukocytes, we hypothesise that chemokine 
nitration (and nitration of CXCL8 specifically), is anti-inflammatory, and occurs during 
times of stress/injury where it acts as a negative regular of inflammation to dampen the 
immune response. 
Simply attempting to measure levels of wild type chemokines does not reflect the 
complexity of the chemokine system, and may not give an accurate portrayal of the 
inflammatory situation 268. The heterogeneous nature of post-translational 
modifications emphasises the need for better understanding of these signalling 
molecules and their variants, with some modifications enhancing/abrogating function, 
and others preventing detection using conventional methods. 
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1.9 SPECIFIC AIMS OF THIS STUDY 
Better understanding of the presence and function of post-translationally nitrated 
chemokines is essential if their potential as therapeutic agents or biomarkers is to be 
actualized.  
1. Characterise the biological activity of chemokines and variants in vitro and in 
vivo ~ I aimed to use wild type, nitrated, mutant and nitrated mutant versions of CXCL8 
in trans-filter, trans-endothelial and in vivo chemotaxis models to assess chemotactic 
function. I aimed to assess GAG binding and GPCR signalling properties of these 
chemokine variants, via surface plasmon resonance (SPR) and calcium flux assays 
respectively.  
2. Develop a method to detect nitrated CXCL8 ~ I aimed to develop an antibody to 
detect nitrated CXCL8 specifically, and to use this antibody to develop an ELISA to 
measure the levels of wild type and nitrated CXCL8 in serum samples from patients with 
a range of diseases. I also aimed to use this antibody to detect wild type and nitrated 
CXCL8 in tissue biopsies from these patients using immunofluorescence staining. 
3. Determine how stress affects CXCL8 production and nitration ~ I aimed to examine 
how different stresses affect the gene and protein expression of CXCL8 in different cell 
types. I aimed to purify and analyse the CXCL8 produced via mass spectrometry for post-
translational modifications. 
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2 MATERIALS AND METHODS 
2.1 LABORATORY PROCEDURE 
All experiments and laboratory work was carried out according to the Control of 
Substances Hazardous to Health (COSHH) and BioCOSHH regulations, and according to 
the University Safety Policy and Newcastle University’s “Safe Working with Biological 
Hazards” and “Safe Working with Chemicals in the Laboratory” guidelines. Cell culture 
work was performed according to the regulations for the containment of class II 
pathogens. Any animal work was approved by the Home Office UK and was carried out 
under project license number 66/4497, protocol number 19b2/19b4. All human tissue 
samples accessed were covered under REC reference number 11/NE/0352. 
2.2 NITRATION OF CHEMOKINES 
Our collaborator Professor Krishna Rajarathnam (University of Texas, Medical Branch), 
kindly provided us with nitrated and non-nitrated CXCL8 and CXCL1 variants. These 
included Y13F CXCL8 and L15Y CXCL1. For the nitrated CXCL8, Y13F CXCL8, CXCL1 and 
L15Y CXCL1 the chemokines at concentrations of 1mg/ml were incubated with 1mM 
peroxynitrite for 15 minutes at 37°C, then dialysed overnight against water. A sample 
was tested using matrix-associated laser desorption/ionisation time-of-flight (MALDI-
TOF) mass spectrometry to ensure nitration was successful. NMR analysis was also 
performed by the group to ensure that incubation with peroxynitrite had not damaged 
the 3D structures of the molecules. These chemokine variants were received from our 
collaborator as lyophilised powder, resuspended to 1μg/ml in sterile PBS and 
immediately stored in 2μl aliquots at -80°C. Each aliquot was defrosted once only for 
use. 
Nitrated CXCL8 was also created in collaboration with Professor Paul Proost 
(Laboratory of Microbiology and Immunology, Rega Institute, KU Leuven). This was 
achieved by three consecutive incubations of 1mg/ml recombinant CXCL8 (72aa) with 
2mM, 2mM and 4nM peroxynitrite for 1 minute each at room temperature. A sample 
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was tested using ion trap mass spectrometry (methods will be discussed later in section 
3.2.7), to confirm that >90% of the sample was nitrated. 
2.3 CELL CULTURE 
2.3.1 General Principles 
All media (if complete) was supplemented with 5-15% Foetal Bovine Serum (FBS), 2mM 
L-Glutamine, 100 U penicillin and 0.1mg/ml streptomycin. Serum-free media consisted 
of 0.1% BSA in RPMI-1640, with 2mM L-Glutamine, 100 U penicillin and 0.1mg/ml 
streptomycin. Cells were cultured at 37°C with 5% C02.  
2.3.2 C1 and C4 Hybridomas  
Abmart provided two colonies (C1 and C4) of mouse hybridoma cells producing an 
antibody raised against wild type and nitrated human CXCL8 peptides. The sequences of 
these peptides are shown below. Cells were grown in complete DMEM Ham’s F-12 with 
1ng/ml IL-6 and 5% normal or charcoal IgG-stripped FBS.  
C1 peptide: Ac-QCIKTY(NO2)SKP-NH2 
C4 peptide: Ac-IKTY(NO2)SKPFHPC-N 
2.3.3 HMEC-1 Cells 
HMEC-1 cells are a human microvascular endothelial cell line 269, and were grown in 
complete MCDB-131 media (ThermoFischer Scientific) (15% FBS) supplemented with 
10ng/ml EGF and 1µg/ml hydrocortisone. Cell morphologies in culture are shown below 
in Figure 2-1. 
2.3.4 AC10 Cells 
AC10 cells are primary human ventricular cardiomyocytes fused with simian virus 40-
transformed human fibroblasts 270. These cells were all grown in complete DMEM media 
(ThermoFischer Scientific) with 12% FBS. Cell morphologies in culture are shown below 
in Figure 2-1. 
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2.3.5 MCF-7 Cells  
MCF-7s are epithelial breast cancer cells derived from a pleural effusion from an 
invasive ductal carcinoma. They are oestrogen and progesterone receptor positive and 
human epidermal growth factor receptor 2 (HER2) negative 271. These cells were all 
grown in complete DMEM media without phenol red (ThermoFischer Scientific), with 
8mM L-Glutamine, and with 10% FBS. Cell morphologies in culture are shown below in 
Figure 2-1. 
2.3.6 MDA-MB-231 Cells  
MDA-MB-231 cells are also epithelial breast cancer cells derived from a pleural effusion 
from an invasive ductal carcinoma. They are oestrogen and progesterone receptor 
negative and HER2 negative, therefore they are representative of triple negative breast 
cancer 272. These cells were all grown in complete DMEM media without phenol red 
(ThermoFischer Scientific), with 8mM L-Glutamine, and with 10% FBS. Cell 
morphologies in culture are shown below in Figure 2-1. 
2.3.7 Primary Human Neutrophils 
Primary neutrophils were isolated from healthy donor blood using a Percoll gradient 
(performed by Professor John Simpson’s group), and were rested for 1 hour in serum-
free RPMI at 37˚C and 5% CO2 before being used in any experiments 273. 
2.3.8 Mycoplasma Testing and Treatment 
MycoAlert™ Mycoplasma Detection Kit (Lonza) was used to test for the presence of 
mycoplasma in cultured cells – following the manufacturer’s instructions. Results were 
read on a luminometer, values of <0.9 were considered negative for contamination, for 
values of 0.9-1.2 it was recommended that cells were quarantined for 24h then retested, 
and values of >1.2 were classed as positive for contamination. MycoZap™ Mycoplasma 
Elimination Reagent (Lonza) was used to treat infected C4 cells as per kit instructions. 
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Figure 2-1. Cell morphologies. The morphologies of AC10, HMEC-1, MCF-7 and MDA-MB-231 
cells in culture. Images taken at 10x magnification. 
2.4 FLOW CYTOMETRY 
2.4.1 General Principles 
Flow cytometry is a technique that measures light scattering and often emission from 
fluorochromes, to analyse single cells as they pass through a laser in a fluid stream.  
The way light is reflected and refracted by cells is dependent upon their size and 
internal structure. Optical detectors measure this light, and convert it into electrical 
pulses in order to give information on the physical characteristics of the cells. Forward 
Scatter (FSC) is a parameter calculated from light scattered in the forward direction of 
the laser and is related to cell size and shape. Side Scatter (SSC) is calculated based on 
light scattered in a direction perpendicular to the beam of the laser, and is related to the 
granularity/contents of the cell. Combining these two parameters can help identify cell 
types. 
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Cells can also be labelled with dyes or fluorochrome-conjugated antibodies to detect 
markers expressed on the surface of the cell. Stimulating fluorochromes at specific 
wavelengths causes excitation, which results in the emission of lower energy and longer 
wavelength light. This emitted light is detected and split by wavelength into individual 
colours. Ideally, a panel of fluorochromes should be selected so that their 
emission/excitation wavelengths are sufficiently separated to allow the detection of 
each fluorochrome individually, as if not there is a chance that the signal of one 
fluorochrome will be artificially increased by photons from the peripheral spectrum of 
another fluorochrome. In addition, fluorochromes can emit a spectrum that will activate 
different detectors to different extents (as opposed to a single wavelength). 
Compensatrion algorithms can be applied in order to minimise this – and for these 
experiments OneComp eBeads (Affymetrix) were used 274.  
2.4.2 Counting Cells  
This method was used to count the number of neutrophils migrated during in vitro 
chemotaxis assays. CountBright Absolute Counting Beads (Life Technologies) were 
brought to room temperature and vortexed. 8μl of beads (or 8000 beads) was then 
added to 200μl of cell suspension from each sample in flow cytometry tubes (BD Falcon) 
and vortexed. Samples were analysed using a FACS Canto II flow cytometer with 1000 
bead events set as the stopping gate. Calculations were performed as per the bead 
manufacturer’s instructions to determine total number of migrated cells per µl as a ratio 
to beads, which was extrapolated out to calculate the percentage of the total number of 
cells that had migrated.  
2.4.3 Cell Characterisation 
This method was used to assess adhesion molecule expression by HMEC-1 cells 
following TNF-α treatment, and to characterise the murine cells migrated during in vivo 
chemotaxis assays. Following centrifugation, cells were resuspended in 100µl of flow 
cytometry buffer (PBS + 2% BSA). Samples were incubated for 1 hour at 4˚C with 
antibodies to detect cell surface markers (all directly conjugated to fluorophores, see 
Table 2-2) at concentrations recommended by the manufacturers. Cells were washed 
twice by centrifugation in flow cytometry buffer. Cells were then stained with a 
live/dead marker. For the air pouch model, the cells were then stained with DAPI at 10% 
of sample volume and analysed using a FACS Canto II flow cytometer. For the 
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intraperitoneal recruitment model, the cells were stained with Sytox Red (1µl added per 
tube and incubated for 15 minutes room temperature) and then analysed and counted 
on the BD Accuri C6 flow cytometer. 
In order to perform compensation, one drop of OneComp eBeads (Affymetrix) was 
added to 100µl containing each antibody individually. Compensation values were 
calculated using the FACSDiva wizard and were then applied to all samples as part of 
gating and analysis using FlowJo V10 software, and the gating strategy used to 
characterise murine cells is shown in Figure 2-2 as an example. 
 
Figure 2-2. Cell characterisation gating strategy. Sequential gating strategy used to analyse in 
vivo peritoneal lavage samples. The monocyte gate is indicated by the blue arrow, and the 
neutrophil gate by the red arrow. 
2.5 WESTERN BLOTTING 
2.5.1 General Principles 
This method involves the use of antibodies to detect a target protein in a sample. The 
sample is denatured and loaded onto an SDS gel to be separated by size (recipes shown 
in Table 2-1). The proteins are then transferred from the gel onto a nitrocellulose 
membrane and detected by chemiluminescence using a primary antibody, secondary 
antibody and an appropriate enzyme-substrate combination. 
2.5.2 Cell Treatment and Lysis 
This method was used to detect ERK phosphorylation as another downstream result of 
GPCR activation in primary human neutrophils stimulated with CXCL8 or CXCL8 
variants.  
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Primary human neutrophils were isolated as described previously, then resuspended in 
serum-free RPMI (2x106 cells in 1ml per treatment tube) and rested for 1 hour at 37˚C 
prior to treatment. Cells were then treated and placed immediately on ice. Cells were 
then centrifuged at 400xg for 5 minutes, washed with ice-cold PBS, and each pellet was 
resuspended in 200μl cell lysis buffer (10ml CellLytic M (Sigma)) plus 1x PhosSTOP™ 
phosphatase inhibitor tablet (Roche) and 1x cOmplete™ protease inhibitor tablet 
(Roche)) on ice for 10 minutes with intermittent vortexing. The CelLytic M 
lysis/extraction reagent contains a low percentage of a mild detergent for minimal 
interference with protein interactions and biological activity. The detergent can be 
dialyzed out as needed and is supplied in a bicine buffer which is suitable for evaluation 
of biological activity.  The supplier withholds the identity of the detergent. After 
incubation cells were centrifuged at 15000xg for 10 minutes at 4˚C, DNA and cell debris 
was pelleted, and the lysate supernatant containing the protein was removed and stored 
at -20˚C. 
2.5.3 Protein Quantification - Bicinchoninic Acid (BCA) Assay 
To quantify the total protein in the lysates, a Bicinchoninic Acid (BCA) assay kit 
(ThermoFisher Scientific) was used. This assay is based on the Biuret reaction (where 
peptide bonds reduce Cu2+ to Cu1+ in an alkaline solution), and forms a purple colour as 
the BCA chelates with Cu1+. The absorbance at 562nm can then be measured on a 
spectrophotometer using a range of protein standards to calculate the protein 
concentrations of each lysate. 
BSA standard concentrations (0, 125, 250, 500, 1000, 2000μg/ml) were diluted in lysis 
buffer and added in triplicate to a 96 well plate (10μl per well). Neat sample lysates, and 
lysates diluted 1/5 in lysis buffer were also added to the plate in duplicate. Reaction 
buffer was prepared as per the manufacturer’s instructions and 200μl was added to each 
well and incubated at 37˚C for 30 minutes before the absorbance at 562nm (with 
wavelength correction) is measured on a Synergy plate reader using Gen5 software 
(BioTek). The unknown protein concentration of the samples is then calculated using a 
standard curve created from the BSA standard concentrations and nonlinear regression. 
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2.5.4 SDS-PAGE Gel Electrophoresis 
Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE) is a method 
used to separate protein molecules according by size as they move through a porous 
acrylamide gel 275. Samples (either cell lysates, human serum, or other patient sample 
types) were mixed with 15μl 4x loading buffer with β-mercaptoethanol (Bio-Rad) and 
lysis buffer to a total volume of 60μl. Due to the addition of β-mercaptoethanol to the 
samples, all experiments were performed under reducing conditions. The volume of 
each sample used was calculated using the concentration measured in the BCA assay so 
as to load the maximum amount of protein (equivalent in all samples) onto the gel. 
Samples were then denatured by heating in a T100™ Thermocycler (Bio-Rad) at 99˚C for 
10 minutes. This destroys the tertiary structure of the proteins by breaking the 
disulphide bonds, allowing the SDS in the gel (recipe for making the gels is described in 
Table 2-1) to associate with the resulting polypeptide chains so that charge is 
proportional to protein size. The samples were then loaded into the wells of the gel, 
along with a well containing 8μl of PageRuler™ protein ladder (ThermoFisher Scientific). 
When an electrical charge is applied to the gel (in a tank with electrophoresis buffer 
(25mM Tris, 250mM glycine, 0.1% SDS)), these proteins will then migrate through the 
gel towards the anode, with smaller proteins running faster than large proteins. Gels 
were run at 180v for 45 minutes – 1 hour.  
Resolving Gel (10%, 10ml) Resolving Gel (18%, 10ml) Stacking Gel (5%, 3ml) 
4ml dH2O 1.25ml dH2O 4.1ml dH2O 
3.3ml 30% Acrylamide 6ml 30% Acrylamide 1ml 30% Acrylamide 
2.5ml 1.5M Tris-HCl pH 8.8 2.5ml 1.5M Tris-HCl pH 8.8 750μl 0.5M Tris-HCl pH 6.8 
100μl 10% SDS 100μl 10% SDS 60μl 10% SDS 
100μl 10% APS 100μl 10% APS 60μl 10% APS 
4μl Electran (TEMED) 10μl Electran (TEMED) 6μl Electran (TEMED) 
Table 2-1. Recipes for a 10% or 18% resolving gel and 5% stacking gel. 
For examining the protein composition of samples, protocols for silver staining (section 
2.5.5) or coomassie blue staining (section 2.5.6) were performed.  
For immunoblotting, following gel electrophoresis proteins were transferred from the 
gel onto a nitrocellulose membrane with 0.2µM pores (Trans-Blot® Turbo# Mini 
Nitrocellulose Transfer Packs, Bio-Rad) using a 10 minute dry transfer method and the 
Trans-Blot® Turbo™ Transfer System (Bio-Rad) as per the manufacturer’s instructions.  
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2.5.5 Silver Staining  
This method was used to test the protein composition of lung samples (listed below) 
(which were run through SDS-PAGE Gel Electrophoresis as described above, but using a 
pre-cast Novex™ 16% Tris-Glycine WedgeWell™ Mini Gel (ThermoFisher Scientific), 
along with a well containing 5μl of Mark12™ Unstained Standard (ThermoFisher 
Scientific) protein standard. Protein components were separated by size, then visualised 
in comparison to a range of standard protein size markers using a silver stain. The gel 
was stained using the SilverQuest™ Silver Staining Kit (ThermoFisher Scientific) as per 
the manufacturer’s instructions. Briefly, the gel was incubated in fixing solution for a 
minimum of 1 hour, washed with 30% ethanol for 10 minutes and incubated in a 
sensitising solution for 10 minutes. The gel was then washed with 30% ethanol followed 
by MilliQ ultrapure water for 10 minutes each, stained for 15 minutes, washed with 
MilliQ water for 20-60 seconds, then developed for 4-8 minutes before being stopped by 
the addition of a stopping solution. After a final wash in MilliQ water, the gel was 
imaged. 
 2x bronchoalveolar lavage samples from lung transplant patients 
 2x bronchoalveolar lavage samples from ventilator-associated pneumonia 
patients 
 1x bronchoalveolar lavage sample from a patient with inhaled chemical burns 
 2x samples from primary nasal musosa/polyp cell secretomes 
 2x samples of perfusate from ex vivo perfused lungs 
2.5.6 Coomassie® Blue Staining  
Similarly to silver staining above, this protocol was used to visualise protein bands on a 
gel. Gels were placed in Coomassie® Blue solution (0.1% Coomassie® R-250 in 40% 
ethanol, 10% acetic acid (ThermoFisher Scientific)) and microwaved for 1 minute, then 
placed on an orbital shaker for 15 minutes at room temperature. The gel was rinsed in 
deionised water, then placed in de-staining solution (10% ethanol and 7.5% acetic acid) 
and microwaved for 1 minute, followed by orbital shaking again until the desired 
staining was achieved. 
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2.5.7 Immunoblotting  
Following transfer, the membrane (now with transferred proteins) was rinsed in PBS 
and placed in block solution (5% BSA in TBS+0.1% Tween-20) for 1 hour at room 
temperature on an orbital shaker. The membrane was then incubated with primary 
antibodies diluted in blocking solution overnight at 4˚C, again on an orbital shaker. The 
membrane was then washed 3x for 5 minutes each in TBS+0.1% Tween-20, and 
incubated with relevant secondary antibodies (HRP-conjugated or biotinylated) diluted 
in block solution for 1 hour at room temperature. If a biotinylated secondary antibody 
was used, the membrane was washed 3 times and incubated with streptavidin-HRP 
(R&D Systems) diluted in block solution at 1/40 for 30 minutes at room temperature. 
Following 3 more washes, membranes were incubated with ECL chemiluminescent 
substrate (SuperSignal West PicoSubstrate, Thermo Scientific) for 5 minutes and signal 
was detected using film (Kodak) developed in ready-made developer and fixer 
(Tentenal, Germany). 
2.5.8 Dot Blots 
This method was used to test the specificity of antibodies, and is similar to a Western 
blot except that protein is directly pipetted onto a nitrocellulose membrane with 0.2µM 
pores (Bio-Rad) in 2µl dots, and left to air dry for 30 minutes. The protocol for detection 
and development then continues as described in section 2.5.7. 
2.6 IMMUNOHISTOCHEMISTRY AND IMMUNOFLUORESCENCE 
2.6.1 General Principles 
Immunohistochemistry involves the use of antibodies against specific markers to detect 
cell types/expression of antigens in fixed/frozen tissue or cells. Immunohistochemistry 
uses enzymes such as horseradish peroxidase or alkaline phosphatase which metabolise 
substrates and give off a colour in order to indicate the presence of the marker, whereas 
immunofluorescence relies on detection using fluorochromes conjugated to antibodies.  
2.6.2 Immunofluorescence  
Samples were fixed in 4% PFA overnight, then embedded in paraffin and cut into 4µm 
sections using standard microtomy. Following de-paraffinisation in xylene (2x 5 minute 
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immersions) and rehydration through graded ethanol (99%, 95%, 70%, H2O), antigen 
retrieval was performed using 10mM Citrate buffer pH 6 or Tris EDTA pH 8 in a 
pressurised environment for 2 minutes, or by incubation in 0.05% Trypsin solution with 
0.1% calcium chloride for 10 minutes in a water bath at 37˚C. Slides were then washed 
and blocked for 30 minutes in a 20% solution of the serum of the secondary antibody 
species diluted in PBS. Slides were then incubated overnight at 4˚C or 1 hour at room 
temperature with primary antibody, washed 3 times for 5 minutes each in PBS+0.1% 
Tween-20, and incubated for 2 hours at room temperature with secondary antibody. 
Following a further 3 washes, slides were incubated in 0.1% Sudan Black B in 70% EtOH 
to reduce any tissue autofluorescence, washed 3 times, mounted with VECTASHIELD 
Antifade Mounting Medium with DAPI (Vectorlabs), and sealed with nail polish. Slides 
were stored wrapped in foil at 4˚C. All antibodies were diluted in PBS, details can be 
found in Table 2-2. Images were taken using a Zeiss AxioImager with Apotome enabled 
or Nikon A1 Upright confocal microscope. 
Frozen sections or chamber slides were fixed in ice-cold methanol for 5 minutes at -
20˚C, then protocol carried out as normal from the addition of the serum block. 
2.6.3 Immunohistochemistry – Haematoxylin and Eosin Staining  
For paraffin-embedded tissue sections, the same de-paraffinisation and rehydration 
protocol described in section 2.6.2 was followed. Slides were incubated in Haematoxylin 
for 1 minute and 20 seconds, then washed for 1 minute in running tap water. Slides 
were then “blued” briefly in Scotts’ tap water before being washed again in running tap 
water for a further 2 minutes. Slides were then stained with Eosin for 30 seconds, before 
being briefly washed and rapidly dehydrated through graded ethanol (70%, 95%, 99%). 
Slides were then cleared in xylene and mounted in DPX. 
2.7 ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISA) 
2.7.1 General Principles 
An enzyme-linked immunosorbent assay (ELISA) is a widely used method of detecting 
and quantifying specific proteins in a sample. The principle involves the sample being 
bound to the wells of a plate (if using a direct method) or to a capture antibody, which is 
bound to the plate (if using a sandwich method). The bound protein is detected using 
52 
 
another antibody, and the reaction developed using an enzyme, which produces a colour 
as it metabolises its substrate.  The optical density of this colour change can then be 
measured by spectrophotometry. The optical density of a range of protein standards 
(known concentrations) is used to create a standard curve, from which the 
concentrations of the protein of interest in the samples are derived in relation to their 
optical densities. 
2.7.2 ELISA Protocol 
For a sandwich ELISAs, Immulon HB4X plate (ThermoFisher Scientific) were coated 
with a capture antibody diluted in coating buffer (15mMNa2CO3, 35mMNaHCO3, pH9.6) 
overnight at room temperature, and then blocked for 1 hour at room temperature with 
5% BSA in PBS + 0.05% Tween20 to prevent non-specific interactions. Samples and 
standards were added to the plate and incubated at room temperature for 2 hours, 
followed by incubation with a detection antibody at room temperature for 2 hours. The 
detection antibody was either directly conjugated to horseradish peroxidase (HRP) 
enzyme or biotinylated. If a biotinylated antibody was used, the plate was then 
incubated with streptavidin-HRP (1/40, R&D Systems). The plate was washed with PBS 
+ 0.05% Tween20 between each of these steps, and unless specified otherwise all 
reagents used were added to the plate in dilutent solution (a 1/10 dilution of block 
solution in wash solution). The reaction was then developed using TMB or OPD 
substrate solution (R&D Systems), and stopped when the colour intensity was deemed 
optimal by adding 1M H2SO4. The optical density of the plate was then read at 450nm for 
TMB development, or 492nm for OPD development, both with wavelength correction on 
a Synergy plate reader using Gen5 software (BioTek). 
For a direct ELISAs, a capture antibody was not used, as the sample were directly coated 
onto the plate (diluted in coating buffer) and incubated overnight at 4°C. The detection 
protocol then proceeds from the blocking step as described above. 
2.8 RNA ISOLATION AND COMPLIMENTARY DNA SYNTHESIS 
In order to minimise contamination, all reagents used were RNase free, and only sterile 
filter tips and sterile autoclaved tubes were used. 
53 
 
2.8.1 RNA Isolation and Analysis 
RNA was isolated from the cells using RNeasy Pro Kit (Qiagen) as per the manufacturer’s 
instructions. The RNA collected was then run on a 1% agarose gel (50ml tris-acetate-
EDTA (TAE) buffer, 0.5g agrose and 0.5μg/ml ethidium bromide) (TAE buffer contains 
40mM Tris, 20mM acetic acid and 1mM EDTA at pH8.0). The gel was then visualised on 
an AlphaImager (Alpha Innotech) to check RNA integrity.  
2.8.2 cDNA Synthesis 
Complimentary DNA (cDNA) was then synthesised from 1μg of RNA from each sample, 
using a Tetro cDNA Synthesis Kit (Bioline), as per the manufacturer’s instructions. The 
reaction mix was placed in a T100™ Thermocycler (Bio-Rad), which was run at 45°C for 
30 minutes, then 85°C for 5 minutes and finally 4°C for 15 minutes. 
2.9 REAL-TIME QUANTITATIVE REVERSE TRANSCRIPTION POLYMERASE 
CHAIN REACTION (RT-QPCR) 
2.9.1 General Principles 
Polymerase Chain Reaction (PCR) is a semi-quantitative technique used to amplify the 
quantity of a specific gene of interest within a sample by using primers specific for this 
gene, which can then be visualised and compared to a “housekeeping” endogenous 
control gene by gel electrophoresis.  
Real-time quantitative PCR (RT-qPCR) is quantitative, as DNA products are detected as 
they are produced by means of a fluorescent signal generated by primer/probes. These 
primer/probes have a fluorescent reporter dye attached to the 5’ end, and a 
fluorescence quencher attached to the 3’ end. In its intact state, the fluorescent signal of 
the primer/probe is quenched, but during the elongation steps of the PCR reaction, the 
reporter dye is cleaved away from the quencher by the polymerase enzyme, meaning its 
signal is detectable, and will increase with each cycle in proportion to the amount of PCR 
product created. 
Firstly an initiation step takes place in order to activate the polymerase enzyme, then 
the reaction progresses as a series of repeated cycles each containing the same series of 
steps involving heating/cooling as shown in Figure 2-3. The denaturing step involves 
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breaking of the hydrogen bonds within the cDNA to create single-stranded cDNA, the 
annealing step then involves the binding of the primer/probes to their target genes on 
the single-stranded cDNA template, and the elongation step then involves the 
polymerase enzyme synthesising a new DNA strand.  
Each cycle consists of two phases; an exponential amplification phase where the 
production doubles, then a plateau phase whereby exhausted resources mean that the 
production levels off. The threshold cycle (Ct) value (which is defined as the cycle 
number where the level of fluorescence detected passes a defined threshold) is key for 
quantifying gene expression. A low Ct value means that few cycles were required in 
order to pass the fluorescence threshold, meaning there was a large amount of this 
cDNA product already present in the sample, i.e. gene expression was high. A high Ct 
value would indicate low gene expression. 
2.9.2 Protocol 
A reaction mix was created (a 20μl total volume containing 1μl cDNA, 1μl TaqMan® 
primer/probe, 10μl of SensiFast Probe Hi-ROX Mix (Bioline), 8μl sterile water) and run 
on a StepOnePlus real-time PCR machine (Applied Biosystems). Running steps were:  
- 95°C for 20 seconds to activate the polymerase 
-  95°C for a further 1 second to denature the cDNA 
-  60°C for 20 seconds to facilitate annealing and elongation.  
These steps were repeated for 40 cycles. 
2.9.3 Analysis 
The data was analysed by using the Ct values reported from the RT-qPCR reaction to 
calculate ΔCt (mean target gene Ct – mean endogenous control gene Ct), ΔΔCt (treated 
sample ΔCt – control sample ΔCt), and therefore fold change in gene expression (2-ΔΔCt). 
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Figure 2-3. RT-qPCR with TaqMan® primer/probes. Denaturing of the DNA is followed by 
annealing of the primer/probes to the single-stranded cDNA. The polymerase enzyme then 
extends the strand, using the cDNA template strand, and in the process cleaves the probe 
allowing the fluorescent reporter to move away from the quencher, thus allowing its signal to be 
detected. The fluorescence detected is proportional to the amount of PCR product synthesised. 
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2.10 ANTIBODIES USED 
Antibodies used in ELISAs, Western blots, dot blots, flow cytometry and 
immunofluorescence are shown below in Table 2-2. 
Method Company Product 
Code 
Antibody Type [Working] 
IF Collaborator  10-E4 clone Anti-human Heparan 
Sulphate 
1/100 
(polyclonal) 
IF Immunoreagents GtxRb-003-
D550NHSX 
Goat anti-rabbit-DyLight®550 
conjugated secondary 
5μg/ml 
IF Immuno 
reagents 
GtxRt-003-
E488NHSX 
Goat anti-rat-DyLight®488 
conjugated secondary antibody 
5μg/ml 
IF Immuno 
reagents 
GtxMs-003-
E488NHSX 
Goat anti-mouse-DyLight®488 
conjugated secondary antibody 
5μg/ml 
IF, ELISA/ 
Blot 
Millipore 06-284 Anti-3-Nitrotyrosine polyclonal 1μg/ml, 
2μg/ml  
IF, ELISA/ 
Blot 
Abcam Ab61392 Anti-3-Nitrotyrosine monoclonal 1μg/ml, 
10μg/ml  
IF Biolegend 127623 Anti-mouse-Ly6G 1μg/ml  
IF, ELISA/Blot Life 
Technologies 
AHC0881 Anti-human-CXCL8 0.2μg/ml, 
1μg/ml 
Western Blot ThermoFisher 
Scientific 
36-8800 Anti-human-pERK1/2 1/5000 
(polyclonal) 
Western Blot - - Serum from Primary Billiary 
Cirrhosis patients (containing 
antibodies against pyruvate 
dehydrogenase complex 2 (PDC-E2) 
1/5000 
Western Blot Sigma AP112P Anti-human-HRP secondary 
antibody 
1/5000 
ELISA/Blot Sigma M-8144 Anti-mouse-IgG1 1/1000 
ELISA/Blot Sigma M-8269 Anti-mouse-IgG2a 1/1000 
ELISA/Blot Sigma M-8394 Anti-mouse-IgG2b 1/1000 
ELISA/Blot Sigma M-9924 Anti-mouse IgG3 1/1000 
ELISA/Blot Sigma A3673 Anti-mouse IgG-HRP secondary 
antibody 
1/5000 
ELISA/Blot Sigma A6154 Anti-rabbit-HRP secondary antibody 1/5000 
ELISA/Blot Sigma A5420 Anti-goat-HRP secondary antibody 1/5000 
ELISA/Blot Bio-Rad MCA1396B Biotinylated anti-histidine6 
secondary antibody 
1μg/ml  
Chemotaxis Abcam Ab89251 Anti-huamn-CXCR1 20μM 
Chemotaxis Abcam Ab10401 Anti-human-CXCR2 20μM 
Flow 
Cytometry 
Abcam Ab25603 PE conjugated anti-mouse-CD45 0.2µg /100µl 
Flow 
Cytometry 
eBioscience 11-0141-82 FITC conjugated Anti-mouse-CD14 0.5µg/100µl 
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Flow 
Cytometry 
Biolegend 127623 APC-Cy7 conjugated Anti-mouse-
Ly6G 
0.5µg/100µl 
Flow 
Cytometry 
Biolegend 353105 PE conjugated Anti-human ICAM-1 0.5µg/100µl 
Flow 
Cytometry 
Biolegend 305805 PE conjugated Anti-human VCAM 0.5µg/100µl 
Flow 
Cytometry 
ThermoFisher 
Scientific 
12-4714-42 Isotype control mouse IgG1k-PE 0.5µg/100µl 
Rega Institute 
ELISA 
protocol 
Collaborator #4576 Goat anti-human CXCL8 1/300 
Rega Institute 
ELISA 
protocol 
R&D MAB208 Mouse anti-human CXCL8 2μg/ml 
Rega Institute 
ELISA 
protocol 
Jackson Immuno 115-035-146 Goat anti-mouse-HRP 1/2500 
Table 2-2. Details of antibodies used throughout this project. 
2.11 STATISTICAL ANALYSIS 
Results are shown as means ± standard error of the mean. “N” denotes the number of 
experimental replicates performed, and “n” denotes the number of technical replicates 
within each experimental replicate. Statistical analysis was performed using a One Way 
ANOVA with Tukey’s post-hoc correction test GraphPad Prism 5.0 software. Values of < 
0.05 were considered to be significant. p=<0.05: *, p=<0.01: **, p=<0.0001: ***, 
p=<0.00001: ****. Stars directly above samples indicate statistical difference from the 
negative control, stars on brackets indicate statistical difference between two samples. 
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3 CHARACTERISING THE BIOLOGICAL FUNCTION OF 
NITRATED CXCL8 
3.1 INTRODUCTION 
One of the reasons that very few therapeutics designed to target chemokines have been 
successful is thought to be the known degree of redundancy within the chemokine 
system. Another is that we have an incomplete understanding of how chemokines are 
regulated and function in an in vivo inflammatory environment, which is likely to differ 
from observed behaviour in reductionist in vitro experimental settings. Detecting 
chemokines by immunoassays such as ELISAs, or by immunohistochemistry in tissue 
sections, merely indicates the presence of the protein, and does not reflect the actual 
biological activity of that protein within the given environment. 
As mentioned previously in section 1.3, chemokines can be altered by a range of post-
translational modifications. Some modifications have been shown to enhance function 
(such as CXCL8 truncation 70), some to abrogate function (such as CXCL12 nitration122), 
and some modified chemokines can antagonise their wild type counterparts. A truncated 
form of CCL5 (3-68aa) is a 10-fold less potent inducer of monocyte and eosinophil 
chemotaxis than full length CCL5 276, and was shown to be detectable in all serum 
samples in a cohort of 297 type 2 diabetes patients, making up ~15% of the total CCL5 
detected 277. High levels of CXCL10 have been associated with viral persistence in 
hepatitis C patients 278, and it has been discovered that this is because the CXCL10 
detected is actually the truncated form of the chemokine, which antagonises the wild 
type molecule 279,280. The amount of citrullinated CXCL5 present in the serum and 
synovial fluid of rheumatoid arthritis patients has also been correlated with disease 
activity, possibly due to this modification increasing the capacity of the chemokine to 
recruit monocytes 281. 
Clearly, analysing only the expression of wild type chemokines does not accurately 
reflect the global inflammatory situation or the contribution of an individual chemokine 
(in all its varying forms) to this response.  
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Understanding the function of these modified chemokines, how they interact with their 
wild type counterparts, and under what circumstances these modifications are likely to 
occur, is essential for utilising these molecules as potential biomarkers, and developing 
new therapeutic interventions to effectively target the chemokine system. As evidenced, 
this is applicable to a range of diseases; autoimmune conditions such as rheumatoid 
arthritis, metabolic conditions such as type 2 diabetes, and viral infection.  
One method of modification is nitration by peroxynitrite, as is hypothesised to occur 
during oxidative stress and ischaemia-reperfusion injury as described in section 1.4. 
Briefly, the spontaneous reaction of the superoxide anion O2- and NO (production of both 
is known to increase during inflammation 96-98) forms peroxynitrite, which mediates 
oxidative damage 108,109,111 and is implicated in the pathology of many diseases 112. 
Peroxynitrite can also post-translationally nitrate proteins within the vicinity of its 
production. In the case of chemokines studied to date, such as CCL2, CCL5 and CXCL12, 
this nitration appears to have anti-inflammatory consequences, reducing the 
chemotactic ability of these molecules 119,122.  This chapter will focus on post-
translational nitration of CXCL8 by peroxynitrite, and will examine the consequences 
this modification has on the biological function of CXCL8. 
3.1.1 Specific Aims 
Focusing on peroxynitrite-mediated nitration of CXCL8, this chapter aimed to examine 
and assess: 
 The ability of nitrated CXCL8 to induce neutrophil chemotaxis in vitro and in vivo 
 
 The ability of nitrated CXCL8 to induce GPCR signalling in neutrophils 
 
 The ability of nitrated CXCL8 to bind GAGs 
 
 On which residues within CXCL8 nitration occurs   
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3.2 SPECIFIC MATERIALS AND METHODS 
3.2.1 Chemotaxis Assays 
3.2.1.1 General Principles 
Chemotaxis assays test the ability of a chemokine to induce the chemotactic migration of 
cells. These assays can be performed in a variety of ways; in vitro in the form of trans-
filter/bare membrane assays or trans-endothelial (where a layer of endothelial cells is 
grown on the filter of a cell culture insert for cells of interest to migrate through), and in 
vivo in mice through the injection of a chemotactic agent into an isolated compartment 
that cells can migrate into and be retrieved from, such as the peritoneum or a pre-
formed air pouch on the back. 
3.2.1.2 In Vitro Trans-filter Chemotaxis 
24 well companion plates (BD Falcon) were blocked by adding 1ml of 2% BSA (diluted 
in PBS and sterile filtered through a 0.2µm filter) to each well, and incubating overnight 
at 4°C. This prevents chemokines binding to the surface of the plate, which would reduce 
the availability of said chemokine to induce chemotaxis. The use of FBS as a blocking 
agent should be avoided, as any bovine chemokines present in this could affect 
reliability of data collected. 
Relevant chemokine solution at 10nM, 20nM or 30nM  diluted in serum-free RPMI (0.1% 
BSA in RPMI-1640 + pen/strep + L-glut) in a total volume of 600µl was added to each 
well of the plate in triplicate, then a cell culture insert with 3µM pores (BD Falcon) was 
carefully inserted into the well to avoid trapping air bubbles. Serum-free RPMI only with 
no chemokine added was used as a negative control. After 1 hour of resting in serum-
free RPMI at 37˚C, 500µl of neutrophil cell suspension (300,000 cells per well diluted in 
serum-free RPMI) was gently pipetted into each insert, and the plates incubated at 37°C 
with 5% CO2 for 1.5 hours to allow cells to migrate. The experimental set-up is shown in 
Figure 3-1A. The number of cells that had migrated through the filter and into the well 
below was counted using flow cytometry as described in section 2.4.2.  
Chemokines used included CXCL8, CXCL1 (R&D), as well as mutant and nitrated 
chemokines generated by our collaborator Dr Krishna Rajarathnam. These included 
61 
 
nitrated CXCL8, Y13F mutant CXCL8, nitrated Y13F mutant CXCL8, nitrated CXCL1, L15Y 
mutant CXCL1 and nitrated L15Y mutant CXCL1. The amino acid sequences of these 
chemokines are shown below, with mutated residues highlighted in red. 
CXCL8: 
SAKELRCQCIKTYSKPFHPKFIKELRVIEDGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS 
Y13F CXCL8: 
SAKELRCQCIKTFSKPFHPKFIKELRVIEDGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS 
CXCL1: 
ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKSN 
L15Y CXCL1: 
ASVATELRCQCLQTYQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKACLNPASPIVKKIIEKMLNSDKSN 
For trans-filter assays using neutralising antibodies, neutrophils were incubated with 
20μM anti-CXCR1 or anti-CXCR2 or both for 30 minutes (incubation was trialled at 37°C, 
room temperature and 4°C in 3 separate experimental runs). Both antibodies are 
described as suitable for GPCR neutralization studies according to their datasheets 
provided by Abcam. 
3.2.1.3 In Vitro Trans-endothelial Chemotaxis 
72 hours prior to the assay, cell culture inserts were seeded with 2x105 HMEC-1 cells in 
1ml complete MCDB-131 media, and incubated at 37°C with 5% CO2. It is important to 
place media in the insert only (not in the well underneath) to discourage cells from 
growing in a “double monolayer” both above and below the filter. When cells were 
deemed to be 80% confluent, 5ng/ml of TNF-α was added to the culture media in the 
insert and incubated overnight. This creates a pro-inflammatory environment, 
encouraging the upregulation of adhesion molecules such as ICAM-1 and VCAM by the 
endothelial monolayer. Confluency of the monolayer was closely monitored – if 
endothelial cells are underconfluent, migratory cells can pass through gaps in the 
monolayer, and if they are overconfluent this can inhibit migration. On the day the assay 
was performed, the endothelial monolayer was washed once in serum-free RPMI, then 
the plate was set up, incubated and analysed as described in section 3.2.1.2. The 
experimental set-up is shown in Figure 3-1B. After the incubation, inserts were removed 
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and stained with haematoxylin and eosin to check the HMEC-1 monolayer confluency as 
described in section 2.6.3. 
 
Figure 3-1. Chemotaxis assay experimental set-up. Diagrammatic representation of A) a 
trans-filter chemotaxis assay and B) a trans-endothelial chemotaxis assay. 
3.2.1.4 In Vitro Ibidi® μ- Slide Chemotaxis 
24 hours prior to the assay, Ibidi® μ-slides Chemotaxis (ibiTreat), plugs (Ibidi®) and 
serum-free RPMI were placed in an incubator at 37°C with 5% CO2 in order to allow 
gases to equilibrate and minimise the formation of air bubbles as the assay is set up.  
On the day of the assay, primary neutrophils were isolated and rested as described 
previously in section 2.3.7. The assay was then set-up according to Ibidi®’s Application 
Note 17, following instructions for “2D chemotaxis experiments without gel”. Briefly, 
3x106 neutrophils/ml were seeded into the central channel which was then sealed using 
the plugs provided, and a gradient of 30nM (highest concentration) CXCL8 or nitrated 
CXCL8 was created, and the chambers either side of the channel were sealed (Figure 3-
2A). This exposes the neutrophils to a linear chemokine gradient across the channel. A 
negative control experimental chamber was then set up using serum-free RPMI only (no 
gradient), and controls using 30nM CXCL8 or nitrated CXCL8 on both sides of the 
channel were also set up to test for chemokinesis as opposed to chemotaxis (Figure 3-
2B). The slides were then imaged every 2 minutes for 3 hours using a Nikon TiE Multi-
Modality microscope with a 10x phase contrast lense, and images analysed using Fiji’s 
manual tracking plug-in by tracking 40 individual randomly chosen cells through all 
images. An example of an image with 40 randomly selected cells for tracking in shown 
below in Figure 3-2C. These tracks were then imported in to Ibidi®’s Chemotaxis and 
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Migration Tool, where they were animated and analysed for parameters including 
velocity, directness, Euclidean distance and forward migration index.   
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Figure 3-2. Diagrammatic representation of the experimental set up using Ibidi®’s μ-slide 
Chemotaxis equipment and analysis of images performed using FIJI. Experimental set-ups 
showing a negative control containing serum-free RPMI (white) in both chambers, and A) 30nM 
gradient of wild type CXCL8 (red) and nitrated CXCL8 (blue) created by adding serum-free RPMI 
to one chamber and chemokine to the other, or B) no gradient with 30nM of wild type CXCL8 
(red) or nitrated CXCL8 (blue) in both chambers, with neutrophils around the central channel 
and arrows indicating the direction of cell movement towards the area of highest concentration. 
Images of each of the three experiments per slide are taken every 2 minutes for 3 hours using a 
10x phase contrast lens on a Nikon TiE Multi-Modality microscope, and an example image 
opened in FIJI with 40 cells randomly selected for tracking (red circles) is shown in C). Each cell 
is tracked through all images, and tracks are then uploaded and analysed using Ibidi®’s 
Chemotaxis and Migration Tool. 
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3.2.2 In Vivo Murine Air Pouch Recruitment 
3.2.2.1 General Principles 
The aim of this model is to create a stable fluid-filled subcutaneous pouch on the back of 
a mouse, which mimics a synovial joint cavity. This pouch can then be injected with a 
chemotactic agent, then later flushed out and the contents analysed. This creates a 
sealed environment into which cells can migrate and be retrieved from. 
3.2.2.2 Air Pouch Chemotaxis 
Female 7-8 week old BALBC female mice were used in this study. 
Stable, fluid-filled air pouches were created on the backs of the mice by injecting 3ml of 
sterile air subcutaneously under general anaesthetic (isoflurane) on the first day. On the 
second, fourth and fifth day, 1ml of sterile air is injection to top up the pouch as shown 
in Figure 3-3. 
On the sixth day, the mice were split into groups and 500µl sterile PBS with 0.5% 
carboxymethylcellulose (CMC) ± chemokine was injected subcutaneously into the air 
pouch. For optimisation experiments concentrations of 0.1µg, 1µg and 3µg wild type 
CXCL8 were used, and for the final experiment 1µg of wild type CXCL8 or nitrated CXCL8 
was administered. The initial CXCL8 concentrations tested were based on successful 
neutrophil recruitment observed in response to 0.1-10μg of CXCL8 administered in a 
murine in vivo recruitment experiment conducted by our collaborator Professor Krishna 
Rajarathnam 55. 
Mice were then left for 4 hours to allow cells to migrate into the air pouch. After mice 
were sacrificed via intraperitoneal Euthatal injection, pouches were lavaged twice with 
1ml sterile PBS + 3mM EDTA each time. The lavage samples were then centrifuged at 
500xg for 5 minutes, and resuspended in 125µl flow cytometry buffer (PBS + 2% BSA). 
TALI total cell counts were performed on 25µl of each sample, and the remaining 100µl 
was stained with fluorescently conjugated primary antibodies for 1 hour at 4˚C, and 
analysed using the FACS Canto II flow cytometer. Samples were analysed using FlowJo 
v10 software as described in section 2.4.3. 
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Figure 3-3. Murine air pouch model. Schematic diagram of the generation of a stable fluid-
filled pouch on the back of a mouse through a series of injections of sterile air. 
3.2.3 In Vivo Murine Intraperitoneal Recruitment 
3.2.3.1 General Principles 
This model was used to replace the air pouch recruitment model. The aim was to use the 
peritoneum as a naturally occurring sealed cavity, which cells can migrate to and be 
harvested from. This model should encompass less basal inflammation than the air 
pouch model, due to the lack of repeated injections and separation of the skin needed to 
create the pouch. 
3.2.3.2 Intraperitoneal Chemotaxis 
Female 7-8 week old BALBC female mice were used in this study. On the day of the 
assay, mice were split into groups to receive injections of 500µl of sterile clinical grade 
saline ± chemokine into the peritoneum. Mice were then left for 6 hours to allow cells to 
migrate into the peritoneum. After mice were culled via cervical dislocation under 
anaesthesia, pouches were lavaged three times with 1ml sterile PBS + 3mM EDTA each 
time. The lavage samples were then centrifuged at 500xG for 5 minutes, and 
resuspended in 100µl flow cytometry buffer, stained with fluorescently conjugated 
primary antibodies for 1 hour at 4˚C and analysed using the BD Accuri c6 flow cytometer 
as described in section 2.4.3. Data was analysed using FlowJo v10 software. 
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3.2.4 Calcium Flux Assays  
3.2.4.1 General Principles 
This technique was used to measure the release of intracellular calcium stores as a 
result of GCPR activation in primary human neutrophils stimulated with CXCL8 or 
CXCL8 variants. This method involves the loading of primary neutrophils with Indo-1 
AM in order to measure cellular calcium levels. Indo-1 is excited by the UV laser and its 
emission changes depending upon whether it is bound to calcium (~420nm) or free 
(~510nm). Measuring the ratio of these two wavelengths upon addition of a stimulant 
can inform whether or not the stimulant activates receptor signalling through changes in 
intracellular calcium concentration. Ionomycin (an ionophoric antibiotic) is used as a 
positive control to raise intracellular calcium levels by allowing transfer of calcium 
across the cell membrane. 
3.2.4.2 Measuring Calcium Flux in Neutrophils 
Primary neutrophils were isolated and rested as described previously. Cells were 
washed in HBSS supplemented with 1mM CaCl2, 1mM MgCl2 and 1% FBS (v/v), and 
resuspended to 1x107 cells/ml. Cells were then stained with 3µM Indo-1 (ThermoFisher 
Scientific) for 30 minutes at 37˚C and washed twice in supplemented HBSS by 
centrifugation at 400xg for 5 minutes. Cells were resuspended and split into individual 
testing tubes, each containing 3x106 cells in 1ml of supplemented HBSS, and rested in a 
37 ˚C waterbath for 30 minutes before analysis using a Fortessa X20 flow cytometer. A 
baseline reading at both wavelengths was recorded for 1 minute, before the tube was 
removed and PBS (for the negative control tube) or 30nM chemokine (CXCL8, nitrated 
CXCL8, Y13F CXCL8, nitrated Y13F CXCL8), was added. Fluorescence was recorded for a 
further 5 minutes, then the tube was removed again and 2mM Ionomycin was added and 
the response recorded for a further 2 minutes. Ratio of 420nm emission to 510nm 
emission was calculated using FlowJo v10 software. 
3.2.5 Flow-Based Adhesion Assays - Cellix™ VenaFlux 
3.2.5.1 General Principles 
Assays were performed using a Cellix™ machine to determine how primary blood 
neutrophils adhere to an HMEC-1 cell monolayer under flow conditions, after 
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stimulation with CXCL8 or the variants described in the chemotaxis assays above. This 
experimental set up involves an 8-channel chip (Vena8 Endothelial+ Biochips, Cellix™ 
Ltd.) attached to a remotely controlled pump system by a set of needles connected to 
tubes as shown below in Figure 3-4. Prior to the assay, the chips can be coated with 
either a ligand of interest, or an adherent cell type. A suspension of test cells, such a 
neutrophils or monocytes, can then be added to the chip, and flown across by the pump 
in order to allow the imaging and measurement of adhering cells. 
3.2.5.2 Assay Protocol 
The day before the assay, Venaflux chip channels were coated with fibronectin at 
100μg/ml (10μl per channel) overnight, then 250,000 HMEC-1s (previously stimulated 
with varying concentrations TNF-α overnight) were seeded onto each of the chip’s 8 
channels and left to adhere for 1 hour at 37°C. Unstimulated HMEC-1s were used as a 
negative control. 
HMEC-1 monolayers were then treated with a range of concentrations of CXCL8, or 
CXCL8 variants in duplicate for 1 hour at room temperature. Controls received media 
only without chemokine. Neutrophils isolated from healthy donor blood were purified, 
rested for 1 hour in serum-free RPMI at 37˚C, and stained with 1mM DiOC6(3) then 
300,000 were pipetted onto each channel in the chip in succession, flown over the chip 
at 0.5 dyne/cm2, and adherent cells were visualised using the Cellix™ machine. Adherent 
cells were counted from 5 sequential images per position and 5 positions per channel, 
using ImageJ software, and averages were calculated. 
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Figure 3-4. Cellix™ assay experimental set-up. A) Cellix™ microfluidics Mirus Evo pump and 
8-tube multiflow. B) Vena 8 Endothelial+ chip, showing the 8 channels coated with fibronectin 
followed by a layer of endothelial cells. Fluorescent neutrophils dyed with DiOCe(3) are then 
flown across the channel and images taken periodically in order to count the number of 
adherent neutrophils. 
3.2.5.3 Assay Optimisation 
The assay was set up as described previously in section 3.2.5.2, assessing the optimum 
method of detaching HMEC-1 cells from flasks (PBS + 3mM EDTA, Trypsin or Accutase), 
and the optimum concentration of TNF-α to treat HMEC-1s with after seeding onto the 
chip (1-10ng/ml) which was assessed by ICAM-1 and VCAM upregulation (assessed by 
flow cytometry following the basic protocol described in section 2.4.3) and CXCL8 
production (assessed by R&D’s IL8 Duoset ELISA Kit). 
I also tested seeding the chip by growing HMEC-1 cells overnight on the chip under flow 
conditions using the KimaPump, with a flow rate of 200µl/minute for 2 minutes, 
followed by 1 minute of no flow in repeated cycles. 
The final protocol involved detachment of HMEC-1s using PBS + 3mM EDTA, followed by 
static growth on the chip then treatment with 5ng/ml TNF-α overnight. 
70 
 
3.2.5.4 Neutrophil Adhesion to a Chemokine-Treated HMEC-1 Monolayer 
The day before the assay, Venaflux chip channels were coated with fibronectin and 
seeded with HMEC-1s (previously stimulated with TNF-α overnight, or unstimulated as 
a negative control) were seeded onto the chip and left to adhere for 1 hour at 37°C.  
HMEC-1 monolayers were treated with a range of concentrations of wild type CXCL8, 
nitrated CXCL8, Y13F mutant CXCL8 or nitrated Y13F mutant CXCL8 in duplicate for 1 
hour at room temperature. Controls received media only. Neutrophils were isolated, 
flown across each channel in turn, imaged, and the number of adherent cells counted as 
described above. 
3.2.5.5 Immunofluorescence – Heparan Sulphate 
Immunofluorescence was performed on HMEC-1 cells seeded onto chamber slides and 
frozen, following detachment from flasks using PBS+3mM EDTA, Accutase or Trypsin. 
This was done to visualise the extent of GAG degradation resulting from each of the 
detachment methods, and was performed as described in section 2.6.2. Briefly, an anti-
human heparan sulphate primary antibody (10-E4 clone donated by Laura Ferreras) 
was used at 1/100 and detected with a goat anti-mouse-Dylight488 secondary antibody. 
Chamber slides were imaged using a Zeiss AxioImager microscope. 
3.2.6 Surface Plasmon Resonance 
3.2.6.1 General Principles 
Surface plasmon resonance (SPR), performed using Biacore Systems, is a reproducible 
technique used to study the interactions between molecules without the need for 
labelling. Firstly the ligand is immobilized onto the surface of the sensorchip (a glass 
slide coated with a 50nm layer of gold), and then the analyte is flown over the surface. 
Binding of the analyte to the ligand on the sensorchip surface generates a response, 
which is proportional to the bound mass, and can be sensitive to changes in the order of 
picograms per mm2. As binding events are monitored in real time a range of interaction 
characteristics can be determined. The gold coating on the sensorchip acts as an 
electrically conducting surface, and upon binding, electron charge density waves 
(plasmons) are generated, reducing the polarised light reflected at a specific angle (the 
resonance angle) in proportion to the mass bound to the surface. The interface must be 
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in conditions of total internal reflection for SPR to occur. Alterations in binding can 
therefore be read out in resonance units (RU) 282. This is shown diagrammatically below 
in Figure 3-5A. 
SA sensorchips (pre-coated with streptavidin), and a running buffer of HBS-P (10mM 
HEPES pH7.4, 150mM NaCl, 0.005% P20) were used for these experiments. Unless 
stated all reagents are from GE Healthcare. 
3.2.6.2 Heparin Immobilization 
Biotinylated heparin was kindly provided by Dr Hugues Lortat-Jacob (Institut de 
Biologie Structurale, Grenoble, France). Briefly, 1mM heparin (9kDa; Sigma) is dissolved 
in PBS and incubated with 10mM biotin-LC-hydrazide for 24hr at room temperature. 
The biotinylated heparin is then dialysed against water to remove any free biotin in the 
solution. It is essential that GAGs such as heparin are non-biotinylated at the reducing 
end in order for them to be correctly presented on the surface of the sensorchip. 
Biotinylated heparin was diluted to a concentration of 16μg/ml in 300mM NaCl and 
injected using the Biacore Wizard until a target of 200RU was reached. 
3.2.6.3  SPR Protocol 
Following immobilization of heparin onto the sensorchip surface, SPR was then 
performed to compare the ability of CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated 
Y13F CXCL8 (all at 5-1000nM), to bind to the heparin. Chemokines were flown across 
the chip at 30μl/min for 2 minutes followed by a 300 second dissociation phase (Figure 
3-5B). RU from a flow cell coated with streptavidin only (no biotinylated heparin) was 
subtracted from the results from the heparin-coated flow cells and analysis was 
performed using BIAevaluation 4.1 software. 
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Figure 3-5. The principles of surface plasmon resonance. A) Diagrammatic representation of 
a surface plasmon resonance (SPR) experiment. The ligand (biotinylated heparin) is flown 
across the gold-coated sensorchip, where it is immobilised through the interactions between the 
biotin on the heparin molecules and the streptavidin already pre-coated onto the chip surface. 
The analyte (chemokine) is them flown across the chip where, if it binds to the immobilized 
heparin, it will cause a shift in the refractive index and change the SPR angle. B) Diagram of a 
typical sonogram, showing the change in resonance unit (RU) during analyte binding 
(association) and dissociation. The more the analyte binds, the higher the RU. 
3.2.7 Ion Trap Mass Spectrometry 
3.2.7.1  General Principles 
Mass spectrometry is a technique, which uses the ratio of mass/charge (m/z) of a 
compound to determine its molecular mass. Samples are diluted in acid and injected 
manually or through an attached HPLC system (with 50% outlet diverted into the mass 
spectrometer), into a small diameter needle at high voltage, which sprays the sample 
into droplets. The proteins within these droplets are positively charged (due to binding 
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protons from the acid), and so travel towards the instrument, which is negatively 
charged. High temperatures and a flow of heated nitrogen cause the droplets to 
evaporate during the spray. Ions are then held in a 3-dimensional multipolar field within 
the ion trap by a repelling potential, and through collisions with helium ions also present 
within the trap (this causes the ions to lose kinetic energy and focuses them in the 
centre of the trap). The radio frequency (RF) of the ion trap is then increased and ions 
are ejected out according to their m/z. The mass to charge ratio of each ion is recorded 
as it hits the detector 283. This is shown diagrammatically below in Figure 3-6. Usually 
chemokines (if diluted in 0.1% TFA or 0.1% acetic acid) will produce ions carrying 5 – 
15 protons. 
This technique was used to assess the nitration of CXCL8 after peroxynitrite incubation, 
and to analyse the chemokine variants Y13F CXCL8 and nitrated Y13F CXCL8. 
 
Figure 3-6. The principles of ion trap mass spectrometry. Positively charged protein ions 
(red circles) are held in the ion trap containing helium ions (green) by a 3-dimensional 
multipolar field. As the relative frequency of the ion trap is increased, ions will begin to move out 
of the trap according to their m/z, where they will then be detected and their relative intensities 
plotted. 
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3.2.7.2  ZipTip® Preparation of Samples for Manual Injection 
Any salts, detergents and contaminants must be removed from the samples before they 
can be manually injected into the mass spectrometer. This is done through ZipTip® 
purification (Merck Millipore). ZipTips are 2-20μl pipette tips with a small reverse phase 
C4 chromatography column within the tip.  
Firstly, the tip must be prepared before the sample can be purified. This is done by 
pipetting up, then ejecting out into a waste tube, 10μl of 50% acetonitrile (repeat 10 
times), then 0.1% TFA (repeat 10 times). The entire volume of the sample should then 
be pipetted up (where the proteins will bind to the column within the tip), and then 
ejected out into the waste tube. Contaminants are then removed from the sample by 
pipetting up and ejecting out 10μl of 0.1% acetic acid 10 times, then 10μl of 10% 
acetonitrile in 0.1% TFA 10 times. The sample is then eluted from the column by 
pipetting up 10μl of 50% acetonitrile in 0.1% TFA twice, each time ejecting into a clean 
tube. 
3.2.7.3  Sample Running – Mass Spectrometry (MS) 
The sample can then be manually injected into the mass spectrometer (Esquire LC, 
Bruker Daltonics, Germany).  
Using Bruker’s mass spectrometer software, the sample is set to run at 2μl/minute, at a 
tune of 1500m/z (as this was found to be optimal for CXCL8), while scanning for peaks 
from 500-2200m/z. The machine will display a range of ion peaks, plotting m/z on the x-
axis and relative intensity on the y-axis. Data should be acquired from the start. 
3.2.7.4  Sample Running – Mass Spectrometry/Mass Spectrometry (MS2) 
MS2 involves selecting only one individual ion, (± 4Da), and retaining this ion within the 
ion trap while excluding all others. This is usually the most abundant ion i.e. the ion with 
the highest relative intensity. The kinetic energy of the ion trap is then increased to 
increase collisions between the protein ions and helium ions in order to fragment them.  
This kinetic energy intensity is controlled by an “Amp” setting, which was set to 0.9-1.0 
for CXCL8, as this was found to be the optimal setting to cleave the protein at the 
aspartic acid (D)-proline (P) bond creating two daughter fragments. Setting this value 
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too low will prevent fragmentation, and setting it too high will result in multiple 
cleavages at many sites. 
The most abundant peaks selected for fragmentation were the 1198.3 peak for wild type 
CXCL8, the 1204.7 peak for CXCL8 with one nitration. We also attempted to fragment a 
1210 peak for nitrated CXCL8, which would be indicative of a molecule with two 
nitrations. A range of calculated ions for both wild type and nitrated CXCL8, and their 
m/z values are shown in Table 3-1. 
Fragmentation of the 1198.3 or 1204.7 ions at the D-P bond produces a C-terminal 
fragment and an N-terminal fragment. We could then analyse the m/zs of these 
fragments to determine at which part of the chemokine contains the nitrated residue.  
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 Wild Type CXCL8 (72aa) Nitrated CXCL8 (one nitration) (72aa) 
Equation (m+z)/z (m+z)/z 
Molecular Mass 8381 8381 + 45 = 8426 
Ion +3 protons (8381+3)/3 = 2794.6 (8426+3)/3 = 2809.7 
Ion +4 protons 2096.4 2107.5 
Ion +5 protons 1677.2 1686.2 
Ion +6 protons 1397.8 1405.3 
Ion +7 protons 1198.3 1204.7 
Ion +8 protons 1048.625 1054.25 
Ion +9 protons 932.2 937.2 
Ion +10 protons 839.1 843.6 
Table 3-1.Mass spectrometry CXCL8 and nitrated CXCL8 ions. Different possible ions of wild 
type CXCL8 and nitrated CXCL8 and their m/z values. The most abundant ions are in red. 
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3.3 RESULTS 
3.3.1 Assessing the Ability of CXCL8 and CXCL8 Variants to Induce Neutrophil 
Chemotaxis in Vitro 
In order to determine the effect that nitration, loss of tyrosine (Y) 13, and nitration 
without the presence of Y13 had on the ability of CXCL8 to induce neutrophil chemotaxis 
in vitro, trans-filter chemotaxis assays were performed to assess the percentage of 
300,000 neutrophils that would migrate through the insert into the well of the plate 
below in response to 10nM, 20nM or 30nM of CXCL8, nitrated CXCL8, Y13F CXCL8 and 
nitrated Y13F CXCL8. The results in Figure 3-7A show that wild type CXCL8 induces 
chemotaxis at all concentrations tested (p=0.00001 at 10nM, 20nM and 30nM), whereas 
the nitrated CXCL8 has almost no chemotactic function at any of the concentrations 
tested. The Y13F mutant showed equal if not higher levels of chemotaxis induction than 
the wild type molecule, and the nitrated Y13F mutant showed a reduction in the 
induction of chemotaxis when compared to the non-nitrated Y13F chemokine 
(p=0.00001 at 10nM and 20nM, and p=0.0001 at 30nM). In order to assess migration in 
a slightly more physiologically relevant model, experiments were repeated with 
neutrophils migrating through a confluent monolayer of HMEC-1 endothelial cells grown 
on the filter. This mimics neutrophils infiltrating tissue by migrating through the wall of 
a blood vessel. The results shown in Figure 3-7B demonstrate that the nitrated 
chemokine is also unable to induce chemotaxis through an endothelial monolayer. 
Interestingly, the ability of the Y13F mutant CXCL8 to induce chemotaxis appears to be 
impaired when cells must cross an endothelial barrier than through the filter alone, 
although the nitration of this mutant reduces chemotactic ability further, as it did in 
trans-filter assays. 
As tyrosine is one of the key residues targeted by peroxynitrite, we aimed to assess how 
nitration would affect CXCL1 – which signals through CXCR2 (like CXCL8) but does not 
contain any tyrosine residues naturally. We also aimed to see how introducing a 
tyrosine into this chemokine artificially through the use of an L15Y mutant CXCL1 
variant, and then nitrating it, would affect function. 
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Trans-filter chemotaxis assays were performed as described for CXCL8 and its variants; 
migration of primary blood neutrophils in response to 10nM, 20nM or 30nM of wild 
type CXCL1, nitrated CXCL1, L15Y mutant CXCL1, and nitrated L15Y CXCL1 was assessed 
and migrated cells counted using flow cytometry. As with CXCL8, nitration of CXCL1 
abolished chemotactic function, however unlike CXCL8 the same effect was observed for 
the nitrated L15Y mutant (see Figure 3-8A). This suggests that tyrosine is not the only 
target for peroxynitrite, and that other residues must be present within CXCL1 which 
are targets for peroxynitrite and essential for the induction of chemotaxis. As CXCL1 
does not contain any tryptophan residues, this is likely to be a cysteine or histidine 
residue, or a combination of multiple residues which further analysis would be needed 
to confirm. The L15Y mutant CXCL1 could still induce some degree of chemotaxis of 
neutrophils, although this was reduced in comparison to the values observed for the 
wild type CXCL1. As with CXCL8, these experiments were repeated in trans-endothelial 
chemotaxis assays. However, as shown in Figure 3-8B, the percentage of neutrophils 
that migrated in response to each chemokine varied more so than in the trans-filter 
assays, and none were found to be significant in comparison to the negative control 
group.  
Chemotaxis assays were also performed in vitro using Ibidi® µ-slide chemotaxis assays, 
using time-lapse microscopic analysis to assess neutrophil migration in response to a 
gradient of 30nM wild type or nitrated CXCL8, in order to assess the neutrophil response 
as the cells are actually migrating.  
The trajectory plots and analysis in Figure 3-9 show that neutrophils migrated towards 
wild type CXCL8 with a greater forward migration index, velocity, directness and 
Euclidean distance than both the negative control and the same concentration of 
nitrated CXCL8. No difference in any measurement was found between the negative 
control and nitrated CXCL8. 
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Figure 3-7. Ability of wild type CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated Y13F 
CXCL8 to induce neutrophil migration in vitro. A) Trans-filter chemotaxis assay, and B) 
Trans-endothelial chemotaxis assay, showing percentage of total neutrophils that migrated 
through a bare filter in response to 10nM, 20nM or 30nM of wild type CXCL8, nitrated CXCL8, 
Y13F mutant CXCL8, and nitrated Y13F mutant CXCL8. C) Images taken at 20x and 40x show the 
confluent layer of HMEC-1 cells stained with haematoxylin. Data shown in A) is combined from 
N=2, in B) is combined from N=3, and in C) is representative N=3 experimental replicates (using 
neutrophils isolated from different blood donors), each with n=3 technical replicates. Statistical 
analysis was performed using a One Way ANOVA with Tukey’s post-test for each concentration 
individually. 
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Figure 3-8. Ability of wild type CXCL11, nitrated CXCL1, L15Y CXCL1 and nitrated L15Y 
CXCL1 to induce neutrophil migration in vitro. A) Trans-filter chemotaxis assay, and B) 
Trans-endothelial chemotaxis assay, showing percentage of total neutrophils that migrated 
through a bare filter in response to 10nM, 20nM or 30nM of wild type CXCL1, nitrated CXCL1, 
L15Y mutant CXCL1, and nitrated L15Y mutant CXCL1. C) Images taken at 20x and 40x show the 
confluent layer of HMEC-1 cells stained with haematoxylin. Data shown in A) is combined from 
N=2, in B) is combined from N=3, and in C) is representative of N=3 experimental replicates 
(using neutrophils isolated from different blood donors), each with n=3 technical replicates. 
Statistical analysis was performed using a One Way ANOVA with Tukey’s post-test for each 
concentration individually. 
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Figure 3-9. Ability of CXCL8 and Nitrated CXCL8 to induce neutrophil migration using 
Ibidi® µ-Slides and time-lapse microscopic analysis. The cells were seeded onto the slides 
and a chemotactic gradient was created using serum-free media (SFM) as a negative control and 
media containing either 30nM wild type or nitrated CXCL8. Cells were observed under a Nikon 
Multi-Modality inverted microscope, with one image taken every 2 minutes for 3 hours. Image 
analysis was performed using FIJI’s manual tracking plugin, and the trajectories of 40 randomly 
chosen cells were plotted and analysed using the Chemotaxis and Migration Tool. A) Trajectory 
animations showing neutrophil chemotaxis in response to SFM, 30nM wild type CXCL8 or 30nM 
nitrated CXCL8. B) Trajectory analysis showing the mean forward migration index 
(perpendicular (⊥) and parallel (ll) to the direction of the chemokine gradient), velocity, 
Euclidean distance and directness of the cells analysed. Data shown in A) is representative of, 
and B) is combined from, N=3 experimental replicates (using neutrophils isolated from different 
blood donors), each with n=1 technical replicate. Statistical analysis was performed using a One 
Way ANOVA with Tukey’s post-test. 
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3.3.2 Assessing the Ability of CXCL8 and Nitrated CXCL8 to Induce Neutrophil 
Chemotaxis in vivo 
Having shown that nitration of CXCL8 impairs its ability to induce the migration of 
primary human neutrophils in vitro, I aimed to use the murine air pouch model to assess 
its functionality in vivo. Initial experiments were performed to optimise the 
concentration of CXCL8 needed to induce neutrophil recruitment, therefore PBS + 0.5% 
CMC ± 1μg or 3μg of CXCL8 was injected into the pouch. 4 hours later the pouch was 
lavaged and cells recovered, stained and analysed by flow cytometry. As shown in Figure 
3-10A, as a general trend both 1μg and 3μg of CXCL8 appeared to induce the recruitment 
of neutrophils to the pouch at a higher level than the PBS only control, although this did 
not reach statistical significance. Monocyte/macrophage/dendritic cell recruitment 
appeared to stay at a constant basal level. In addition to analysis of cells within the 
pouch, 1cm2 sections of skin from the pouch was removed, embedded in paraffin and 
then stained with haematoxylin and eosin and for Ly6G to detect any neutrophils 
recruited to the skin of the pouch itself. This analysis found that 1µg CXCL8 induced the 
most inflammatory cell infiltrate (Figure 3-10B) and neutrophil infiltrate (Figure 3-10C) 
to the skin of the pouch. Thus, 1µg CXCL8 was used in all subsequent experiments. 
Experiments went on to compare cellular migration into the air pouch in response to 
1µg CXCL8, 1µg nitrated CXCL8 or both together, however high neutrophil migration 
was found in response to all treatment groups, including the negative control group. No 
differences were observed between treatments in either intrapouch cell counts (Figure 
3-11A) or immunohistochemical (Figure 3-11B and C) analysis.  
I therefore used a different model - intraperitoneal recruitment - for subsequent 
experiments. Sterile clinical grade saline alone (negative control) or containing 1µg 
CXCL8 was injected into the peritoneum of the mice, and cells that had migrated into the 
peritoneum were assessed 6 hours later. These conditions were assessed alongside an 
additional control group of mice who received no treatment. In this model, some 
neutrophil recruitment was seen in response to the negative control group injected with 
saline in comparison to the “no treatment” group, and the CXCL8-treated group showed 
greater neutrophil recruitment than either control group (Figure 3-12A), although this 
was not statistically significant. Minimal recruitment of 
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monocytes/macrophages/dendritic cells was observed in all groups, and showed no 
difference between treatments. Immunohistochemical staining for Ly6G+ neutrophils in 
livers taken from these mice showed no significant changes in numbers of infiltrating 
neutrophils, demonstrating that the neutrophil response is specific and localised to the 
peritoneum (Figure 3-12B). 
The same experimental design was then used to compare neutrophil recruitment in 
response to nitrated CXCL8, in comparison to wild type CXCL8 (Figure 3-13A). Again, 
injection of wild type CXCL8 induced a significant increase in neutrophil recruitment in 
comparison to both the control groups (p=<0.05) and nitrated CXCL8 group (p=<0.05). 
Injection of nitrated CXCL8 did not induce an increase in neutrophil recruitment in 
comparison to injection of saline alone. None ofthe treatments tested induced an 
increase in migration of monocytes/macrophages/dendritic cells. As before, no increase 
in neutrophil migration to the liver was observed in any treatment group (Figure 3-
13B). 
Nitrated CXCL8 is therefore unable to induce migration of primary human neutrophils in 
vitro, or murine neutrophils in vivo.  
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Figure 3-10. Optimising murine intra-pouch recruitment in response to CXCL8. A) Total 
neutrophil (red dots) and monocyte/macrophage/dendritic cell (blue dots) migration into air 
pouches 4 hours after intrapouch administration of PBS + 0.5% CMC, 1µg or 3 µg CXL8 (in PBS + 
0.5% CMC) was determined. Cells were counted using a TALI automatic cell counter, then 
stained for CD45, CD14 and Ly6G. Amounts of each cell type (gated at CD45+ Ly6G+ or CD45+ 
CD14+) were recorded using a FACS Canto III flow cytometer and analysed using FlowJo V10 
software. Each symbol represents an animal. 1cm skin sections were shaved and removed from 
the back of 2 animals per group and stained with B) Haematoxylin and Eosin, or C) anti-Ly6G 
primary antibody (127623, Biolegend) detected with a Dylight-488 conjugated secondary 
antibody (GtxMs-003-E488NHSX, Immunoreagents) to show neutrophil recruitment to the skin 
of the pouch. No primary antibody control is shown indented (NP), as are close-up images of 
individual Ly6G+ cells. Images were taken at 10x magnification, and images shown are 
representative of 5 sections analysed per animal. Statistical analysis was performed using a One 
Way ANOVA with Tukey’s post-test. 
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Figure 3-11. Murine intra-pouch recruitment in response to CXCL8 or nitrated CXCL8. A) 
Total neutrophil (red dots) and monocyte/macrophage/dendritic cell (blue dots) migration into 
air pouches 4 hours after intrapouch administration of PBS + 0.5% CMC, 1µg CXL8 (in PBS + 
0.5% CMC), 1µg Nitrated CXL8 (in PBS + 0.5% CMC), or 1µg of each CXCL8 and Nitrated CXCL8 
together, was determined. Cells were counted by using a TALI automatic cell counter, then 
stained for CD45, CD14 and Ly6G. Amounts of each cell type (gated at CD45+ Ly6G+ or CD45+ 
CD14+) were recorded using a FACS Canto III flow cytometer and analysed using FlowJo V10 
software. Each symbol represents an animal. 1cm skin sections were shaved and removed from 
the back of 2 animals per group and stained with B) Haematoxylin and Eosin, or C) anti-Ly6G 
primary antibody (127623, Biolegend) detected with a Dylight-488 conjugated secondary 
antibody (GtxMs-003-E488NHSX, Immunoreagents) to show neutrophil recruitment to the skin 
of the pouch. No primary antibody control is shown indented (NP), as are close-up images of 
individual Ly6G+ cells. Images were taken at 10x magnification, and images shown are 
representative of 5 sections analysed per animal. Statistical analysis was performed using a One 
Way ANOVA with Tukey’s post-test. 
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Figure 3-12. Murine intra-peritoneal recruitment in response to CXCL8.  A) Total 
neutrophil (red dots) and monocyte (blue dots) migration into the mouse peritoneum 6 hours 
after intra-peritoneal administration of sterile clinical grade saline or 1μg wild type CXCL8. 
500μl PBS ± 1μg of CXCL8 was injected in to the peritoneum of the mice, and was left for 6 hours 
to allow cells to migrate. Mice were then sacrificed, and the peritoneum lavaged with PBS + 3mM 
EDTA to collect cells. The lavage was then stained and the cells analysed and counted using a BD 
Accuri C6 flow cytometer. Shown are the total numbers of live neutrophils (Sytox Red- CD45+ 
Ly6G+, red dots) and live monocyte/macrophage/dendritic cells measured as a control (Sytox 
Red- CD45+ CD14+). Each dot represents an individual animal. B) Sections from the large lobe of 
the liver stained with anti-Ly6G primary antibody (127623, Biolegend) detected with a Dylight-
488 conjugated secondary antibody (GtxMs-003-E488NHSX, Immunoreagents). No primary 
antibody control =NP. Close-up images of individual Ly6G+ cells are indented. Images taken at 
20x magnification, and images are representative of 5 sections stained from n=1 no treatment 
mouse, and n=2 mice from the other treatment groups. Statistical analysis was performed using 
a One Way ANOVA with Tukey’s post-test. 
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Figure 3-13. Murine intra-peritoneal recruitment in response to CXCL8 or nitrated CXCL8. 
A) Total neutrophil (red dots) and monocyte (blue dots) migration into the mouse peritoneum 6 
hours after intra-peritoneal administration of sterile clinical grade saline, 1μg wild type CXCL8 
or 1μg nitrated CXCL8. 500μl PBS ± 1μg of chemokine was injected in to the peritoneum the 
mice, and was left for 6 hours to allow cells to migrate. Mice were then sacrificed, and the 
peritoneum lavaged with PBS + 3mM EDTA to collect cells. The lavage was then stained and the 
cells analysed and counted using a BD Accuri C6 flow cytometer. Shown are the total numbers of 
live neutrophils (Sytox Red- CD45+ Ly6G+, red dots) and live monocyte/macrophage/dendritic 
cells measured as a control (Sytox Red- CD45+ CD14+). Each dot represents an individual animal. 
B) Sections from the large lobe of the liver stained with anti-Ly6G primary antibody (127623, 
Biolegend) detected with a Dylight-488 conjugated secondary antibody (GtxMs-003-E488NHSX, 
Immunoreagents). No primary antibody control is shown indented (NP), as are close-up images 
of individual Ly6G+ cells. Images taken at 20x magnification, and images are representative of 5 
sections stained from n=1 no treatment mouse, and n=2 mice from the other treatment groups. 
Statistical analysis was performed using a One Way ANOVA with Tukey’s post-test. 
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3.3.3 Assessing the Receptor Signalling Capabilities of CXCL8 and CXCL8 Variants  
In order to discover which aspects of chemokine biology (i.e. GAG binding or GPCR 
signalling) were affected by nitration and thus were the cause of the decrease in 
neutrophil recruitment seen after nitration, further experiments were performed.  
Calcium flux assays were used to measure the ability of CXCL8, nitrated CXCL8, Y13F 
CXCL8 and nitrated Y13F CXCL8 to induce GPCR signalling and subsequent calcium 
mobilization in primary neutrophils labelled with Indo-1. Results in Figure 3-14A and B 
show that CXCL8 induced a calcium flux of ~350nM, a significant increase in comparison 
to neutrophils stimulated with PBS only (p=<0.001). Nitrated CXCL8 induced a 10-fold 
lower amount of calcium flux than wild type CXCL8 (p=<0.01), which was not 
statistically different from that of PBS-stimulated neutrophils which were used as a 
negative control. Y13F and nitrated Y13F CXCL8 also showed a significantly impaired 
ability to induce calcium flux, when compared to wild type CXCL8 (p=<0.05). Again, it 
appears that the loss of tyrosine 13 does inhibit chemokine function in the Y13F mutant 
chemokine, however a far more substantial inhibition occurs when tyrosine 13 is 
present and nitrated.  
To verify these results, neutrophils were treated for 2, 5 or 10 minutes with 30nM of 
each of the chemokine variants, and Western blot analysis was performed on the lysates 
to detect phosphorylated-ERK as another downstream consequence of GPCR signalling. 
The results in Figure 3-15 show that CXCL8-treatment for 2 and 5, but not 10, minutes 
induces rapid ERK phosphorylation, with less phosphorylated ERK detected in 
neutrophils stimulated with Y13F or nitrated Y13F CXCL8. Stimulation with nitrated 
CXCL8 did not induce any detectable ERK phosphorylation. 
As mentioned previously, both CXCR1 and CXCR2 are known to be involved in 
neutrophil chemotaxis in response to large and small concentrations of CXCL8 
respectively. I aimed to confirm which of the two receptors was largely responsible for 
the signalling cascade resulting in calcium flux and ERK phosphorylation in response to 
wild type CXCL8. Thus trans-filter chemotaxis assays were performed, where 
neutrophils were incubated with 20μM neutralizing antibodies against CXCR1 and/or 
CXCR2 prior to migration in response to wild type CXCL8 only. The results in Figure 3-
16 show that 30nM CXCL8 induces a significant increase in neutrophil migration in 
comparison to the negative control (p=<0.05), and only the CXCR1 neutralizing antibody 
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used at 20µM decreases this migration, although this decrease was not found to be 
statistically significant. Incubation with the anti-CXCR2 antibody showed no reduction in 
migration, and no additional reduction when used in combination with the anti-CXCR1 
antibody. 
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Figure 3-14. Ability of wild type CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated Y13F 
CXCL8 to induce calcium signalling in neutrophils. A) Calcium flux in response to PBS, 30nM 
of CXCL8, nitrated CXCL8, Y13F CXCL8 or nitrated Y13F CXCL8 added to the cells after 60 
seconds (red arrow). 10µg/ml of Ionomycin was used as a positive control and added at 300 
seconds (blue arrow). B) Calcium release (nM) in response to the above treatments calculated 
using the equation [Ca2+] = kd x (R – Rmin) / (Rmax – R), where the kd = 844 nM/L 284,285. C) 
Haematoxylin and Eosin staining of a cytospin collected from the cell population, showing a high 
percentage purity of neutrophils. Images were taken using light microscopy at 20x and 40x 
magnification. Data shown in A) and C) is representative of, and in B) is combined from, N=3 
experimental replicates (using neutrophils isolated from different blood donors), each with n=1 
technical replicate. Statistical analysis was performed using a One Way ANOVA with Tukey’s 
post-test. 
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Figure 3-15. Ability of wild type CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated Y13F 
CXCL8 to induce ERK phosphorylation in neutrophils. Isolated neutrophils were treated for 
2, 5 or 10 minutes with 30nM of the chemokine variants, with unstimulated cells used as a 
negative control. Lysates where then prepared and used in Western blotting experiments with 
an anti-phosphorylated ERK1/2 antibody (36-8800, ThermoFisher Scientific) followed by an 
anti-rabbit-HRP antibody (A6154, Sigma), as well as anti-pyruvate dehydrogenase complex 
(PDC-E2) antibody as loading control followed by anti-human-HRP antibody (AP112P, Sigma). 
Data shown is representative of N=3 experimental replicates (using neutrophils isolated from 
different blood donors), each with n=1 technical replicate. 
 
Figure 3-16. Migration of neutrophils in response to CXCL8 following incubation with 
anti-CXCR1/CXCR2 antibodies. Trans-filter chemotaxis assays showing percentage of total 
neutrophils that migrated through a bare filter in response to 30nM CXCL8 after pre-treatment 
with 20μM anti-CXCR1 antibody (Ab89251, Abcam), anti-CXCR2 antibody (Ab10401, Abcam) or 
both antibodies together. Data shown is representative of N=3 experimental replicates (using 
neutrophils isolated from different blood donors), each with n=3 technical replicates. Statistical 
analysis was performed using a One Way ANOVA with Tukey’s post-test. 
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3.3.4 Assessing the GAG Binding Capabilities of CXCL8 and CXCL8 Variants  
In order to assess the ability of the CXCL8 variants to bind to GAGs, flow-based adhesion 
assays were performed using Cellix™ technology, whereby neutrophils were flown over 
an HMEC-1 endothelial cell monolayer untreated or pre-treated with TNF-α ± 
chemokine. This aimed to test the ability of the chemokine variants to bind to GAGs 
present on the endothelial cells, as measured by subsequent neutrophil adherence. 
Initial experiments involved optimising the detachment method used to remove HMEC-1 
cells from tissue culture flasks before seeding onto Cellix™ VenaFlux Endothelial+ 
Biochips, and the concentration of TNF-α needed to stimulate the endothelial cells once 
coated onto the Biochip. This was done in order to induce an adequate increase in 
adhesion molecule expression, but without increasing the production of CXCL8 
significantly. 
Single immunofluorescence staining of chamber slides in Figure 3-17 below shows that 
detachment of cells with trypsin decreases expression of heparan sulphate for up to 6 
hours, detachment with Accutase decreases expression for up to 2 hours, and 
detachment with PBS + 3mM EDTA does not affect heparan sulphate expression. 
Therefore, the latter was the detachment method used in all subsequent experiments to 
avoid the degradation/cleavage of GAGs as much as possible. To assess the optimum 
TNF-α concentration to use for stimulation and upregulation of adhesion molecule 
expression, HMEC-1 cells were treated for 2 hours or 16 hours with 1-10ng/ml of TNF-α, 
then stained for ICAM-1 and VCAM and analysed by flow cytometry. Cell supernatant 
was also collected and analysed for CXCL8 production by ELISA. All concentrations 
tested induced a significant upregulation of both VCAM and ICAM-1 when HMEC-1 cells 
were treated for both 2 hours and 16 hours, whereas CXCL8 production only increased 
significantly when cells were treated with 10ng/ml TNF-α for 2 hours or with 2.5, 5 and 
10ng/ml for 16 hours (Figure 3-18A and B). 
In order to achieve maximum upregulation of adhesion molecules, the 16 hour 
treatment was taken forward to be assessed in a flow-based adhesion assay, to measure 
the number of neutrophils adhering to channels coated with HMEC-1 monolayers 
previously treated with the varying concentrations of TNF-α. Time-lapse images were 
taken of each channel as neutrophils were flown across at 0.5 dyne/cm2; a physiological 
flow rate mimicking that of the circulation. The number of adhering neutrophils were 
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then counted in each image, and calculated for each channel as shown in Figure 3-19A 
below. Figure 3-19B shows representative images from each channel, and an example 
image of a confluent HMEC-1 monolayer coating a channel. Only 5ng/ml and 10ng/ml 
TNF-α treatment inducing significant adhesion of neutrophils above the level of the 
negative control group (p=<0.001).  
Various experiments were then performed to assess how pre-treatment of the HMEC-1 
endothelial layer with CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated Y13F CXCL8 
would affect neutrophil adhesion. This was attempted with HMEC-1 cells grown both 
statically and under flow conditions on the chip using a Kima pump, with 5ng/ml TNF-α 
treatment administered to the HMEC-1 cells statically at both 2 hours and 16 hours, and 
with varying concentration of the chemokine variants added to the HMEC-1 monolayers. 
Results proved inconsistent (data not shown), with no additional adhesion seen in 
response to CXCL8 treatment + TNF-α treatment above the level of TNF-α treatment 
alone. 
As an alternative method to assess GAG binding, Surface Plasmon Resonance (SPR) was 
performed to assess the ability of CXCL8, nitrated CXCL8, Y13F CXCL8 and nitrated Y13F 
CXCL8 to bind to immobilized heparin as a model GAG under flow conditions. Results in 
Figure 3-20 show that nitration of both wild type and Y13F mutant CXCl8 almost 
completely abolishes binding to heparin. Nitration therefore affects CXCL8 function 
through inhibition of GAG binding as well as receptor signalling. Loss of Y13 without 
nitration shows a smaller decrease in binding in comparison to the wild type CXCL8 
(Figure 3-20)., and also indicates altered binding properties for the Y13F mutant in 
comparison to the wild type chemokine. While neither curve reached saturation under 
the experimental conditions used, the binding curve observed for wild type CXCL8 
shows two distinct binding modes indicated by the different trajectories within the 
curve – the fast off rate (at 200-250 seconds) and then binding which does not return to 
baseline (at 250-600 seconds).  The former is indicative of chemokine monomers which 
quickly dissociate from the immobilised heparin, whereas the latter is indicative of 
chemokine oligomers forming on the surface of the chip as the multiple GAG-binding 
domains within oligomersers mean that the oligomer never fully detaches from the chip 
surface– when one binding domain dissociates another immediately re-associates. The 
binding curve observed for Y13F CXCL8 indicates only monomeric binding occurred in 
the case of the mutant chemokine. 
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Figure 3-17. Single immunofluorescence staining to detect Heparan Sulphate expression 
by HMEC-1 cells 2, 6 or 24 hours after detachment from flasks using PBS + 3mM EDTA, 
Accutase or Trypsin. Staining was performed using an anti-human heparan sulphate antibody 
(10E4 clone) donated by a collaborator, and detected with a Goat anti-mouse-DyLight®488 
conjugated secondary antibody (GtxMs-003-E488NHSX, Immunoreagents). No primary antibody 
control is shown indented (NP). Images were taken at 20x magnification, and images shown are 
representative of 5 fields of view imaged per chamber.  
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Figure 3-18. CXCL8 Production, and VCAM and ICAM-1 expression following TNF-α 
treatment. HMEC-1 cell expression of CXCL8 assessed using Peprotech’s CXCL8 ELISA kit, and 
expression of VCAM (305805, Biolegend) and ICAM-1 (353105, Biolegend) assessed using flow 
cytometry as the percentage increase in mean fluorescence intensity as compared to the isotype 
control (12-4714-42, ThermoFisher Scientific), which is indicated at 100% by the dotted line, 
after A) 2 hours and B) 16 hours of treatment with 0-10ng/ml TNF-α. Data shown in A) is 
representative of N=3 experimental replicates, each with n=3 technical replicates, and in B) of 
N=2 experimental replicates, each with n=3 technical replicates. Statistical analysis was 
performed using a One Way ANOVA with Tukey’s post-test. 
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Figure 3-19. Neutrophil adhesion to an HMEC-1 monolayer treated for 16 hours with 0-
10ng/ml TNF-α. Neutrophils were flown over HMEC-1 cell monolayers which has been pre-
treated for 16 hours with a range of TNF-α concentrations (ng/ml) at 0.5 dyne/cm2. Adhering 
neutrophils were counted using ImageJ, from 5 sequential images per position, 5 positions per 
channel. B) Fluorescent images of DiOCe(3) labelled neutrophils adhering to an HMEC-1 cell 
monolayer, and a brightfield image of the HMEC-1 monolayer. Both were taken using the Cellix™ 
imaging platform at 20x magnification. Data shown in A) and B) is representative of N=2 
experimental replicates (using neutrophils isolated from different blood donors), each with n=2 
technical replicates. Statistical analysis was performed using a One Way ANOVA with Tukey’s 
post-test. 
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Figure 3-20. Altered heparin binding ability of CXCL8 when nitrated and/or mutated. 
Biacore was used to assess the ability of wild type CXCL8, nitrated CXCL8, Y13F mutant CXCL8 
and nitrated Y13F CXCL8 to bind heparin.  50- 1000nM chemokine was flowed over immobilised 
heparin (159.6RU bound) and the alteration in resonance units (RU) as a result of binding is 
shown. Data shown is representative of N=3 experimental replicates, each with n=1 technical 
replicate.  
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3.3.5 Assessing the Ability of Nitrated CXCL8 to Inhibit the Function of CXCL8 
Having found that nitration of CXCL8 impairs its ability to signal through its GPCRs and 
to bind to GAGs, I aimed to assess whether the nitrated chemokine was capable of 
inhibiting its wild type counterpart when neutrophils were treated with both 
chemokines in an equimolar ratio (30nM). In chemotaxis assays, Figure 3-21 shows that, 
as previously found, CXCL8 induces significant migration of neutrophils above the 
negative control in both trans-filter (A) (p=<0.001) and trans-endothelial (B) (p=<0.01) 
assays, and nitrated CXCL8 does not induce migration above the level of the negative 
control. Addition of both CXCL8 and nitrated CXCL8 together also shows significant 
migration in comparison to the negative control (A) (p=<0.001) (B) (p=<0.05), and this 
was found to be no different to treatment with CXCL8 alone.  
The same pattern was observed in calcium flux assays shown in Figure 3-22A and B; 
addition of CXCL8 and nitrated CXCL8 together showed a significant increase in calcium 
release in comparison to the PBS control group (p=<0.05), but this was no different to 
calcium release after neutrophils were treated with CXCL8 alone.  
Nitrated CXCL8 is therefore unable to inhibit the function of wild type CXCL8, when used 
at equimolar concentrations. Higher concentrations were not assessed in this study. 
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Figure 3-21. Ability of nitrated CXCL8 to inhibit neutrophil migration in response to wild 
type CXCL8 in vitro. A) Trans-filter chemotaxis assays and, B) Trans-endothelial chemotaxis 
assays, showing percentage of total neutrophils that migrated through a bare filter in response 
to 30nM wild type CXCL8, 30nM nitrated CXCL8, or 30nM of both together. C) Images taken at 
20x and 40x show the confluent layer of HMEC-1 cells stained with haematoxylin. Data shown 
for A), B) and C) is representative of N=3 experimental replicates (using neutrophils isolated 
from different blood donors), each with n=3 technical replicates. Statistical analysis was 
performed using a One Way ANOVA with Tukey’s post-test.  
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Figure 3-22. Ability of nitrated CXCL8 to inhibit the calcium signalling of wild type CXCL8 
in neutrophils in vitro. A) Calcium flux in response to PBS, 30nM wild type CXCL8, 30nM 
nitrated CXCL8, or 30nM of each together added at 60 seconds (red arrows). 10µg/ml of 
Ionomycin was used as a positive control added at 300 seconds (blue arrows). B) Calcium 
release (nM) in response to the above treatments calculated using the equation [Ca2+] = kd x (R – 
Rmin) / (Rmax – R), where the kd = 844 nM/L 284,285.  C) Haematoxylin and Eosin staining of a 
cytospin collected from the cell population, showing a high percentage purity of neutrophils. 
Images were taken using light microscopy at 20x and 40x magnification. Data shown in A) and C) 
are representative of, and B) is combined from N=3 experimental replicates (using neutrophils 
isolated from different blood donors), each with n=1 technical replicate. 
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3.3.6 Determining Which Residues within CXCL8 Are Targets For Nitration by 
Peroxynitrite 
In order to determine exactly which residues within CXCL8 were nitrated after 
incubation with peroxynitrite, I aimed to use ion trap mass spectrometry to fractionate 
the chemokine and assess the weights of the resulting fragments. 
As described in section 3.2.7, nitrated CXCL8 was injected into the mass spectrometer 
and analysed by standard mass spectrometry. Then, through mass spectrometry/mass 
spectrometry (MS2) analysis, the most abundant peak (1205) was isolated, retained 
within the ion trap, then fractionated at the D-P bond to create an N-terminal fragment 
(1493.01), and a C-terminal fragment (820.14) as shown in Figure 3-23A. The charge 
state of each ion was determined by the number of peaks present within 1Da of each 
other, i.e. the 819.42 peak was determined to be triple charged, as between this peak 
and the peak at 820.42 there were three smaller peaks, each 0.33Da apart. Figure 3-23B 
demonstrates how these fragments were analysed, using the ion mass and the charge to 
calculate the molecular weight of each fragment. The amino acid sequence of each 
fragment is also shown in Figure 3-23C. The C-terminal fragments of both the wild type 
and nitrated chemokines had the same m/z and therefore same molecular mass, but the 
N-terminal fragment of the nitrated chemokine was found to have a molecular mass 
45Da larger than that of the wild type chemokine. I can therefore conclude that 
incubation with peroxynitrite nitrates CXCL8 on one residue present within the N-
terminal half of the chemokine. I attempted to perform MS3 analysis by isolating only 
the N-terminal ion (1493) and increasing the amplitude in order to fragment this ion 
into two daughter ions in order to further deduce which residue within the N-terminal 
fragment was nitrated, however this proved unsuccessful, resulting in either inadequate 
or excessive fragmentation.  
ELISAs and dot blots were then performed to assess whether nitrated CXCL8 could be 
detect using an anti-3NT antibody. This proved successful in both experimental settings 
as shown in Figure 3-24, confirming that the addition of the single nitrate group on the 
N-terminal half of the chemokine observed during MS2 analysis is located on the sole 
tyrosine residue within CXCL8; Y13.  
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The same MS2 analysis principle was applied to nitrated Y13F CXCL8, which also 
showed no alteration to the C-terminal fragment of the chemokine, but a 45Da increase 
in mass of the N-terminal fragment in comparison to the calculated value for the N-
terminal fragment of non-nitrated Y13F CXCL8 (Figure 3-25). This suggests that even 
with the substitution of Y13 for F, incubation with peroxynitrite nitrates this mutant 
CXCL8 on one residue present within the N-terminal half of the chemokine. 
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Figure 3-23. MS2 analysis of nitrated CXCL8. A) Shows the compound spectra for MS2 
analysis of nitrated CXCL8. Nitrated CXCL8 was manually injected at and analysed by ion trap 
mass spectrometry. The most abundant ion was the 1205 peak, which corresponds to a +7 
charged ion of the full length chemokine with one NO2 group added (+45Da). This ion was 
selected and held within the ion trap, then fragmented to break the D-P bond, thus cleaving the 
chemokine into a C-terminal peptide and an N-terminal peptide. A triple charged ion of 820.14 
corresponds to a peptide with no additional NO2 groups, whereas the quadruple charged ion of 
1493.01 (red arrow) is consistent with a peptide plus one NO2 group – therefore, incubation of 
CXCL8 with peroxynitrite results in one NO2 group being added to an amino acid within the N-
terminal section of the chemokine. B) Shows the calculation method derived from the equation 
“peak readout = (m+z/z)” to determine the molecular mass of each ion. C) The CXCL8 amino acid 
sequence with the relative amino acids highlighted in red for each peak analysed. Data shown is 
from N=1 experiment, with n=1 technical replicate.  
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Figure 3-24. Assessing whether nitration of CXCL8 occurs on Y13. A) Direct ELISA using a 
3NT polyclonal antibody (06-284, Millipore) at 1µg/ml followed by an anti-rabbit-HRP antibody 
(A6154, Sigma) to detect varying concentrations of wild type CXCL8, nitrated CXCL8 and 
nitrated BSA. Each concentration was tested in triplicate. B) Dot blot using the same 3NT 
polyclonal antibody, and a CXCL8 polyclonal antibody (AHC0881, Life Technologies) at 1µg/ml 
to detect 50ng of wild type CXCL8, nitrated CXCL8 and nitrated BSA. Data shown in A) is from 
N=1 experiment, each with n=3 technical replicates, and data shown in B) is representative of 
N=3 experimental replicates, each with n=1 technical replicate. 
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Figure 3-25. MS2 analysis of nitrated Y13F CXCL8. A) Shows the compound spectra for MS2 
analysis of nitrated Y13F CXCL8. Nitrated Y13F CXCL8 was manually injected at and analysed by 
ion trap mass spectrometry. The most abundant ion was the 1202.5 peak, which corresponds to 
a +7 charged ion of the full length chemokine with one NO2 group added (+45Da). This ion was 
selected and held within the ion trap, then fragmented to break the D-P bond, thus cleaving the 
chemokine into a C-terminal peptide and an N-terminal peptide. A triple charged ion of 820.24 
corresponds to a peptide with no additional NO2 groups, whereas the quadruple charged ion of 
1477.88 (red arrow) is consistent with a peptide plus one NO2 group – therefore, incubation of 
Y13F CXCL8 with peroxynitrite results in one NO2 group being added to an amino acid within the 
N-terminal section of the chemokine. B) Shows the calculation method derived from the 
equation “peak readout = (m+z/z)” to determine the molecular mass of each ion. C) The Y13F 
CXCL8 amino acid sequence with the relative amino acids highlighted in red for each peak 
analysed. Data shown is from N=1 experiment, with n=1 technical replicate. 
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3.4 DISCUSSION 
This chapter has highlighted the importance of studying post-translational nitration as 
an important mechanism of chemokine regulation, as it clearly has a profound impact on 
chemokine function both in vitro and in vivo. 
3.4.1 CXCL8 Nitration and Chemotactic Function 
Nitration of CXCL8 almost completely abolished primary human neutrophil chemotaxis 
in trans-filter chemotaxis assays, suggesting that nitration must affect the ability of 
CXCL8 to bind to CXCR1 and/or CXCR2 receptors, as no endothelial cells are present and 
therefore GAG binding is not applicable in this experimental setting. As observed in 
trans-filter assays, nitration of CXCL8 prevents it from inducing neutrophil migration 
through a monolayer of HMEC-1 endothelial cells in trans-endothelial chemotaxis 
assays. The nitrated chemokine also failed to recruit murine neutrophils to the mouse 
peritoneum in vivo.  
Calcium flux assays and Western blots detecting ERK phosphorylation confirmed that 
this reduction in migration is at least partly due to the impaired ability of the nitrated 
chemokine to signal through its GPCRs present on primary human neutrophils.  Visual 
inspection of the SPR data curves reveals gross differences in binding stability and 
crosslinking between wild type and nitrated CXCL8, which suggests that nitration also 
impairs the ability of CXCL8 to bind to immobilised heparin, suggesting that impaired 
GAG binding also contributes to the chemokine’s lack of chemotactic capacity following 
incubation with peroxynitrite. Nitrated CXCL8 cannot inhibit the function of wild type 
CXCL8 when administered at equimolar ratios (30nM) in both chemotaxis assays and 
calcium flux assays. This is likely due to both GAG binding and receptor binding being 
impaired, although the latter is not confirmed. I have shown that nitration can inhibit 
GPCR signalling, but further experiments would need to be conducted to confirm if this 
is due to impaired binding. 
These effects are unlikely to be attributed to the charge of the molecule as this is 
unaffected by nitration 95. NMR analysis performed by Dr Rajarathnam (see Figure 3-26) 
shows the superimposed spectra for wild type CXCL8 (black) in comparison to nitrated 
CXCL8 (red). As the vast majority of the spectra align, this shows that nitration has very 
107 
 
little influence on chemokine tertiary structure, and so any changes in function must be 
due to nitration and cannot be attributed to global structural changes. 
 
Figure 3-24. NMR data showing the superimposed spectra for wild type CXCL8 (black) and 
nitrated CXCL8 (red). The high degree of alignment indicated nitration does not affect the 3D 
folded structure of the chemokine. Unaligned peaks arise due to arginine side chains (Professor 
Krishan Rajarathnam, unpublished data). 
3.4.2 CXCL8 and Y13 
The loss of Y13 achieved through generation of the Y13F mutant chemokine either did 
not affect, or slightly increased the chemotactic response of neutrophils, particularly at 
lower concentrations of 10nM (p=<0.001) or 20nM (p=<0.01). This indicates that Y13 is 
not essential for GPCR signalling or chemotactic function, as its loss does not prevent 
this response. A slight reduction in calcium flux was observed after neutrophils were 
treated with the Y13F mutant CXCL8 in comparison to wild type CXCL8 (p=<0.05), 
which could be attributed to partially impaired GPCR binding caused by the loss of Y13 
which forms a hydrogen bond with D14 of CXCR1 185, however this is not significant 
enough to impair migration. In trans-endothelial assays, fewer neutrophils migrated in 
response to the Y13F mutant than had migrated in response to this variant in trans-filter 
assays, however migration was not completely abolished, with percentages reducing 
from as high as 40% to as low as 10%. This suggests that Y13 could be involved in 
CXCL8’s interaction with GAGs, although some effect on chemokine 
dimerization/oligomerisation is also possible, and could be indicated by the SPR 
experiments. This data confirmed that the Y13F mutant CXCL8 has a slightly reduced 
ability to bind to heparin than wild type CXCL8, and the patterns of the binding curves 
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generated also suggest different modes of binding. It appears that the wild type 
chemokine binds both as monomers (indicated by rapid dissociation) and as oligomers 
with increased avidity (indicated by a stable reading above baseline after dissociation 
caused when one GAG-binding domain within the oligomer immediately re-associates 
with the immobilised heparin as another dissociates). The rapid dissociation and return 
to baseline observed in the Y13F CXCL8 binding curve indicates that the mutant 
chemokine binds as a monomer only. This data could suggest that the substitution of 
tyrosine for phenylalanine in the Y13F mutant could affect the chemokine’s ability to 
dimerise, although is not clear how this substitution would affect dimerization, as 
position 13 within CXCL8 is located at the periphery of the protein and not at the dimer 
interface as shown in Figure 1-7C, therefore further study would be required to 
determine if substituting tyrosine for phenylalanine does compromise dimerization. If 
proven to be true, however, this could explain the reduction in neutrophil trans-
endothelial migration observed in response to the Y13F mutant CXCL8 in comparison to 
the wild type chemokine. Both tyrosine and phenylalanine have hydrophobic side chains 
286, however substitution of tyrosine for phenylalanine will result in a change in the 
residue from polar to non-polar, and could affect the ability to form hydrogen bonds 287 
– these alterations could possibly be responsible for the differences in chemotactic 
capacity observed between the wild type and mutant CXCL8. 
 As the nitrated Y13F mutant showed a reduction in the induction of chemotaxis when 
compared to the non-nitrated Y13F chemokine, there must be other residues within 
CXCL8 other than tyrosine, (or possibly the phenylalanine mutated in 288,289), which is a 
target for peroxynitrite and is partly responsible for the induction of chemotaxis.  
Ion trap MS2 analysis of nitrated CXCL8 and nitrated Y13F CXCL8 was performed in an 
attempt to determine which residues within the chemokines are modified by 
peroxynitrite, that cause the altered functionality observed in other experiments. These 
experiments confirmed that incubation of both wild type and Y13F CXCL8 with 
peroxynitrite result in the addition of one nitrate group to the N-terminal half of the 
chemokine. In the case of wild type CXCL8, this residue is confirmed to be Y13, as 
nitrated CXCL8 has shown to be detectable using an anti-3NT antibody, and the only 
tyrosine residue present within CXCL8 is Y13.  
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Initially the rationale behind generating the Y13F mutant CXCL8 was to mutate in a 
residue which could not be nitrated in order to confirm whether Y13 is the only target 
for nitration that will affect function, however evidence has since come to light that 
suggests that the phenylalanine actually is capable of being nitrated. This suggests that 
the nitration observed in MS2 analysis of nitrated Y13F CXCL8 is actually on F13 288,289, 
and is supported by the fact that nitrated CXCL8 and nitrated Y13F CXCL8 showed 
statistically different functionality in trans-filter chemotaxis assays (30nM p=<0.05), 
which would not be the case if any residue other than the altered amino acid at position 
13 was responsible for functionality and modified by peroxynitrite. This therefore 
implies that nitration at position 13 affects function regardless of the actual residue 
present, if that residue is a target for nitration. 
3.4.3 CXCL1 Nitration and Chemotactic Function 
To investigate the effect that nitration has on a chemokine with no naturally occurring 
tyrosine residues, and the subsequent effect of adding and then nitrating a tyrosine 
residue, CXCL1 was studied in addition to CXCL8. 
Incubation of CXCL1 with peroxynitrite also inhibited its ability to induce neutrophil 
migration in trans-filter chemotaxis assays (p=<0.001), as it did in the case of CXCL8. 
This indicates that other amino acids (as CXCL1 contains no tyrosine, tryptophan or 
phenylalanine residues), which can be targets for peroxynitrite such as cysteine or 
histidine, must be required for CXCL1 function; the nitration or oxidation of which 
impairs its chemotactic ability. Nitration following introduction of a tyrosine residue 
artificially also induced no neutrophil migration. In trans-endothelial chemotaxis assays, 
although baseline migration in response to the negative control appears slightly higher 
in this experiment (which could be due to more activated donor neutrophils), migration 
in response to nitrated CXCL1 is reduced to this level in the trans-endothelial assay as it 
was in the trans-filter. Substitution of leucine at position 15 for tyrosine is shown to 
reduce chemotaxis by roughly half when compared to the wild type CXCL1. This 
indicates that L15 is in part, but not completely, responsible for the induction of 
neutrophil migration. This is not confirmed in the literature, however, L15 is within the 
N-loop of CXCL1 290 which is a region of the chemokine known to be important in GPCR 
binding 2. The addition of a tyrosine residue, which is then nitrated, produces the same 
effect as nitrating the wild type chemokine. Nitration therefore equally impairs the 
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function of CXCL1 regardless of the loss of leucine/introduction of tyrosine at position 
15. Inconsistent results in trans-endothelial chemotaxis assays could be due to 
endogenous chemokine production by the HMEC-1 cells influencing neutrophil 
migration, or issues with neutrophil preparations. However, as the aim of these 
experiments was to explore the importance of tyrosine residues in nitration, and this 
question was largely answered by trans-filter chemotaxis assays, these experiments 
were not optimised further. 
As with CXCL8, NMR analysis provided by Dr Rajarathnam (University of Texas Medical 
Branch) indicates that nitration of CXCL1 does not affect its tertiary structure, as the 
majority of the wild type spectra (black) aligns with that of the nitrated chemokine (red) 
(see Figure 3-27). The few superimposed peaks which do not align arise from arginine 
side chains. Both leucine and tyrosine contain hydrophobic side chains, meaning they 
are relegated to the centre of the folded protein. The L15Y substitution is therefore 
unlikely to change the 3D fold structure of CXCL1, and the reduction in migration seen in 
the mutant chemokine compared to the wild type is unlikely to be due to 3D structural 
changes 286,287. However, leucine is non-polar, whereas tyrosine is polar, and 
interactions with leucine mainly occur through van der Waals forces, whereas tyrosine 
can also interact via hydrogen bond formation and aromatic stacking 287.The reduction 
in chemotaxis seen in response to the L15Y mutant could possibly be attributed to these 
potentially altered characteristics. 
As CXCL1 does not contain any naturally occurring tyrosine residues, the reduction in 
function of wild type CXCL1 after incubation with peroxynitrite suggests that tyrosine 
cannot be the only residue that is a target for nitration and affects function. This means 
that we cannot predict how nitration will affect any given chemokine based on the 
location and number of tyrosine residues within its structure as initially hoped. 
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Figure 3-25. NMR data showing the superimposed spectra for wild type CXCL1 (black) and 
nitrated CXCL1 (red). The high degree of alignment indicated nitration does not affect the 3D 
folded structure of the chemokine. Unaligned peaks arise due to arginine side chains (Professor 
Krishan Rajarathnam, unpublished data). 
3.4.4 Future Studies 
Further analysis could be performed to determine if nitration affects the ability of CXCL8 
to form dimers, which are known to have a lower affinity for the chemokine’s receptors, 
but a higher affinity for GAGs. The effect that dimerization would have on the function of 
the chemokine would likely depend on the ratio and positioning of wild type and 
nitrated monomers within the chemokine oligomer.  
It would also be interesting to assess whether nitration affects the binding ability and 
affinity of CXCL8 for the atypical chemokine receptor ACKR1, as binding of the nitrated 
chemokine to this receptor would mean less is available for the wild type chemokine to 
bind to, which could potentially result in increased inflammation. 
Chemotaxis assays and calcium flux assays to assess the function of nitrated CXCL8 and 
its ability to inhibit wild type CXCL8 could also be repeated using higher concentrations 
of chemokines. While the concentration range used (10-30nM) suggests that nitration 
abrogates CXCL8 function, testing a range of higher concentrations could show that 
nitration shifts the bell-shaped curve of the chemokine response to the right, meaning 
that the nitrated chemokine could still be functional, but at much higher concentrations 
than the wild type chemokine. This is shown diagrammatically in Figure 3-28 below, and 
could be the case as 30nM nitrated CXCL8 did appear to induce slight calcium flux, and 
1000nM nitrated CXCL8 did give a small heparin binding signal above background in 
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SPR analysis. However, no significant difference between nitrated CXCL8 and negative 
controls has been observed in any experimental settings, suggesting the shift in 
functionality is quite substantial and therefore difficult to study as it is likely that very 
large concentrations of nitrated chemokine would be needed to achieve functionality 
comparable to that of wild type CXCL8.  
 
Figure 3-26. Hypothetical chemokine activity curves for CXCL8 and nitrated CXCL8. 
Diagram depicting the narrow window of CXCL8 and nitrated CXCL8 functionality observed by 
testing a limited range of concentrations. 
Further point mutational analysis could be performed to synthesise a Y13 mutant 
variant of CXCL8 that is unable to be nitrated at this position, to fully determine the role 
of tyrosine in nitration and subsequent function alterations. MS2 analysis of CXCL1 
could also help determine which amino acid is nitrated in the case of this chemokine. 
This chapter has shown that nitration of CXCL8 reduces its ability to induce neutrophil 
migration in vitro and in vivo, that this is due to impaired receptor signalling and GAG 
binding, and that nitrated CXCL8 is unable to inhibit wild type CXCL8 at equimolar 
ratios.  These studies have also shown that these effects are mediated by the addition of 
one nitrate group on the N-terminal half of CXCL8, which is confirmed to be on Y13.  
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4 DEVELOPING A METHOD TO DETECT NITRATED CXCL8 
IN BIOLOGICAL SAMPLES 
4.1 INTRODUCTION 
Work described in the previous chapter showed that nitration of CXCL8 by peroxynitrite 
affects the chemokine’s biological function and inhibits its ability to recruit neutrophils 
in vitro and in vivo. Nitration could therefore be said to render the inflammatory CXCL8 
non-functional. These studies were conducted using CXCL8 which was nitrated by 
incubation with peroxynitrite in a laboratory setting, and while natural nitration of 
CXCL12 has been detected122, there is a need to prove that this modification also occurs 
in vivo in the case of CXCL8. 
The alteration in function caused by nitration means that it is essential to be able to 
differentiate between modified and unmodified chemokines, and measure both 
accurately in order to gain a complete understanding of the inflammatory situation. 
Previous work by Catriona Barker showed that nitrated CCL5 was detectable with 
currently available antibodies raised against the wild type chemokine, but nitrated CCL2 
was not (Catriona Barker, PhD thesis). Measuring wild type chemokines only may not 
represent the true amount that has been produced and subsequently modified. In 
addition, unknowingly measuring both modified and unmodified chemokines together, 
but assuming this amount detected to be wild type chemokine only, is also 
misrepresentative. This could explain why the levels of many chemokines have been 
correlated with different disease states, but none have been developed further into 
clinical diagnostic assays. Increased levels of CXCL8 have been correlated with 
hepatocellular carcinoma265, chronic obstructive pulmonary disease246, acute 
respiratory distress248, osteoarthritis291 and Alzheimer’s disease255 to name a few. 
Measuring the ratio of wild type to nitrated CXCL8 could increase the significance of 
using this chemokine as a biomarker of disease severity or progression. 
Detection of nitrated chemokines will improve our understanding of when they are 
produced and why, which could in turn improve understanding of the pathology of many 
diseases. Some disease/inflammatory states are more likely to facilitate nitration than 
others. For example, if peroxynitrite-mediated nitration occurs as a result of IRI and 
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oxidative stress as hypothesised, then the amount of nitrated CXCL8 or its ratio to wild 
type CXCL8 could be an important indicator of IRI severity. This could therefore be 
applicable in an organ transplant situation, where detecting nitrated chemokines like 
CXCL8 could be indicative of IRI in donor organs prior to transplant and in patient 
samples post-transplant.  
The detection of other forms of chemokine modification, such as citrullination and 
truncation could also be further explored as any modification has the potential to alter 
epitopes and thus affect chemokine detectability, though this is beyond the scope of this 
project.  
4.1.1 Specific Aims 
 Assess whether commercially available antibodies can detect nitrated CXCL8 
 Develop a novel antibody specific for nitrated CXCL8 
 Develop the novel antibody into an ELISA to measure nitrated CXCL8 in patient 
samples 
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4.2 SPECIFIC MATERIALS AND METHODS 
4.2.1 Sandwich ELISA 
4.2.1.1 Assessing Commercially Available CXCL8 ELISA Kits 
R&D’s Human CXCL8 Duoset ELISA kit (DY208), and Peprotech’s Human CXCL8 ELISA 
kit (900-T18) were used as per the manufacturer’s instructions. 
4.2.1.2 Developing a Sandwich ELISA to Detect Nitrated CXCL8 
A basic sandwich ELISA protocol (as described in section 2.7.2) was followed, trialling 
different capture and detection antibody combinations. For biotinylation of AbD31649.1, 
a Lightning-Link® Kit (Innova Biosciences) was used as per the manufacturer’s 
instructions. 
4.2.2 High Performance Liquid Chromatography  
4.2.2.1 Antibody Purification from C1 Hybridoma Cells 
The antibody was purified from stored C1 ascites by high performance liquid 
chromatography (HPLC) using Hitrap protein G sepharose columns. 500ml batches of 
media were centrifuged to remove cells, filtered, and then run through columns at a flow 
rate of 0.3ml/minute overnight. The bound antibody was eluted using 0.1M glycine + 
0.15M NaCl pH 2.6 and then concentrated. 
4.2.2.2 Size Exclusion Serum Fractionation 
This method used Superose 12 size exclusion chromatography columns (GE Healthcare), 
to fractionate normal human serum spiked with 10µg wild type CXCL8 or 6.6µg nitrated 
CXCL8. This would allow fractions containing high molecular weight/high abundance 
proteins to be diluted more than fractions containing the low molecular weight 
chemokine. The column was equilibrated with PBS at a flow rate of 
0.5ml/minute. Serum was clarified by centrifugation at 18,000xg for 5 minutes and 
filtration through a 0.45µm filter, then diluted in PBS to 16mg/ml. CXCL8 or nitrated 
CXCL8 (10µg or 6.6µg respectively), was then added into 0.5ml of the diluted serum, 
which was loaded onto the column with PBS and run at 0.5ml/minute. 26x 1ml fractions 
were collected. To each fraction 5μl of Insulin at 10mg/ml was added as a protein 
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carrier to aid precipitation (as this is 3kDa it can be run off the bottom of any gel). To 
each fraction 0.5ml of 30% (w/v) trichloroacetic acid was added and fractions were left 
on ice for 30 minutes. Samples were then centrifuged at 18000xg (4°C) for 15 
minutes. The supernatant was aspirated off and 400μl of ice-cold acetone added to each 
pellet, vortexed and re-centrifuged at 18,000xg (4°C) for 15 minutes. Supernatant was 
again aspirated and the pellet allowed to dry. 1x SDS-PAGE loading buffer was added 
(see below) to fractions and the pellet resuspended using a pipette tip. 
Fraction 8: 50μl  
Fractions 9 and 10: 100μl  
Fractions 11, 12, 13 & 14: 300μl  
Fractions 15-24: 50μl  
0.5μl NaOH was added to re-neturalise the samples, which were then boiled for 5 
minutes and extensively vortexed before spinning and loading onto an 18% SDS-PAGE 
gel (2μg). A Western blot was then performed as described in section 2.5 to detect 
CXCL8 and nitrated CXCL8.  
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4.3 RESULTS 
4.3.1 Assessing the Ability of Commercially Available ELISA Kits to Detect 
Nitrated CXCL8 
Data from a previous PhD student, Catriona Barker, showed that nitration of CCL2 
prevents its detection by commercially available antibodies raised against the wild type 
molecule. Experiments were therefore conducted to assess whether commercially 
available ELISA kits and antibodies raised against wild type CXCL8 could detect nitrated 
CXCL8. Initial results in Figure 4-1 below show that two standard human CXCL8 ELISA 
Kits (from Peprotech and R&D Systems) were unable to detect nitrated CXCL8 to the 
same degree as the wild type chemokine, when used as per the manufacturer’s 
instructions. R&D’s kit showed an 8-fold lower OD reading, and Peprotech’s kit a 7.7-fold 
lower OD reading, for the detection of 2000pg/ml of nitrated CXCL8 compared to the 
same concentration of wild type CXCL8.  Further experiments were performed, which 
involved splitting the kits into their individual antibody components, to test the ability of 
each capture and detection antibody to bind nitrated CXCL8 individually, in direct ELISA 
assays. For these experiments, chemokine was coated directly onto the plate, and was 
detected using the biotinylated detection antibodies and streptavidin-HRP, or capture 
antibodies followed by HRP-conjugated relevant secondary antibodies. It was found that 
neither the capture nor detection antibodies from either kit were able to recognise the 
nitrated chemokine with the same affinity as the wild type chemokine. Both capture 
antibodies showed a ~6-fold lower OD reading, and both detection antibodies showed a 
~13-fold lower OD reading, for the detection of nitrated CXCL8 than for wild type 
CXCL8, both at 100ng/ml. 
A polyclonal rabbit anti-human CXCL8 antibody (AHC0881, Life Technologies), was then 
tested in the same manner using a direct ELISA method. Unlike the others tested, this 
antibody was found to have equal affinity for both wild type and nitrated CXCL8, as 
shown in Figure 4-2A. These results were confirmed by testing the antibody in a dot blot 
assay, where the same results were observed as shown in Figure 4-2B.  
These initial experiments showed that current commercially available antibodies can 
either only detect wild type CXCL8, or in the case of one antibody, both wild type and 
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nitrated CXCL8, but currently there is no antibody available that can detect only the 
nitrated form of CXCL8 specifically.  
 
Figure 4-1. Nitration of CXCL8 alters its detectability by ELISA. Peprotech’s CXCL8 ELISA kit 
A) and R&D’s Human CXCL8 Duoset ELISA kit B) do not detect nitrated CXCL8 with the same 
affinity as wild type CXCL8. Varying concentrations of wild type CXCL8 or nitrated CXCL8 were 
detected using the sandwich ELISA kits intact as per the manufacturer’s instructions. The 
capture and detection antibodies from each kit were also assessed individually in direct ELISA 
settings at their recommended working concentrations, to assess their ability to bind to wild 
type CXCL8 or nitrated CXCL8 coated directly onto ELISA plates at varying concentrations. 
Biotinylated secondary antibodies were detected using streptavidin-HRP, Peprotech’s capture 
antibody was detected using an anti-rabbit-HRP antibody (A6154, Sigma), R&D’s capture 
antibody was detected using an anti-mouse-HRP antibody (A3673, Sigma). Data shown is from 
N=1 experimental replicate, with n=3 technical replicates. 
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Figure 4-2. AHC0881 anti-CXCL8 polyclonal antibody has equal affinity for wild type and 
nitrated CXCL8. The ability of AHC0881 (Life Technologies) to detect varying concentrations of 
wild type and nitrated CXCL8 when used at 1µg/ml was tested in a direct ELISA A) and a dot blot 
B), both developed using an anti-rabbit-HRP secondary antibody (A6154, Sigma). Data shown in 
A) and B) is from N=1 experimental replicate, with n=1 technical replicate. 
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4.3.2 Assessing the Concentration of Wild Type CXCL8 in a Range of Samples 
Before attempting to develop an anti-nitrated CXCL8 antibody, I assessed the 
concentration of wild type CXCL8, and the concentration of total protein, in a number of 
different respiratory samples as a reference point.  
Respiratory samples were selected as the lung is known to be a positive control tissue 
for CXCL8, and CXCL8 is known to be expressed at high levels in many respiratory 
conditions 139,246,247. These samples included bronchoalveolar lavage (BAL) samples 
from lung transplant patients, ventilator-associated pneumonia (VAP) patients, and one 
patient with inhaled chemical burns, along with perfusate samples taken at different 
time-points from lungs perfused ex vivo before transplantation, and secretions from 
primary nasal mucosa/polyp cells isolated and cultured ex vivo. Normal human serum 
samples were also tested to provide a systemic and non-diseased point of comparison. 
Results in Figure 4-3A show that normal human serum contains naturally low levels of 
CXCL8, ranging from 10pg/ml to 123pg/ml. BALs samples from VAP patients were 
found to contain varying concentrations of CXCL8 from 1.2ng/ml to 25ng/ml, with four 
samples showing no detectable CXCL8 present (Figure 4-3B). Nasal polyp cells secreted 
13ng/ml CXCL8, whereas nasal mucosa cells secreted 113.5ng/ml (Figure 4-3C), and the 
BAL sample from the inhaled chemical burns patient contained 60pg/ml CXCL8 (Figure 
4-3D). Of the perfusate samples analysed, only one lung sample showed no detectable 
CXCL8 at any of the time-points analysed (NCL15). All other samples showed a gradual 
increase in CXCL8 from the start to the end of perfusion at 1.5-2.5 hours, which is 
unsurprising as the ex vivo organ perfusion system is a closed circuit, so any CXCL8 
secreted by the lung will continue to circulate and accumulate over time. However, what 
can be considered as the total wild type CXCL8 produced, (i.e. the amount present at the 
last time point of perfusion), varied greatly from ~50pg/ml to ~1ng/ml (Figure 4-4A). A 
similar degree of variation was observed in BALs samples from lung transplant patients, 
with 26 of the 42 samples analysed showing no detectable CXCL8, and 16 samples 
containing detectable CXCL8 ranging from 58pg/ml to 2ng/ml (Figure 4-4B). 
Two samples from each of these groups were then assessed for total protein 
concentration by BCA assay, as shown in Figure 4-5A.  The protein composition that 
made up this total was assessed by gel electrophoresis and silver staining as shown in 
Figure 4-5B, to separate the protein components by size. The BAL samples showed total 
121 
 
protein concentrations of 422µg/ml for the inhaled chemical burns patient, and 
347µg/ml and 369µg/ml for the two lung transplant patients. One of the VAP patient 
BAL samples had 580µg/ml total protein, and the other had a higher concentration at 
13,707µg/ml. All of the BAL samples had an abundance of one high molecular weight 
protein (97.4 - 116.3 kDa) and a low molecular weight protein (6-14.4 kDA), with some 
fainter protein bands detected in between these two. The primary nasal mucosa cell 
secretion had 1036µg/ml of protein, which was shown to be composed of many 
different bands of protein at many different molecular weights. The two perfusate 
samples analysed showed much higher protein concentrations than the other samples 
tested, at 46.6mg/ml and 47.3mg/ml, and this was shown to be largely due to an 
abundance of one particular protein with a molecular weight between 97.4 and 116.3 
kDa.  
These data together suggest that any anti-nitrated CXCL8 antibody developed would 
have to be able to detect concentrations of CXCL8 in the low pg/ml range, and would 
have to be able to detect this CXCL8 within a complex mix of many different proteins of 
different sizes and abundances.   
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Figure 4-3. Amount of wild type CXCL8 present in a range of respiratory samples. A) 4 
normal human serum samples, B) 10 bronchoalveolar lavage (BAL) samples from patients with 
ventilator-associated pneumonia (VAP) (coded “RVI”), C) 2 samples of cell secretions from 
cultured primary nasal mucosa cells (coded “NM”) or polyp cells (coded “NP”), and D) a BAL 
sample from an inhaled chemical burns patient, were assessed using the Prof Paul Proost’s 
CXCL8 sandwich ELISA assay developed in-house (Rega Institute, KU Leuven). Capture antibody 
used was a goat anti-human CXCL8 (#4576), followed by a mouse anti-human CXCL8 secondary 
antibody (MAB208, R&D), and an anti-mouse-HRP conjugated tertiary antibody (Jackson 
ImmunoReagents 115-035-146). Development was performed with TMB substrate, and the 
plate was read at 450nm (corrected). Data shown is from N=1 experimental replicate, with n=2 
technical replicates. 
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Figure 4-4. Amount of wild type CXCL8 present in a range of samples. A) perfusate samples 
taken at different timepoints for 6 ex vivo normothermic perfused lungs from the Develop UK 
study (coded “NCL”), and B) 42 bronchoalveolar lavage (BAL) samples from lung transplant 
patients (coded “TW”), was assessed using the Prof Paul Proost’s CXCL8 sandwich ELISA assay 
developed in-house (Rega Institute, KU Leuven). Capture antibody used was a goat anti-human 
CXCL8 (#4576), followed by a mouse anti-human CXCL8 secondary antibody (MAB208, R&D), 
and an anti-mouse-HRP conjugated tertiary antibody (Jackson ImmunoReagents 115-035-146). 
Development was performed with TMB substrate, and the plate was read at 450nm (corrected). 
For B) the results from 16 of the samples are shown, as the other 26 samples were below the 
31.25pg/ml detection limit of the assay. Data shown is from N=1 experimental replicate, with 
n=2 technical replicates. 
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Figure 4-5. Total protein content and composition of samples. The protein content of two 
samples from each group was assessed by A) Bicinchoninic Acid assay and B) gel electrophoresis 
followed by silver staining. Data shown in A) is from N=1 experimental replicate, with n=2 
technical replicates and B) is from N=1 experimental replicate, with n=1 technical replicate. 
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4.3.3 Abmart Antibody Candidate Validation 
The results in section 4.3.2 highlight the need to develop an antibody that will 
specifically recognise nitrated, but not wild type, CXCL8 in highly complex samples. 
Efforts to this end were made in collaboration with Abmart. 
Two colonies (C1 and C4) of hybridoma cell were generated by Abmart. These cells were 
generated to produce a monoclonal antibody raised against a short CXCL8 peptide 
containing a nitrated tyrosine residue, which would recognise nitrated CXCL8 
specifically (and not the wild type chemokine), shown below.  
Wild type peptide: Ac-QCIKTYSKP-NH2 
C1 peptide: Ac-QCIKTY(NO2)SKP-NH2 
C4 peptide: Ac-IKTY(NO2)SKPFHPC-N 
4.3.3.1 Detection of Antibody Production by C1 Cells 
All C4 cells received had tested positive for mycoplasma upon arrival, therefore they 
were not cultured further, but treatment for mycoplasma infection was attempted as 
described in section 2.3.8.  A direct ELISA and Western blot using C1 cell media collected 
from various time-points confirmed that C1 cells were producing detectable amounts of 
antibody (see Figure 4-6). These experiments also confirmed that cryo-freezing cells in 
liquid nitrogen then resurrecting them did not affect the amount of antibody produced. 
Growing cells in media containing normal FBS, or charcoal-IgG-stripped FBS (which is 
necessary for ease of antibody purification) also did not affect antibody production. Cells 
were therefore grown and expanded in media containing charcoal-IgG-stripped FBS, and 
media containing the antibody was collected and stored upon cell passaging or freezing. 
4.3.3.2 Purification of Antibody from Collected Media 
Collected media was pooled, filtered and antibody was purified using HPLC with Hitrap 
protein G sepharose columns, eluted and concentrated to 8.6mg/ml.  
A direct ELISA and Western blot (shown in Figure 4-7) using samples of each eluted 
fraction confirmed that fractions 4-10 contained eluted antibody. 
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4.3.3.3 C1 Antibody and C4 Ascites Isotype Testing 
Abmart stated that both colonies should produce a monoclonal antibody, so in order to 
validate which isotype the purified antibody was, a direct ELISA and Western blot were 
performed using secondary antibodies against the heavy chains of specific IgG isotypes 
1, 2a, 2b and 3 to detect the C1 antibody. The experiments were also performed on a 
sample of unpurified C4 ascites sent to us by the company.  
As shown in Figure 4-8 below, the C1 antibody was not in fact monoclonal, but tested 
positive as a mix of IgG1 and IgG3, and the C4 ascites was positive for IgG1, IgG2a, IgG2b 
and IgG3.  
4.3.3.4 C1 Antibody and C4 Ascites Specificity Validation 
Although neither the C1 antibody nor C4 ascites was monoclonal, they would still be 
suitable for use in both the intended ELISA and tissue immunohistochemistry if they 
could successfully detect the presence of nitrated CXCL8 without detecting the wild type 
chemokine. To assess this, both dot blots and direct ELISAs were performed, using a 3NT 
antibody and nitrated BSA as controls, as well as the polyclonal rabbit anti-human 
CXCL8 antibody (AHC0881, Life Technologies), which was known to detect both wild 
type and nitrated CXCL8. 
As shown in Figure 4-9A, the C1 antibody did not detect the wild type CXCL8, or the 
nitrated BSA in an ELISA, though neither did it detect the nitrated CXCL8 (lines in the 
red colour scheme). The controls were successful, as the CXCL8 polyclonal antibody 
detected both wild type and nitrated CXCL8 but not nitrated BSA (lines in the green 
colour scheme), and the 3NT antibody detected both the nitrated CXCL8 and nitrated 
BSA but not the wild type CXCL8 (lines in the blue colour scheme), as expected. Similar 
results were achieved using a dot blot technique (detecting chemokine directly spotted 
onto nitrocellulose membrane) as shown in Figure 4-9B. In this case, the C1 antibody 
could detect the short C1 peptide it was raised against, but could not detect the full 
length nitrated CXCL8 protein. Again, the controls were successful, as the 3NT antibody 
detected the C1 peptide, nitrated BSA and the nitrated CXCL8 – all of which contain 
nitrated tyrosine residues. The CXCL8 polyclonal antibody detected both wild type and 
nitrated CXCL8, without detecting the C1 peptide and nitrated BSA as expected.  
127 
 
The direct ELISA was repeated exactly as stated using the C4 ascites, with the same 
results shown below in Figure 4-10A; the C4 ascites could not detect nitrated CXCL8. 
The dot blot experiment was repeated, using only wild type and nitrated CXCL8, but 
samples were either in their native conformation or denatured. As shown in Figure 4-
10B neither the C1 antibody nor C4 ascites detected either chemokine whether 
denatured or not, and the CXCL8 polyclonal antibody could detect chemokines whether 
denatured or not. 
Work on the C1 and C4 hybridoma cells was not carried forward beyond this stage. 
128 
 
 
 
Figure 4-6. Antibody production by C1 cells. Antibody production by C1 cells is unaffected by 
cryo-freezing followed by resurrection, or by the presence of normal vs. IgG-stripped FBS in 
culture media as determined by a direct ELISA A), and a Western blot B), both with detection 
using an anti-mouse IgG-HRP secondary antibody (A3673, Sigma). Data shown in A) is from N=1 
experimental replicate, with n=3 technical replicates, and in B) is from N=1 experimental 
replicate, n=1 technical replicate.  
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Figure 4-7. Isolating antibody from C1 media. HPLC antibody purification was successful, 
with fractions 4-10 containing eluted antibody, as determined by a direct ELISA A), and a 
Western blot B), both with using detection an anti-mouse IgG-HRP secondary antibody (A3673, 
Sigma). Data shown in A) is from N=1 experimental replicate, with n=3 technical replicates, and 
in B) is from N=1 experimental replicate, n=1 technical replicate.  
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Figure 4-8. C1 antibody and C4 ascites isotyping. Isotypes were detected using antibodies 
against IgG1 (M-8144, Sigma), IgG2a (M-8269, Sigma), IgG2b (M-8394, Sigma) and IgG3 (M-
9924, Sigma), developed with an anti-mouse-HRP secondary antibody (A3673, Sigma). The C1 
antibody was confirmed as being polyclonal IgG1 and IgG3, and not monoclonal as stated. The C4 
ascites was confirmed as positive for IgG1, IgG2a, IgG2b and IgG3. This was determined by a 
direct ELISA (A and B), and a Western blot (C). Data shown in A) and B) is from N=1, n=3 
experiments, and data shown in C) is from N=1 experimental replicate, with n=1 technical 
replicate. 
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Figure 4-9. C1 antibody specificity. C1 antibody used at 20µg/ml cannot detect the full-length 
nitrated CXCL8 protein in either a direct ELISA at a range of concentrations A) or in a dot blot at 
100ng B). The CXCL8 polyclonal antibody used at 5µg/ml (AHC0881, Life Technologies) could 
detect both wild type and nitrated CXCL8 in both experimental conditions, and the 3NT antibody 
used at 5µg/ml (06-284, Millipore) could detect the nitrated CXCL8 and nitrated BSA in the 
ELISA and the dot blot, as well as the C1 peptide in the dot blot. CXCL8 and 3NT primary 
antibodies were detected using an anti-rabbit-HRP secondary antibody (A6154, Sigma), and the 
C1 antibody was detected using an anti-mouse-HRP secondary antibody (A3673, Sigma). Data 
shown in A) is from N=1 experimental replicate, with n=3 technical replicates, and in B) is from 
N=3 experimental replicates, each with n=1 technical replicate. 
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Figure 4-10. C4 ascites specificity. C4 ascites cannot detect the full-length nitrated CXCL8 
protein in a direct ELISA at a range of concentrations A). The CXCL8 polyclonal antibody used 
(AHC0881, Life Technologies) could detect both wild type and nitrated CXCL8, and the 3NT 
antibody (06-284, Millipore) could detect the nitrated CXCL8 and nitrated BSA. Neither the C1 or 
C4 antibodies could detect 100ng of wild type or nitrated CXCL8 (denatured (DN) or 
undenatured) in a dot blot B), whereas the CXCL8 polyclonal antibody could detect both 
chemokines in both structural forms. CXCL8 and 3NT primary antibodies were detected using an 
anti-rabbit-HRP secondary antibody (A6154, Sigma), and the C1 antibody was detected using an 
anti-mouse-HRP secondary antibody (A3673, Sigma). Data shown in A) is from N=1 
experimental replicate, with n=3 technical replicates, and in B) is from N=3 experimental 
replicates, each with n=1 technical replicate. 
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4.3.4 Bio-Rad Antibody Candidate Validation 
Validation of Abmart antibodies was discontinued, and an alternative collaboration was 
sought with Bio-Rad. 
Bio-Rad develop custom recombinant monoclonal HuCAL® antibodies using positive 
and negative screening of peptides or proteins against a phage display library of 
antibodies. This library consists of human antibody genes synthetically made to cover 
>95% of the structural immune repertoire, that are cloned in E.Coli expression vectors. 
Panning and screening was performed to find candidate antibodies that would recognise 
the full-length nitrated CXCL8 protein (which was verified as being nitrated using mass 
spectrometry after incubated with peroxynitrite), but not full-length wild type CXCL8 
protein in Bio-Rad’s optimised direct ELISA assays. Potential candidate antibodies that 
display >5-fold higher specificity for nitrated CXCL8 over wild type CXCL8 were 
produced as bivalent Fab-bacterial alkaline phosphatase fusion antibodies with FLAG® 
and Histidine6 tags (Figure 4-11), and sent to us for further validation. An example of 
Bio-Rad’s initial validation data for the first batch of antibody candidates is shown in 
Figure 4-12. 
Of the first batch of antibody candidates sent (AbD31663.1-AbD31682.1, shortened to 
63-82), none showed higher affinity/selectivity for nitrated CXCL8 over wild type CXCL8 
within the experimental set-up available in our laboratory, using a biotinylated anti-
histidine6 secondary antibody followed by streptavidin-HRP and substrate shown in 
Figure 4-13. This was true in both a direct ELISA assay shown in Figure 4-14A, and in a 
dot blot assay shown in Figure 4-14B.  
Following another round of screening using alternative conditions, five new candidate 
antibodies were sent (AbD31646.1- AbD31650.1, shortened to 46-50). I continued 
validation with four of these candidates, as one (candidate 48) showed minimal 
distinction between wild type and nitrated CXCL8 detectability in Bio-Rad’s initial 
validation studies as shown in Figure 4-15. Initially validation experiments were 
performed as direct ELISA assays (using the same experimental set-up shown in Figure 
4-13) detecting the candidates’ ability to detect nitrated CXCL8 and wild type CXCL8, 
coated in 3 different concentration ranges. In each of these assessments nitrated BSA 
was also used at the highest concentration tested as a negative control, assessing the 
candidates’ ability to bind to a non-specific nitrated protein.  The highest range of 
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concentrations (1-100ng/ml) is shown as the first column of graphs in Figure 4-16 
below, and at this range, only 46 (Figure 4-16A) and 49 (Figure 4-16C) showed 
reasonable degrees of specificity for nitrated CXCL8 over wild type CXCL8, but only for 
detection of the highest concentrations tested in each range. Candidates 46 and 49 
retained their specificity for nitrated CXCl8 over wild type CXCL8 when a lower range of 
concentrations (0.1-10ng/ml) was tested as shown in the second column of graphs, 
although this specificity was lost when the concentrations were reduced further to 0.1-
1ng/ml in the third column. Candidate 47 showed a higher affinity for wild type CXCL8 
than nitrated CXCL8 at all concentrations tested (Figure 4-16B), and 50 showed similar 
affinities at all concentrations tested (Figure 4-16D).  
For clarity, the detection of the highest concentration tested in each range is shown 
alone in Figure 4-17, with the OD readings for wild type CXCL8, nitrated CXCL8 and 
nitrated BSA grouped together for each antibody candidate.  46 showed an increased 
affinity for nitrated CXCL8 over wild type CXCL8 of ~5-fold when tested with 100ng/ml 
of either chemokine, ~11-fold at 10ng/ml and ~1-fold at 1ng/ml respectively. 49 
showed corresponding values of ~2-fold, ~6-fold and ~1.3-fold. The candidates 46 and 
49 therefore show specificity for nitrated CXCL8 at all concentrations tested, but with a 
detection sensitivity of between 1 and 10ng/ml. For all of the antibody candidates 
except 47, as the concentration ranges decreased the ability to distinguish between wild 
type and nitrated CXCL8 is reduced, as is the signal observed. 
Work therefore progressed using candidates 46 and 49. 
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Figure 4-11. Structure of HuCAL® antibodies. Bivalent monoclonal antibody structure shown, 
with two antigen binding regions connected by an alkaline phosphatase dimerization domain 
with FLAG® and Histidine6 tags. 
4.3.4.1 First Candidate Analysis 
 
Figure 4-12. Bio-Rad’s initial validation of the first batch of antibody candidates. 
Antibodies were tested by Bio-Rad in direct ELISA assays using their standard protocol.  
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Figure 4-13. Direct ELISA experimental set-up using Bio-Rad antibody candidates as 
detection antibodies. 
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Figure 4-14. Validating the first batch of Bio-Rad antibody candidates. The ability of the 
antibodies to detect 250ng wild type or nitrated CXCL8 in a direct ELISA (detection was carried 
out using a biotinylated anti-histidine6 secondary antibody (MCA1396B, Bio-Rad), streptavidin-
HRP and TMB substrate, and the plate was read at 450nm (corrected)) or B) 100ng wild type or 
nitrated CXCL8 in dot blot assays, when used at 2µg/ml. Data shown in A) is from N=1 
experimental replicate, with n=3 technical replicates, and in B) is from N=3 experimental 
replicates, with n=1 technical replicate. 
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4.3.4.2 Second Candidate Analysis 
 
Figure 4-15. Bio-Rad’s initial validation of the second batch of antibody candidates. 
Antibodies were tested by Bio-Rad in direct ELISA assays using their standard protocol.  
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Figure 4-16. Validating the second batch of Bio-Rad antibody candidates using a direct 
ELISA. The ability of the antibodies A) AbD31646.1, B) AbD31647.1, C) AbD31649.1 and D) 
Abd31650.1 to detect 3 different concentration ranges of wild type or nitrated CXCL8 in a direct 
ELISA, when used at 2µg/ml. Concentration ranges tested were 1-100ng/ml (first column), 0.1-
10ng/ml second column) and 0.1-1ng/ml (third column). Nitrated BSA was used as a control to 
test cross-reactivity with a non-specific nitrated protein at the highest concentration in each 
range. Detection was carried out using a biotinylated anti-histidine6 secondary antibody 
(MCA1396B, Bio-Rad), streptavidin-HRP and TMB substrate, and the plate was read at 450nm 
(corrected). Data shown is from N=1 experimental replicate, with n=3 technical replicates. 
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Figure 4-17. Validating the second batch of Bio-Rad antibody candidates using a direct 
ELISA. The highest concentrations in each of the three ranges tested are shown, with the OD 
readings for the detection of wild type CXCL8, nitrated CXCL8 and nitrated BSA grouped 
together for each antibody. A) shows the detection of 100ng/ml from the highest concentration 
range, B) shows the detection of 10ng/ml from the median concentration range, and C) shows 
the detection of 1ng/ml from the lowest concentration range. Detection was carried out using a 
biotinylated anti-histidine6 secondary antibody (MCA1396B, Bio-Rad), streptavidin-HRP and 
TMB substrate, and the plate was read at 450nm (corrected). Data shown is from N=1 
experimental replicate, with n=3 technical replicates. 
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4.3.4.3 Validating Abd31646.1 and Abd31349.1 Specificity 
Having found that candidates 46 and 49 showed the most differential specificity for 
nitrated CXCL8 over wild type CXCL8 (while showing no cross-reactivity with nitrated 
BSA) in direct ELISA assays, I aimed to assess the specificity of these two candidates in a 
dot blot assay. CXCL8, nitrated CXCL8, nitrated BSA and nitrated CXCL1 were all added 
to nitrocellulose membrane in 2µl dots at 6.2ng total (as the previous direct ELISA 
results indicated that the detection limit of 46 and 49 was between 1ng/ml and 
10ng/ml). Figure 4-18A shows that detection with a rabbit polyclonal anti-CXCL8 
antibody (AHC0881) showed clear positive signals for CXCL8 and nitrated CXCL8, with 
no signal for nitrated BSA or nitrated CXCL1 as expected. 46 showed no clear signal for 
the detection of any sample, whereas 49 did show a positive signal for nitrated CXCL8 
only.  Detection of the same samples with a 3NT antibody confirmed the presence of 
nitrated tyrosine residues in samples spiked with nitrated CXCL8, but not CXCL1 as this 
does not contain any tyrosine residues. No signal was observed for nitrated BSA, 
although the signal could be below the detection limit as low concentrations of the 
protein were added to the membrane. 
As these initial experiments were conducted with each chemokine diluted in PBS, I then 
aimed to assess if these two candidates were able to show the same selectivity when 
detecting nitrated CXCL8 in a complex mix of proteins. This was tested by spiking PBS or 
normal human serum with nitrated CXCL8 or wild type CXCL8, and assessing antibody 
detection as previously described. Higher sample concentrations were used in this assay 
to increase signal. Figure 4-18B shows the detection of 100ng of wild type CXCL8 or 
nitrated CXCL8 in 2µl of PBS or normal human serum. Basal PBS and serum without the 
addition of any chemokine were included as negative controls. Detection with AHC0881 
showed a clear signal for both wild type and nitrated CXCL8 in both PBS and serum as 
expected, with no signal detected for the basal PBS control and some signal for the 
serum control, indicating the natural presence of CXCL8 within this sample. Both 46 and 
49 also showed no signal for the basal PBS, and a clear increase in signal was observed 
when either PBS or serum was spiked with nitrated CXCL8. 46 does also appear to show 
a faint signal for wild type CXCL8 at these higher concentrations used. Both antibodies 
did, however, also give a positive signal for basal serum.  
142 
 
The same signal for basal serum was observed when samples were tested in direct 
ELISA assays detected with 49 alone as shown in Figure 4-19; a signal which did not 
increase despite the addition of varying concentrations of nitrated CXCL8 and was 
greater than the signal for equivalent concentrations of nitrated CXCL8 diluted in PBS. 
These data together suggested that either the antibodies were binding to other non-
specific proteins present in serum, or there exists a very high concentration of nitrated 
CXCL8 naturally present in serum.  
In order to test these theories, I spiked normal human serum with 10µg wild type CXCL8 
or 6.6µg nitrated CXCL8 and performed fractionation by size exclusion chromatography. 
Figure 4-20 shows the HPLC trace, indicating that the majority of the protein was eluted 
in fractions 6-23, with maximum elution occurring in fraction 12. 
The fractions could then be diluted differentially to prevent the dilution of the 
chemokine but allowing high abundance proteins to be diluted enough to be run on an 
18% SDS gel. Firstly, the serum samples were run on such a gel and stained with 
Coomassie® Blue to visualise the molecular weights of the proteins present in each 
fraction. The results are shown in Figure 4-21. In Figure 4-21A (showing the staining of 
fraction from serum spiked with wild type CXCL8), fractions 7-13 are shown to contain a 
high abundance of high molecular weight proteins. Figure 4-21B shows the same results 
in fractions 6-11 for serum spiked with nitrated CXCL8.  In both cases, fractions 15-18 
show protein bands around the molecular weight of chemokines such as CXCL8 at 8-
10kDa. 
Fractions were then run on triplicate18% SDS-PAGE followed by Western blot analysis 
with detection using a rabbit polyclonal anti-CXCL8 antibody (AHC0881) know to detect 
both wild type and nitrated CXCL8 spiked into the samples. Detection was also 
performed using antibodies 46 and 49, to assess their specificity for nitrated CXCL8. The 
results in Figure 4-22A show that the CXCL8 polyclonal antibody detects both wild type 
and nitrated CXCL8 with bands at the correct molecular weights for CXCL8 monomers, 
and nitrated CXCL8 monomers and dimers. Detection with 46 (Figure 4-22B) shows that 
this antibody does recognise other non-specific proteins present in serum, with clear 
defined bands visible at 25 and 55 kDa in fractions 11-16 from serum samples spiked 
with both wild type and nitrated CXCL8, as well as non-specific background staining 
present on the membrane. Detection with 49 showed a slightly cleaner membrane with 
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less non-specific background staining (Figure 4-22C). This antibody also detected clear 
defined bands at 25 and 55 kDa, but these were only present in the fraction from serum 
samples spiked with nitrated CXCL8 and not wild type CXCL8.  When exposed for a 
longer time (as indicated by the black arrow) bands at the correct molecular weight for 
nitrated CXCL8 were also visible. Both 46 and 49 therefore recognise other non-specific 
proteins present in serum, in addition to nitrated CXCL8. 
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Figure 4-18. Validating the specificity of AbD31646.1 and AbD31649.1 using a dot blot. A) 
6.2ng of CXCL8, nitrated CXCL8, nitrated BSA or nitrated CXCL1 were added in 2µl dots to 
nitrocellulose membrane in replicate strips. B) 100ng of CXCL8 or nitrated CXCL8 was spiked in 
to PBS or serum and added as a 2µl dots to nitrocellulose membrane in replicate strips. For both 
A) and B) Each strip was incubated with a different primary antibody for detection; a rabbit 
polyclonal anti-CXCL8 antibody (AHC0881) at 1μg/ml, a 3NT antibody (ab61392, Abcam) at 
1μg/ml, AbD31646.1 at 2μg/ml or AbD31649.1 at 2μg/ml. AHC0881 was detected using an anti-
rabbit-HRP secondary antibody (A6154, Sigma), ab61392 with an anti-mouse-HRP secondary 
antibody (A3673, Sigma), and AbD31646.1/AbD31649.1 using a biotinylated anti-histidine6 
secondary antibody (MCA1396B, Bio-Rad), streptavidin-HRP and ECL substrate.  Data shown is 
from N=3 experimental replicates, each with n=1 technical replicates. 
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Figure 4-19. Validating the specificity of Abd31649.1 using a direct ELISA. Nitrated CXCL8 
was coated onto an Immulon HB4X ELISA plate at a range of concentrations (pg/ml) in either 
PBS or normal human serum. Detection was performed using AbD31649.1 at 2µg/ml, followed 
by a biotinylated anti-histidine6 secondary antibody (MCA1396B, Bio-Rad), streptavidin-HRP 
and ECL substrate.  Data shown is from N=1 experimental replicates, each with n=2 technical 
replicates. 
 
 
Figure 4-20. Spiked serum fractionating by size exclusion high performance liquid 
chromatography (HPLC). UV trace of the HPLC performed showing the elution of protein, as 
8mg /0.5ml of serum spiked with A) 10μg of wild type CXCL8 or B) 6.6μg of nitrated CXCL8 was 
flown through a Superose 12 column at 0.5ml/minute. The trace shows peaks corresponding to 
the elution of the protein and salt. Data shown is from N=1 experimental replicate, with n=1 
technical replicate. 
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Figure 4-21. Coomassie® Blue analysis to determine protein content of spiked serum 
fractions. Fractions from size exclusion high performance liquid chromatography (HPLC) 
performed on serum samples spiked with A) 10μg of wild type CXCL8 or B) 6.6μg of nitrated 
CXCL8 run on 18% SDS-PAGE and stained with Coomassie® Blue. Data shown is from N=1 
experimental replicate, with n=1 technical replicate. 
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Figure 4-22. Validating the specificity of AbD31646.1 and AbD31649.1 using a Western 
blot. SDS-PAGE and Western blot analysis of spiked serum samples fractionated by size 
exclusion high performance liquid chromatography (HPLC). Gels were run in triplicate and the 
resulting membranes after protein transfer were stained with A) a rabbit polyclonal anti-CXCL8 
antibody (AHC0881) at 1μg/ml, B) AbD31646.1 at 2μg/ml and C) AbD31649.1 at 2μg/ml. 
Detection for A) was carried out using an anti-rabbit-HRP secondary antibody (A6154, Sigma), 
and for B) and C) using a biotinylated anti-histidine6 secondary antibody (MCA1396B, Bio-Rad), 
streptavidin-HRP and ECL substrate.  Red arrows indicate possible correct detection of nitrated 
CXCL8 monomers. Data shown is from N=2 experimental replicates, each with n=1 technical 
replicate. 
  
148 
 
4.3.4.4 Developing a Sandwich ELISA using AbD31649.1 
Both antibody candidates 46 and 49 were shown to have specificity for nitrated CXCL8 
over wild type CXCL8. Both were also shown to cross-react with non-specific proteins 
present in human serum. Thus neither antibody is suitable for use in a direct ELISA. As 
49 gave a cleaner Western blot with less non-specific background staining, this antibody 
was carried forward for development into a sandwich ELISA assay. 
Initial experiments involved using 48 as a capture antibody at a range of concentrations, 
as this antibody was shown by Bio-Rad to have affinity for both wild type and nitrated 
CXCL8 (Figure 4-15). It was therefore used in attempts to capture both wild type CXCL8 
and nitrated CXCL8 diluted to 10ng/ml in PBS.  This concentration was known to be 
within detection limits for wild type CXCL8 when using the detection antibody from 
R&D’s Human CXCL8 Duoset ELISA kit, and for nitrated CXCL8 when using 49 as the 
detection antibody. As the 48 and 49 antibodies were of the same format, to avoid cross-
reactivity that would result from using the biotinylated anti-histidine6 antibody as a 
tertiary step, 49 was directly biotinylated using Lightning-Link® Rapid Biotin Kit 
(Expedeon). This experimental set-up is shown in Figure 4-23. Results shown in Figure 
4-24A for the detection of nitrated CXCL8 indicate cross-reactivity between the 
detection antibody (49) and the capture antibody (48), due to almost identical signals 
being observed when nitrated CXCL8 was added in comparison to PBS only. Figure 4-
24B shows the detection of wild type CXCL8 using R&D’s IL8 Duoset detection antibody 
after capture with 48, with no signal observed at any concentration of capture antibody 
used. These results indicate that 48 and 49, and 48 and AHC0881 are both incompatible 
as capture-detection antibody pairs. 
Further sandwich ELISA development trials were carried out at the Rega Institute, KU 
Leuven. These involved testing a polyclonal goat anti-CXCL8 antibody (Rega #4576) that 
the group have developed in house, and regularly use in CXCL8 ELISA assays, for use as a 
potential capture antibody. This experimental set-up is shown in Figure 4-25. The 
capture antibody was coated at a dilution of 1/100 (triple the concentration than the 
group regularly use the antibody at). Wild type CXCL8 (at a range of concentrations) was 
detected using a mouse anti-CXCL8 monoclonal secondary antibody, followed by a 
biotinylated anti-mouse tertiary antibody. Nitrated CXCL8 (at a range of concentrations) 
was detected using biotinylated 49. While a clear S-shaped curve of detection was 
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observed for wild type CXCL8 in this assay, no signal was observed for any of the 
concentrations of nitrated CXCL8 used (the highest of which were again within the 
known detection limit of the detection antibody 49) (Figure 4-26). Rega #4576 was also 
therefore deemed unsuitable as a capture antibody for use in this sandwich ELISA. 
The next potential capture antibody trialled was the polyclonal rabbit anti-human 
CXCL8 antibody (AHC0881, Life Technologies). The protocol was followed exactly as 
described above, using this capture antibody instead of Rega #4576 as shown in Figure 
4-27. Again, a clear S-shaped curve of detection was observed for wild type CXCL8. A 
signal above background was observed for 10ng/ml nitrated CXCL8 (OD at 450nm of 
0.313) (Figure 4-28), although not for any lower concentrations of nitrated CXCL8 
tested. This capture-detection antibody pair was therefore taken forward for further 
development to improve assay sensitivity. 
A checkerboard-style sandwich ELISA assay was performed to determine the optimal 
concentrations of AHC0881 and 49 to be used in combination. Results in Figure 4-29 
show that, at the range of concentrations trialled, 5µg/ml was the optimal concentration 
for both antibodies to be used at together. Further development work is required if this 
anitbody pair is to be suitable for the selective detection of low levels of nitrated CXCL8 
in biological samples. 
 
Figure 4-23. Sandwich ELISA experimental set-up using AbD31648.1 as a capture 
antibody. 
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Figure 4-24. Sandwich ELISA trial using AbD31648.1 as a capture antibody. AbD31648.1 
was coated onto an Immulon HB4X ELISA plate at a range of concentrations (µg/ml) in coating 
buffer. Chemokine was then added at 10ng/ml, followed by A) nitrated CXCL8 detection using 
biotinylated-AbD31649.1 at 2µg/ml then streptavidin-HRP followed by TMB substrate.or B) 
wild type CXCL8 detection using R&D’s Human CXCL8 Duoset ELISA kit detection antibody (HRP 
conjugated) The plate was read at 450nm (corrected). Data shown is from N=1 experimental 
replicate, with n=3 technical replicates.  
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Figure 4-25. Sandwich ELISA experimental set-up using Rega #4576 polyclonal goat anti-
CXCL8 as a capture antibody.  
 
 
Figure 4-26. Sandwich ELISA trial using Rega #4576 polyclonal goat anti-CXCL8 as a 
capture antibody. Rega #4576 was coated onto an Immulon 4HBX ELISA plate at 1/100 in 
coating buffer. Chemokine was then added at a range of concentrations (ng/ml). Wild type 
CXCL8 was detected using a mouse-anti-CXCL8 secondary antibody then biotinylated anti-
mouse tertiary antibody. Nitrated CXCL8 detection using biotinylated-AbD31649.1 at 2µg/ml. 
For both streptavidin-HRP was added followed by TMB substrate. The plate was read at 450nm 
(corrected). Data shown is from N=1 experimental replicate, with n=3 technical replicates. 
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Figure 4-27. Sandwich ELISA experimental set-up using polyclonal rabbit anti-human 
CXCL8 (AHC0881, Life Technologies) as a capture antibody.  
 
 
Figure 4-28. Sandwich ELISA trial using polyclonal rabbit anti-human CXCL8 (AHC0881, 
Life Technologies) as a capture antibody. AHC0881 was coated onto an Immulon 4HBX ELISA 
plate at 1µg/ml in coating buffer. Chemokine was then added at a range of concentrations 
(ng/ml). Wild type CXCL8 was detected using a mouse-anti-CXCL8 secondary antibody then 
biotinylated anti-mouse tertiary antibody. Nitrated CXCL8 detection using biotinylated-
AbD31649.1 at 2µg/ml. For both streptavidin-HRP was added followed by TMB substrate. The 
plate was read at 450nm (corrected). Data shown is from N=1 experimental replicate, with n=3 
technical replicates. 
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Figure 4-29. Checkerboard sandwich ELISA to optimise the concentration of capture and 
detection antibodies. AHC0881 was coated onto an Immulon 4HBX ELISA plate at a range of 
concentrations (µg/ml) in coating buffer. Nitrated CXCL8 was then added at a constant 
concentration of 10ng/ml, and detected with a range of concentrations (µg/ml) of AbD31649.1 
followed by biotinylated anti-histidine6 secondary antibody (MCA1396B, Bio-Rad), streptavidin-
HRP and OPD substrate. The plate was read at 492nm (corrected). The same assay was also 
performed as a direct ELISA assay (black line) to determine if sensitivity was improved by the 
addition of a capture antibody. Data shown is from N=1 experimental replicate, with n=3 
technical replicates. 
 
4.3.4.5 Validating AbD31649.1 for Use in Immunofluorescence 
With the aim of using the novel Bio-Rad antibody Abd31649.1 to detect the presence of 
nitrated CXCL8 in patient tissue biopsy samples (the amount of which could be 
correlated with disease severity), attempts were made to validate the use of this 
antibody in immunofluorescence staining. In all experiments, double 
immunofluorescence staining was also performed to detect CXCL8 (polyclonal rabbit 
anti-CXCL8, AHC0881, Life Technologies) and 3NT (ab61392, Abcam) as a likely 
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indicator of the potential presence of nitrated CXCL8. In order for staining to be 
considered specific, any signal visualised with AbD31649.1 should only occur in the 
areas where CXCL8 and 3NT appear to co-localise.       
Initial experiments were trialled using unfixed frozen chamber slides in order to bypass 
the need for any optimisation of antigen retrieval methods. Chambers were seeded with 
HMEC-1 cells (cultured as described in section 2.3.3), and treated with different 
stressing agents in order to increase the expression of CXCL8 and its possible nitration. 
These included a bacterial-derived stressing agent (1µg/ml LPS for 6 hours) and an 
oxidative stressing agent (200µM H2O2 for 2 hours followed by 4 hour recovery).  A 
previous PhD student, Catriona Barker, had optimised these treatments.  Staining was 
then performed to detect CXCL8 (detected using a Dylight-550 conjugated secondary 
antibody (red)), and 3NT (detected using a Dylight-488 conjugated secondary antibody 
(green)), or nitrated CXCL8 using AbD31649.1 at 25µg/ml (a 1/50 dilution) (detected 
using a biotinylated anti-histidine6 secondary antibody and streptavidin-Alexa594 
(red)). Results in Figure 4-30 show that both LPS and H2O2 treatment induce an 
upregulation of CXCL8 expression, with H2O2 also inducing an upregulation of 3NT 
expression that co-localises with the CXCL8 staining, indicating the potential presence of 
nitrated CXCL8. No positive staining was seen in chambers treated the same way but 
stained using AbD31649.1.    
Experiments were repeated as shown in Figure 4-31, with the H2O2 treatment changed 
to a 6 hour treatment with 600µM peroxynitrite (also previously optimised by Catriona 
Barker), in an attempt to increase protein nitration. In this case, results indicated that 
treatment with LPS but not peroxynitrite increased the upregulation of both CXCL8 and 
3NT, and only the LPS-treated cells showed any positive staining with AbD31649.1.  This 
staining appears to be granular and is only present in the nucleus and does not appear in 
the cytoplasmic regions of the cells where CXCL8 and 3NT co-localise, indicating that 
this could be non-specific staining.  
The same staining protocol was tested in paraffin-embedded lung sections, as lung is a 
known positive control tissue for CXCL8, which expresses high levels of 3NT.  Results are 
shown in Figure 4-32. Antigen retrieval was performed using Citrate buffer for CXCL8 
and 3NT (as was previously optimised for these antibodies), and Citrate buffer, Tris 
EDTA buffer, or trypsin enzymatic digestion for AbD31649.1.  Staining for CXCL8 and 
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3NT showed intense expression of both markers across the lung tissue, with much of the 
staining co-localising. Only antigen retrieval using Tris EDTA gave any positive staining 
when AbD31649.1 was used, and this resembled the granular nuclear staining observed 
in treated chamber slides, not the strong cytoplasmic staining   observed for CXCL8 and 
3NT in both tissue and cells.
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Figure 4-30. Using AbD31649.1 in immunofluorescence staining. HMEC-1 cells were treated in chamber slides for 6 hours with 1µg/ml LPS, and 
for 2 hours with 200µM H2O2 followed by 4 hours of recovery in normal media. Slides were fixed in ice-cold methanol, and stained for both CXCL8 
(AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary antibody (red) (GtxRb-003-D550NHSX, 
Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 conjugated secondary antibody (green) (GtxMs-003-
E488NHSX, Immunoreagents), or AbD31649.1 (detected using a biotinylated anti-histidine6 secondary antibody and streptavidin-Alexa594 (red)) to 
detect the potential presence of nitrated CXCL8 (NO2-CXCL8). Close-up images of individual CXCL8+ 3NT+ cells are shown indented. Images were 
taken at 20x magnification, and images shown are representative of 5 fields of view imaged per chamber. 
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Figure 4-31. Using AbD31649.1 in immunofluorescence staining. HMEC-1 cells were treated in chamber slides for 6 hours with 1µg/ml LPS, and 
for 2 hours with 600µM peroxynitrite. Slides were fixed in ice-cold methanol, and stained for both CXCL8 (AHC0881, Life Technologies) detected 
using an anti-rabbit-DyLight550 conjugated secondary antibody (red) (GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) 
detected using an anti-mouse-DyLight488 conjugated secondary antibody (green) (GtxMs-003-E488NHSX, Immunoreagents), or AbD31649.1 
(detected using a biotinylated anti-histidine6 secondary antibody and streptavidin-Alexa594 (red)) to detect the potential presence of nitrated 
CXCL8 (NO2-CXCL8). Close-up images of individual CXCL8+ 3NT+ cells are shown indented. Images were taken at 20x magnification, and images 
shown are representative of 5 fields of view imaged per chamber.
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Figure 4-32.Using AbD31649.1 in immunofluorescence staining. Paraffin-embedded lung 
sections were processed and stained for both CXCL8 (AHC0881, Life Technologies) detected 
using an anti-rabbit-DyLight550 conjugated secondary antibody (red) (GtxRb-003-D550NHSX, 
Immunoreagents)and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 
conjugated secondary antibody (green) (GtxMs-003-E488NHSX, Immunoreagents), or 
AbD31649.1 (detected using a biotinylated anti-histidine6 secondary antibody and streptavidin-
Alexa594 (red)) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). Different 
antigen retrieval methods were trialled for AbD31649.1 staining. No primary antibody control is 
shown indented (NP), as are close-up images of individual NO2-CXCL8+ cells. Images were taken 
at 20x magnification, and shown are representative of 5 fields of view imaged per chamber. 
Insert - no primary antibody control. 
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4.3.5 Detection of Nitrated CXCL8 in a Bronchoalveolar Lavage Sample from a 
Patient with Ventilator-Associated Pneumonia 
Due to the sandwich ELISA for nitrated CXCL8 still being under development, I 
attempted to detect naturally occurring nitrated CXCL8 using a Western blot method. 
The samples selected for analysis were some of the bronchoalveolar lavage (BAL) 
samples from ventilator-associated pneumonia (VAP) patients, as these samples 
contained relatively high levels of wild type CXCL8 as assessed by ELISA (Figure 4-3), 
which was therefore also likely to be detectable by Western blot, and relatively low 
levels of total protein (Figure 4-5), which meant these samples could likely be run 
undiluted on an 18% SDS-PAGE gel. BAL samples from healthy control patients were 
also included, and the secretions from primary nasal mucosa cells (NM16) was also 
included as a positive control for the detection of wild type CXCL8, due to its high CXCL8 
content. Samples were run on triplicate g, and detection was performed using a rabbit 
polyclonal anti-CXCL8 antibody (AHC0881) know to detect both wild type and nitrated 
CXCL8, Bio-Rad candidate 49 and a 3-NT antibody – positive staining of the same band 
with all three antibodies would indicate the presence of nitrated CXCL8. 
Figure 4-33A shows that all 5 VAP patient BAL samples (RVI 1, 4, 9, 11 and 23) contain 
detectable levels of wild type CXCL8, which is supported by previous ELISA data in 
Figure 4-3. Sample RVI 1 also shows that this band is also visible when detected with 49 
(Figure 4-33B) and 3-NT antibodies (Figure 4-33C), indicated by the red arrows. These 
results suggest that this sample contains naturally occurring nitrated CXCL8. Control 
patient BAL samples were negative for CXCL8 (Figure 4-33A), nitrated CXCL8 (Figure 4-
33B) and 3-NT (Figure 4-33C), and NM16 was positive for CXCL8 (Figure 4-33A) but 
negative for nitrated CXCL8 (Figure 4-33B) and 3-NT (Figure 4-33C).  
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Figure 4-33. Detection of naturally occurring nitrated CXCL8. SDS-PAGE and Western blot 
analysis of 5 bronchoalveolar lavage (BAL) samples from patients with ventilator-associated 
pneumonia (VAP) (coded “RVI”), 3 BAL samples from healthy controls, and 1 sample of cell 
secretions from cultured primary nasal mucosa cells (coded “NM”). Gels were run in triplicate 
and the resulting membranes after protein transfer were stained with A) a rabbit polyclonal 
anti-CXCL8 antibody (AHC0881) at 1μg/ml, B) AbD31649.1 at 2μg/ml and C) 3NT (ab61392, 
Abcam) at 1μg/ml. Detection for A) was carried out using an anti-rabbit-HRP secondary 
antibody (A6154, Sigma), for B) using a biotinylated anti-histidine6 secondary antibody 
(MCA1396B, Bio-Rad) followed by streptavidin-HRP, and for C) using an anti-mouse-HRP 
secondary antibody (A3673, Sigma), all followed by ECL substrate.  Red arrows indicate possible 
correct detection of nitrated CXCL8 monomers. Data shown is from N=1 experimental replicate, 
with n=1 technical replicate. 
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4.4 DISCUSSION 
Currently available anti-CXCL8 antibodies are either specific for wild type CXCL8 only, 
or are capable of recognising both wild type and nitrated CXCL8. None, however, exist 
that are specific for nitrated CXCL8 only.  
Analysis of wild type CXCL8 concentration and total protein concentration in a range of 
respiratory samples showed that CXCL8 can be present at a wide range of 
concentrations, from as low as 10pg/ml in normal human serum, to as high as 25ng/ml 
in VAP patients BAL samples and 113.5ng/ml in primary nasal mucosal cell secretions. 
These values detected are in agreement with the general trend reported in the literature, 
where CXCL8 is present at low concentrations during health, and increases up to low 
ng/ml ranges during disease 245,292,293, however such high CXCL8 concentrations as 
found in the primary cell secretions have only been reported previously in monocytes 
infected with M. Tuberculosis 294-297. In addition to varying concentrations of CXCL8, 
these samples also showed a large degree of variation in their total protein 
concentrations and compositions. For example, the BAL sample from the inhaled 
chemical burns patient showed a total protein concentration of 422µg/ml, which was 
made up of a large number of proteins present at low abundance, whereas perfusate 
samples had a protein concentration over 10-fold higher (~47mg/ml), which were 
largely comprised of one high molecular weight protein present in abundance. Therefore 
any novel antibody developed would need to be able to detect a large range of 
concentrations of the nitrated CXCL8, from within a highly complex mixture of proteins, 
where the chemokine is likely present as a very small minority. 
Attempts at developing such an antibody in collaboration with Abmart were 
disappointing. The cells provided were continually mycoplasma infected, the antibodies 
produced by the cells were not monoclonal, and while they were capable of recognising 
the linear peptides they were raised against, neither the C1 purified antibody nor the C4 
ascites could recognise the full nitrated chemokine in its native form, in a direct ELISA or 
dot blot assay. 
Bio-Rad have had previous success in generating antibodies against post-translationally 
modified proteins, such as AbyD03055, which recognises a modified version of the DJ-1 
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protein with one oxidised cysteine residue at position 106 298. It was hopeful, therefore, 
that their phage display library and screening methods would yield more positive 
results than the previous attempts. The second set of antibody candidate proved to be 
most successful, as both 46 and 49 could specifically detect nitrated CXCL8, but not wild 
type CXCL8, to a sensitivity of between 1ng/ml and 10ng/ml. However, Western blot 
analysis of fractionated serum spiked with CXCL8/nitrated CXCL8 confirmed that both 
antibodies bound to other proteins present in serum, due to the presence of clear 
defined bands particularly at 25kDa and 55kDa. These are higher molecular weights 
than the 8381/8426 Da signal expected for CXCL8/nitrated CXCL8 respectively. For 46 
these bands were visible in fractions from both wild type and nitrated CXCL8-spiked 
serum, but 49 only detected bands at these weights in fractions from serum spiked with 
nitrated CXCL8. These are unlikely to be due to nitrated CXCL8 being bound to higher 
molecular weight carrier proteins such as albumin, as the weights do not correspond 
and the samples had been denatured, meaning any interacting proteins should have 
dissociated. The band seen at 55kDa could be due to the antibodies cross-reacting with 
Activated Protein C (a zymogen present in human plasma) 299,300, or Transthyretin (TTR) 
(a transport protein in the serum and cerebrospinal fluid)301.  The 25kDa band could be 
due to cross-reaction with serum amyloid P302.  These proteins should be present in 
both serum samples whether they were spiked with wild type CXCL8 or nitrated CXCL8, 
and so does not explain why 49 detected these bands only in the serum sample spiked 
with nitrated CXCL8. The possibility exists that the non-specific positive signals 
observed when staining with the Bio-Rad candidates could be due to the secondary 
antibodies or streptavidin-conjugated HRP (and not the Bio-Rad candidate primary 
antibodies) binding to other proteins, as “no primary antibody” controls were not 
assessed. This is potentially unlikely as the secondary antibodies used were raised 
against the histidine6 tag and so should not cross-react with serum proteins, but it is 
something that should be validated for both the secondary antibody and tertiary HRP 
detection reagents. These results meant that the antibodies would need to be 
incorporated into a sandwich ELISA assay, where a capture and detection system would 
solve the issue of cross-reactivity.  
Several capture and detection antibody combinations were trialled, and the results are 
summarised below in Table 4-1. Bio-Rad’s 48 was unsuccessful as a capture antibody, as 
49 appears to cross-react with this when used to detect nitrated CXCL8 (due to identical 
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signal observed between wells incubated with nitrated CXCL8 or PBS as a negative 
control). The curved pattern of binding observed is likely due to the different 
concentrations of 48 coated, as the chemokine and detection antibody 49 were used at 
constant concentrations (10ng/ml and 2μg/ml respectively). Candidate 48 was also 
unsuccessful when used as a capture antibody to detect wild type CXCL8, as no signal 
was observed. This suggests that either this antibody is inefficient at binding wild type 
CXCL8 (unlikely as Bio-Rad’s initial validation data showed that it bound both wild type 
and nitrated CXCL8), or that this antibody and the detection antibody from R&D’s 
Human CXCL8 ELISA Duoset kit bind to the same epitope on CXCL8, making them 
incompatible as a sandwich ELISA antibody pair.  
It is likely that this is also the reason that using the 3NT antibody (capture) and 49 
(detection) was unsuccessful (data not shown), as for 49 to differentiate between wild 
type and nitrated CXCL8, where the only difference is one nitrated tyrosine residue, its 
binding will likely involve this residue, which in this experimental set-up would be 
already bound to the 3NT capture antibody and therefore be unavailable to the 
detection antibody. 
The Rega #4576 antibody was also unsuccessful as a capture antibody, as its use with 49 
as a detection antibody showed no signal for nitrated CXCL8, suggesting that this 
antibody, like the commercially available antibodies tested, cannot bind to nitrated 
CXCL8. 
The rabbit polyclonal anti-CXCL8 antibody (AHC0881) showed some promise as a 
capture antibody, as its use with 49 as a detection antibody gave a positive signal for the 
detection of 10ng/ml nitrated CXCL8 diluted in PBS. A checkerboard ELISA suggests that 
using both antibodies at 5µg/ml would produce a maximum detection signal, but further 
studies are needed to determine if this antibody pair would also detect wild type CXCL8 
diluted in PBS, and both wild type and nitrated CXCL8 in a more complex mix such as 
serum when used at these concentrations. While AHC0881 showed equal affinity for 
wild type and nitrated CXCL8 in initial studies, it was apparent that this affinity was 
within the range of low ng/ml, which is considerably lower affinity than antibodies used 
in commercial CXCL8 ELISA kits, whose affinity is low pg/ml. This antibody pairing 
needs to be optimised further in order to try to improve the sensitivity and lower limit 
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of detection if this sandwich ELISA antibody pair is to be used to detect nitrated CXCL8 
in any patient samples.  
Use of 49 in immunofluorescence yielded uncertain results, with some granular staining 
observed. Due to time and resource constraints more experimental replicates would 
need to be performed in order to confirm this staining pattern. It is worth noting, 
however, that if results in Chapter 3 are correct and nitration of CXCL8 prevents its 
binding to GAGs, then it is likely that very little nitrated chemokine would actually be 
immobilised on the cell surface and thus be detectable using immunofluorescence. This 
again highlights the importance of developing an ELISA assay to detect unbound 
nitrated CXCL8 in cell media or patient biological fluids. 
In summary this chapter has shown that it is possible to generate an antibody, which 
shows specificity for nitrated CXCL8 over wild type CXCL8 which, with further 
development, could potentially be used to detect nitrated CXCL8 in patient samples. In 
the longer term, the creation of a panel-type assay to detect and measure all forms of 
modification (nitration, citrullination, truncation, glycosylation etc.) of a chemokine 
would give the most complete and accurate information about chemokine expression 
and natural regulation. I have shown that, even with antibody candidate 49 in its current 
un-optimised state, it is possible to detect naturally occurring nitrated CXCL8, as was 
found in one BAL sample from a VAP patient. While preliminary, this result could be the 
first recorded detection of naturally occurring nitrated CXCL8, and should be 
corroborated by the testing of greater numbers of patient samples from a range of 
diseases.  If nitration could be confirmed as being a direct result of IRI (through its 
detection in organ transplant patient samples for example, then a panel–type assay 
detecting wild type and nitrated forms of a range of pro and anti-inflammatory 
chemokines could prove to be an even more accurate indicator of IRI severity still. 
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Capture Antibody Sample Detection Antibody Detection Method Result 
AbD31648.1 at 10-
1μg/ml  in coating 
buffer 
10ng/ml 
CXCL8/nitrated 
CXCL8 in PBS 
Biotinylated AbD31649.1 
at 2μg/ml 
Streptavidin-HRP - 
TMB 
FAIL. No difference in signal observed between incubation with 
nitrated CXCL8 and PBS. Likely that the capture antibody cross-
reacted with the detection antibody. 
Rabbit anti-3NT 
(ab61392) at 5μg/ml  
in coating buffer 
5-200pg/ml 
nitrated CXCL8 in 
serum 
AbD31649.1 at 2μg/ml Biotinylated anti-
histidine6 
(MCA1396B)– 
streptavidin-HRP - 
TMB 
FAIL. No development (data not shown). Likely that the capture 
and detection antibodies bind the same epitope on nitrated 
CXCL8 and so are incompatible. 
Rega  #4576 at 1/100 
in coating buffer 
0.1-10ng/ml 
CXCL8/nitrated 
CXCL8 in PBS 
Biotinylated AbD31649.1 
at 2μg/ml 
Streptavidin-HRP - 
TMB 
FAIL. No detectable signal for nitrated CXCL8. Likely that the 
capture antibody cannot bind nitrated CXCL8. 
Rabbit polyclonal anti-
CXCL8 (AHC0881) at 
1/100 in coating buffer 
0.1-10ng/ml 
CXCL8/nitrated 
CXCL8 in PBS 
Biotinylated AbD31649.1 
at 2μg/ml 
Streptavidin-HRP - 
TMB 
SUCCESS. Weak detection signal for 10ng/ml nitrated CXCL8. 
Table 4-1.Summary of trialled sandwich ELISA assay set-ups.  
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5 DETERMINING HOW STRESS AFFECTS CXCL8 
PRODUCTION AND NITRATION 
Some of the work described in this chapter was carried out with the assistance of 
Charlotte Skipsey (Undergraduate Student) and Emily Astles (Masters Student), whom I 
supervised throughout their dissertation projects. 
5.1 INTRODUCTION 
The immune system has evolved over time to combat assaults and insults from a range 
of sources such as pathogens, irritants or inflammatory cellular components. In order to 
efficiently deal with each challenge, the immune system must be able to elicit targeted 
responses from specialised immune cell types in response to specific stimuli.  
Chemokine signalling is an important aspect of this response. Homeostatic chemokines 
like CXCL12/13/14 or CCL18/19/21 are constitutively expressed under normal 
physiological conditions, whereas the expression of inflammatory chemokines like 
CXCL1/2/3/5/6/7/8 or CCL2/3/5/7 is upregulated during times of stress 303, usually in 
response to pro-inflammatory cytokines such as TNF-α 304, IL-1β 305 or IFN-γ 306. It is 
worth noting that many chemokines such as CXCL9/10/11, or CCL1/17/20/22, cannot 
be clearly classified as solely homeostatic or solely inflammatory, and these are known 
as dual-function 303. The expression of select chemokines not only ensures that only 
certain leukocytes are recruited at the correct time-points during inflammation, but the 
effects these chemokines have on leukocytes can also influence how these cells behave 
within the inflammatory environment once they have migrated and infiltrated into the 
tissue 307.  The signalling pathways initiated by chemokine-GPCR binding depend upon 
the cell type (this can be both leukocytes and tissue cells of the affected organ) and 
transcription factors involved, and it is the cross talk between multiple signalling 
pathways that fine-tunes the end response to one that is appropriate for the stimulus.  
CXCL8 production is a key pathogenic aspect of a huge range of diseases, from infections 
to autoimmune disorders and cancers, and understanding how nitrated CXCL8 functions 
and under what conditions it is produced, could help improve our knowledge of the 
biological processes underlying many diseases. 
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I aimed to assess CXCL8 production and nitration in response to stress using two 
different disease models. A breast cancer model and a cardiac model were chosen as in 
both environments CXCL8 is known to be expressed and implicated in disease 
pathophysiology, and both environments are susceptible to oxidative stress during 
disease, that could facilitate nitration. 
5.1.1 CXCL8 in Breast Cancers 
Breast cancer cells commonly express the CXCL8 GPCRs CXCR1 and CXCR2, making 
CXCL8 an important factor in breast cancer initiation, development and metastasis 308 . 
Serum levels of CXCL8 are elevated in breast cancer patients in comparison to control 
samples 309, and high expression is mostly correlated with oestrogen receptor negative 
(ER-), progesterone receptor negative (PR-) and human epidermal growth factor 
receptor-2 negative (HER2-) cancers 308,310. CXCL8 was found to be expressed in invasive 
ductal grade I and III tumours, and was mainly produced by the epithelial cells. It was 
found to be higher in grade III than I, and be upregulated in distant metastasis 311.  
Many solid tumours including breast cancer tumours often possess a group of stem cells 
that are capable of self-renewal, contribute to metastasis and resistance to 
chemotherapy. These cells also express CXCR1 – and blocking the interactions between 
CXCR1 and CXCL8 using a CXCR1-specific neutralizing antibody or Repertaxin (a 
CXCR1/CXCR2 inhibitor) prevents CXCL8-mediated cancer stem cell recruitment and 
survival 312. 
There is also potential for CXCL8 to be post-translationally nitrated in breast cancer, as 
CXCL8 is produced by triple negative breast cancers, primary tumour-derived cells, and 
the MDA-MB-231 immortalised breast cancer cell line in response to hypoxia, which 
causes an increase in production of reactive oxygen and nitrogen species 313 . These 
reactive species and CXCL8 are therefore produced in the same environment and 
potentially by the same cells. Expression of both CXCL8 and iNOS (therefore NO) were 
upregulated in MDA-MB-231 cells in response to hypoxia, IFN-γ, serum starvation and 
exogenous NO in a feed-forward loop 314. Production of CXCL8 within a hypoxic 
environment and in the presence of NO (needed to form peroxynitrite), means that 
nitration of CXCL8 is likely to occur. 
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5.1.2 CXCL8 in the Heart 
CXCL8 expression in the heart is known to be upregulated in certain conditions. CXCL8 
has been shown to increase in the infarct zone post-myocardial infarction 315, and is 
thought to contribute to neovessel formation and angiogenesis in the healing heart 316. 
CXCL8 expression has been shown to increase systemically as well as locally, with 
elevated CXCL8 observed in patient serum within the first 22 hours of acute myocardial 
infarction 317 and in the plasma of patients with a previous history of myocardial 
infarction where it has been correlated with cardiovascular risk factors 318,319, but not in 
myocardial reperfusion in patients undergoing reconstructive mitral valve surgery 320. 
Blockade of CXCL8 using intravenous administration of a monoclonal antibody reduced 
IRI in a rabbit model of myocardial infarction 321. Clearly the expression of CXCL8 within 
the cardiac environment is tightly regulated and only occurs in response to specific 
stimuli.  
The cellular sources of CXCL8 also vary. Isolated human cardiac fibroblasts have been 
shown to secrete CXCL8 and upregulate expression of neutrophil-adhesion markers in 
response to pro-inflammatory stimuli such as treatment with IL-1322. Cardiac 
endothelial cells have also been shown to secrete CXCL8 (thought to promote 
angiogenesis) in response to stimuli from degranulating mast cells during myocardial 
infarction 323. CXCL8 is also known to be produced by macrophages from atheromatous 
plaques 324. These data suggest that cardiac fibroblasts, as well as cardiac endothelial 
cells and leukocytes can mediate neutrophil recruitment to the injured heart through 
CXCL8 production.   
As many of the circumstances described above (where CXCL8 has been reported to be 
upregulated) involve ischaemia and reperfusion, the CXCL8 is likely expressed in an 
environment where oxidative stress is occurring and reactive species are present. CXCL8 
therefore has the potential to be nitrated within these circumstances. 
In both of the diseases described, it must be noted that the CXCL8 detected is likely to 
only be the wild type molecule, and the total amount of both unmodified and modified 
chemokine is still likely unknown. It is important to understand what the source of this 
CXCL8 is in these different diseases (i.e. which cells are the main producers of CXCL8 
under which circumstances), and to understand how the potential for the CXCL8 
169 
 
produced to become nitrated varies in relation to its cellular source and the causative 
stress. 
5.1.3 Specific Aims 
I aimed to determine how different types of stress (bacterial-derived stress induced by 
LPS, nitrative stress induced by peroxynitrite, and oxidative stress induced by hydrogen 
peroxide) would affect the production of CXCL8 in a breast cancer model (using MCF-7 
and MDA-MB-231 cells) and cardiac environment model (using HMEC-1 and AC10 cells). 
I also aimed to assess whether the CXCL8 produced can be nitrated during these 
different inflammatory situations. 
 Determine how different types of stress affect CXCL8 gene and protein 
expression in a breast cancer model 
 Determine how different types of stress affect CXCL8 gene and protein 
expression in a cardiac model 
 Assess the potential for the CXCL8 produced in both of these experimental 
settings to be nitrated in the presence of different types of stressors 
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5.2 SPECIFIC MATERIALS AND METHODS 
5.2.1 Cell Culture and Treatments 
MCF-7 cells, MDA-MB-231 cells, HMEC-1 cells and AC10 cells were cultured as described 
in section 2.3.   
Cells were seeded onto 6 well plates at a density of 20,000-30,000 cells per well and 
were allowed to grow until 80% confluency. 
Cells were then treated with 1μg/ml LPS (Sigma), 600μM peroxynitrite (Cambridge 
Bioscience) (the concentration of which was assessed daily before use using a 
NanoDrop), 200μM hydrogen peroxide (Sigma), or media alone (as an untreated 
negative control) for 2 hours, 6 hours or 16 hours. These concentrations had been 
optimised for a 6 hour treatment by a previous student, Catriona Barker, and the 
additional 2 and 16 hour time-points were added to mimic acute and chronic stress. 
Each treatment was repeated in duplicate. For the LPS and peroxynitrite treatments, the 
cells were left in media containing the stressing agent for the times stated. For the 
hydrogen peroxide treatments, the 6 hour treatment consisted of 2 hours in treated 
media then 4 hours recovery in plain media, and the 16 hour treatment consisted of 2 
hours in treated media then 14 hours recovery in plain media due to its cytotoxic nature. 
Following treatment, the media from each well was removed, centrifuged for 5 minutes 
at 10,000xg and stored at -20°C, then cells were detached for use in RNA isolation or 
functional assessments, or were fixed in ice cold methanol for immunofluorescence 
staining. 
5.2.2 Viability Assays 
This method was used to ensure the treatments concentrations and durations would not 
be cytotoxic to the cells. Following treatments, the media from the wells (containing any 
floating dead cells) was collected. The cells remaining in the plate were then trypsinised 
to detach them, and combined with the media that had been removed (thus combining 
cells that had detached during treatment and cells that remained attached to the plate). 
The cell suspension was then centrifuged at 500xg for 5 minutes, and resuspended in 
plain media. A sample of the cell suspension was stained with an equal volume of 0.4% 
Trypan Blue (Sigma), pipetted onto a haemocytometer, and imaged under the Cellix™ 
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microscope. Images were taken of 4x 1mm2 squares per treatment, with each treatment 
tested in duplicate. The number of live/dead cells was counted manually for each image, 
and the percentage viability was calculated. 
5.2.3 RNA Isolation and cDNA Synthesis 
These methods were carried out using an RNeasy Pro Kit (Qiagen) and Tetro cDNA 
Synthesis Kit (Bioline), as described in 2.8 and as per the manufacturer’s instructions, 
using lysed cells collected from plates after the treatments described above. 
As shown in Figure 5-1 the RNA, when run on a 2% agarose gel and visualised using a 
transilluminator under UV light, shows the two clear bands of the intact ribosomal RNA 
28S and 18S subunits. The concentration and purity (assessed by 260/280 and 260/230 
ratios) of the RNA were measured using a Nanodrop Spectrophotometer.  
 
Figure 5-1. Assessment of RNA integrity. Following RNA isolation as per Qiagen’s RNeasy Pro 
Kit, the RNA was run on a 1% agarose gel and visualised using an AlphaImager. This clearly 
shows in the intact 28S and 18S ribosomal RNA subunits in A) AC10 and HMEC-1 RNA, and B) 
MCF-7 and MDA-MB-231 RNA. Data shown is from N=1 experimental replicate, with n=1 
technical replicate. 
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5.2.4 Proliferation Assay 
Due to breast cancer cell lines being inherently proliferative and self-perpetuating, this 
method was used to assess how acute, moderate, and chronic treatment with each of the 
stressing agents affected proliferation of the MCF-7 and MDA-MB-231 cells.  
Following treatment in 96-well tissue culture plates, cells were incubated with 2% PMS 
(an electron-coupling agent) in 30μg/ml of tetrazolium salt (XTT) labelling reagent (The 
Cell Proliferation Kit II, Roche) at 0, 24, 48 and 72 hours post-treatment. Proliferating 
cells (i.e. those that are metabolically active) cleaved the XTT into a soluble formazan 
dye, which is orange in colour. The concentration of this dye can be read using a 
Synergy™HT spectrophotometer and the Gen5™ software (BioTek), at 450nm 
(corrected). The optical density is a direct correlation to cellular proliferation. 
Initial experiments were performed to determine the optimal time to allow the plate to 
develop for after the addition of the XTT before being read (Figure 5-2), using the 6 hour 
intermediate treatment in both cell lines. This was done to ensure sufficient 
development had occurred to allow for differences between groups to be observed, but 
also to ensure that over-development did not occur, which may obscure differences 
between groups due to XTT depletion, for example, 4 hours of development was deemed 
optimal, and used in all subsequent experiments. 
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Figure 5-2. Optimising the development time for XTT proliferation assays. MCF-7 and 
MDA-MB-231 cells were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite 
for 6 hours, or 200μM hydrogen peroxide 2 hours + 4 hours recovery. Untreated cells and cells in 
recovery periods received complete media. Media containing 30μg/ml XTT was added at 
immediately after treatment (time zero), the cells were then left to metabolise the XTT. The 
optical density of the formazan dye metabolite was read at 1, 2, 3, 4, 5, 6, 20 and 24 hours at 
450nm (corrected), as a direct correlation to cell proliferation. Data shown is combined from 
N=1 experimental replicate, each with n=2 technical replicates. 
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5.2.5  Wound-Healing Assay 
In order to test how acute, moderate, and chronic treatment with each of the stressing 
agents would affect the ability of the MCF-7 and MDA-MB-231 cells to migrate and 
metastasise, wound healing assays were performed as shown below in Figure 5-3A. 
Cells were seeded into 12-well tissue culture plates at 1x105 cells/ml and treated as 
described previously. Cells were then trypsinised, and seeded into 2-well silicone inserts 
(Ibidi®) placed in 24-well tissue culture plates at 5-10x103 cells/70μl per chamber, and 
cultured for 24 hours until >90% confluent. Left-hand chambers contained untreated 
cells, and right-hand chambers contained cells treated with LPS/peroxynitrite/hydrogen 
peroxide. Inserts were then removed, and the two resulting separate cultures were 
washed in PBS to remove cellular debris before being covered with complete media. 
Plates were placed in a Nikon BioStation Incubator with robotic arm and microscope, 
and each well was imaged once every hour for 20 hours to visualise the two separate cell 
cultures migrating to close the gap between them. 
Analysis is performed using Nikon NIS software by adding a line at the average cell front 
at time zero (T0), then moving to the next image taken 1 hour later (T1) and adding 
another line at the point that the average cell front has migrated to. A horizontal 
distance calculating bar can be added between these two lines to assess the distance the 
cells have migrated within this hour. This can then be repeated for the distance migrated 
between T1 and T2, T2 and T3, T3 and T4 etc. which were then averaged, and this was 
performed separately for the two separate populations of cells within the insert. Figure 
5-3B shows the total distance migrated by untreated and hydrogen peroxide treated 
MD-MB-231 cells over 10 hours, to highlight the differential migration that can be 
observed.   
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Figure 5-3. Diagrammatic representation of a wound-healing assay. A) Cells are seeded into 
both chambers of a 2-well insert (Ibidi®) placed in each well of a 24 well tissue culture plate, and 
grown for 24 hours to confluency. The insert is removed leaving a clear gap between the two 
cultures of cells, and the plate placed in a Nikon BioStation incubator and microscope set up. 
Each well of the plate is imaged once every hour for 20 hours as the cells migrate and close the 
gap. Images are taken at 10x and 4x magnification. The time taken for cells to migrate and close 
the gap is analysed using Nikon NIS software. B) Analysis is performed by measuring the 
distance from the average cell front at time zero (T0) and the subsequent image taken 1 hour 
later (T1). This was repeated for T1 to T2, T2 to T3 and T3 to T4 etc., which were then averaged. 
Shown is the image comparing the total migration of untreated (left) vs. hydrogen peroxide 
treated (right) MDA-MB-231 cells after 10 hours (T10), to highlight the differences in migration 
that can be observed. 
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5.2.6 Immunohistochemistry and Immunofluorescence 
5.2.6.1 Sirius Red Staining 
This method was used to histologically assess the extent of the infarct region within 
mouse hearts 1, 3 and 5 days after ligation of the left anterior descending coronary 
artery to induce a myocardial infarction (MI) (Figure 5-4) (surgery performed by Dr 
Rachel Redgrave). 
Following the same de-paraffinisation and rehydration protocol described in section 
2.6.2, slides were incubated in Fast Green for 5 minutes, and then washed in two 
changes of acidified water. Slides were then incubated in PicroSirius Red for 1 hour at 
room temperature then washed in two changes of acidified water. Slides were rapidly 
dehydrated in three changes of 100% ethanol, cleared in xylene and mounted in DPX. 
 
Figure 5-4. Assessment of murine myocardial infarction (MI). PicoSirius Red and Fast Green 
staining of 4µm paraffin embedded sections from a mouse model of myocardial infarction 
generated through permanent ligation of the left anterior descending coronary artery. 
Collagen/fibrosis appears red, healthy myocardium appears green. Labels indicate the left 
ventricle (LV), right ventricle (RV), border zone (BZ) and infarct zone (IZ). Tiled images were 
taken at 10x magnification. 
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5.3 RESULTS 
5.3.1 Cell Viability after Stress 
Initial viability assays were performed to ensure that the acute, intermediate and 
chronic treatments with different stressors administered would not cause such 
extensive cell death as would impair further studies. Cells were therefore treated and 
mixed with an equal volume of 0.4% Trypan Blue (Sigma), then live/dead cells were 
counted using a haemocytometer and light microscope. 
In the breast cancer model, results show that hydrogen peroxide treatment significantly 
reduced MCF-7 cell viability in comparison to that of untreated cells.  Acute hydrogen 
peroxide treatment reduced viability from 92% to 75% (p=<0.001), intermediate 
treatment from 87% to 64% (p=<0.001), and chronic treatment from 91% to 72% 
(p=<0.05) (Figure 5-5A). For MDA-MB-231 cells, only intermediate and chronic 
hydrogen peroxide treatment significantly reduced viability to values of 75% 
(p=<0.001) and 64% (p=<0.001) respectively (Figure 5-5B), in comparison to the 96% 
and 97% observed for matched untreated cells. In in all cases, however, viability was 
still above 60% and so was deemed acceptable. LPS and peroxynitrite treatment did not 
affect viability in either cell line. 
 In the cardiac model, untreated AC10 viability ranged from 95-98.3%. Intermediate 
treatments with both LPS and hydrogen peroxide treatment significantly reduced AC10 
cell viability to 85% (p=<0.01) and 71% (p=<0.001) respectively (Figure 5-6A), however 
as viability was still acceptable in both cases, no adjustments to treatment protocols 
were made. Figure 5-6B shows that none of the treatments significantly reduced HMEC-
1 cell viability from the 94% average observed for untreated cells. Peroxynitrite 
treatment did not affect viability in either cell line. 
All treatments were deemed suitable and carried forward for further experiments. 
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Figure 5-5. Viability of MCF-7 and MDA-MB-231 cells after treatment. A) MCF-7 cells and B) 
MDA-MB-231 cells were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite 
for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 
hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete 
media. Following treatment cells were mixed with an equal volume of 0.4% Trypan Blue, and 
added to a haemocytometer where the number of live (white arrows) and dead (black arrows) 
cells were counted in 4x 1mm2 squares (images shown are representative of one 1mm2 square). 
The percentage of live cells was calculated and averaged. Statistical analysis was performed 
using a One Way ANOVA with Tukey’s post-test. Data shown is combined from N=1 experimental 
replicate, with n=2 technical replicates. 
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Figure 5-6. Viability of AC10 and HMEC-1 cells after treatment. A) AC10 cells and B) HMEC-1 
cells were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 
hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 
hours recovery. Untreated cells and cells in recovery periods received complete media. 
Following treatment cells were mixed with an equal volume of 0.4% Trypan Blue, and added to a 
haemocytometer where the number of live (white arrows) and dead (black arrows) cells were 
counted in 4x 1mm2 squares (images shown are representative of one 1mm2 square). The 
percentage of live cells was calculated and averaged. Statistical analysis was performed using a 
One Way ANOVA with Tukey’s post-test. Data shown is combined from N=1 experimental 
replicate, with n=2 technical replicates. 
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5.3.2 Determining How Stress Affects CXCL8 Production in a Breast Cancer Model 
I aimed to assess how different stressors would affect CXCL8 production in both non-
metastatic (MCF-7) and metastatic (MDA-MB-231) breast cancer cell lines. MCF-7 cells 
and MDA-MB-231 cells were treated, then media was removed, centrifuged, and the 
amount of CXCL8 protein secreted by the cells was measured using R&D’s Human CXCL8 
Duoset ELISA kit. CXCL8 gene expression was measured as fold change relative to HPRT-
1 (an endogenous control gene), using RT-qPCR performed on cDNA from cells that 
were lysed following the removal of their media for protein analysis. This meant that 
CXCL8 gene and protein expression could be assessed in the same cells. 
Results in Figure 5-7E show that in MCF-7 cells, intermediate hydrogen peroxide 
treatment increased CXCL8 gene expression by 38-fold (p=<0.05), and chronic hydrogen 
peroxide treatment increased CXCL8 gene expression by 93-fold (p=<0.001), in 
comparison to matched untreated cells. Acute hydrogen peroxide treatment also 
increased CXCL8 gene expression by 6-fold, however this result was not found to be 
statistically significant. This pattern is mirrored in the CXCL8 protein secretion 
measured (Figure 5-7F), with intermediate hydrogen peroxide treatment inducing the 
secretion of ~40pg/ml CXCL8 in comparison to undetectable levels of CXCL8 in matched 
untreated cells from the same time-point (p=<0.001). Chronic hydrogen peroxide 
induced the secretion of ~126pg/ml CXCL8; a 12.6-fold increase from the ~10pg/ml 
CXCL8 secreted by matched untreated cells from the same time-point (p=<0.001). LPS 
and peroxynitrite treatment induced no increase in CXCL8 gene expression or protein 
secretion, with values for these treatments equivalent to those of matched untreated 
cells (Figure 5-7A-D).   
In MDA-MB-231 cells, acute, intermediate and chronic LPS treatment all increased 
CXCL8 gene expression in comparison to matched untreated cells (Figure 5-8A), 
however as the fold changes for these treatments were 1.9, 1.7 and 2.1 respectively, 
while statistically significant they are unlikely to relate to an actual increase in CXCL8 
gene expression of any consequence. This is confirmed by the results in Figure 5-8B, 
which show that LPS treatments does not induce an increase in CXCL8 secretion above 
the level secreted by matched untreated cells. Both acute and intermediate (but not 
chronic) hydrogen peroxide treatments, however, caused significant increases in CXCL8 
gene expression 3-fold (p=<0.01) and 11-fold (p=<0.001) respectively (Figure 5-8E). 
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Increases in CXCL8 protein expression were also observed in response to intermediate 
and chronic hydrogen peroxide treatment, with the treatments resulting in 1.4ng/ml 
and 2ng/ml CXCL8 secretion respectively, both of which are ~2-fold higher than the 
amount secreted by their respective matched untreated cells (Figure X5-8F). 
Peroxynitrite treatment did not result in any changes in CXCL8 gene or protein 
expression (Figure 5-8C and D). 
It was also observed that MDA-MB-231 cells naturally secrete more CXCL8 than MCF-7 
cells in culture. MDA-MB-231 cells secreted ~280pg/ml CXCL8 after 2 hours in culture, 
which accumulated to ~1ng/ml after 16 hours in culture, in comparison to the 30-
50pg/ml secreted by MCF-7 cells after 2 hour in culture which did not increase with 
time (Figure 5-7 and 5-8).  
Oxidative stress, but not bacterial or nitrative stress, induces a significant upregulation 
in CXCL8 gene and protein expression in MCF-7 and MDA-MB-231 cells, which, as a 
general trend, increased in relation to the duration of treatment increased from acute to 
intermediate, and intermediate to chronic.   
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Figure 5-7. CXCL8 gene and protein expression in MCF-7 cells following stress. MCF-7 cells 
were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, 
or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours 
recovery. Untreated cells and cells in recovery periods received complete media. Following 
treatment, A, C, E) CXCL8 gene expression (as fold change normalised to HPRT1) was assessed 
using RT-qPCR and B, D, F) CXCL8 protein expression in the supernatant was assessed using 
R&D’s Human CXCL8 Duoset ELISA kit. Statistical analysis was performed using a One Way 
ANOVA with Tukey’s post-test.  Data shown in A) and B) is combined from N=3 experimental 
replicates, each with n=2 technical replicates. 
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Figure 5-8. CXCL8 gene and protein expression in MDA-MB-231 cells following stress. 
MDA-MB-231 cells were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite 
for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 
hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete 
media. Following treatment, A, C, E) CXCL8 gene expression (as fold change normalised to 
HPRT1) was assessed using RT-qPCR and B, D, F) CXCL8 protein expression in the supernatant 
was assessed using R&D’s Human CXCL8 Duoset ELISA kit. Statistical analysis was performed 
using a One Way ANOVA with Tukey’s post-test.  Data shown in A) and B) is combined from N=3 
experimental replicates, each with n=2 technical replicates. 
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5.3.3 Determining How Stress Affects the Ability of Breast Cancer Cells to 
Proliferate and Migrate  
Having shown that different stressors can differentially upregulate CXCL8 expression, I 
aimed to assess how these different stressors might affect breast cancer cell 
functionality in terms of their ability to proliferate (to reflect the aggressiveness of a 
tumour) and migrate (to reflect metastasis in the body). 
Following treatment in 96 well plates, cells were allowed to recover for 0, 24, 48 or 72 
hours, after which XTT substrate was added. This was left for 4 hours to allow any 
proliferating cells to metabolise the XTT and produce formazan dye as a product, the 
optical density of which was then read on a spectrophotometer. The OD value measured 
is therefore directly correlated to cell proliferation.  
Results show that acute, intermediate and chronic hydrogen peroxide treatments all 
significantly reduce proliferation immediately after treatment in both MCF-7 (p=<0.05-
0.001) (Figure 5-9) and MDA-MB-231 cells (p=<0.05-0.001) (Figure 5-10) in comparison 
to matched untreated cells. For MCF-7 cells, proliferation was on average 1.4-fold lower 
following acute treatment, 1.3-fold lower following intermediate treatment, and 1.7-fold 
lower following chronic treatment. For MDA-MB-231 cells, proliferation was 1-fold 
lower on average following acute and intermediate treatments, and 1.2-fold lower 
following chronic treatment. Proliferation then remains statically reduced in both cell 
lines from 0-72 hours after treatment, time-points beyond 72 hours were not assessed. 
Treatment for any duration with LPS or peroxynitrite did not significantly alter 
proliferation in either MCF-7 or MDA-MB-231 cells.  
The ability of cells to migrate following treatment was then assessed using wound 
healing assays, whereby untreated cells (left) and treated cells (right) were grown in 2-
well inserts (Ibidi®), which when removed leave a cell-free “wound” between the two 
populations. Cells are then imaged every hour for 20 hours as they migrate to close the 
“wound”, and the average hourly migration of the two cell fronts were calculated 
separately.  
Similarly to the proliferation assays, Figure 5-11 shows that MCF-7 cells that received 
acute, intermediate or chronic hydrogen peroxide treatment migrated at an average of 
3.3μm/hour; significantly less (3-4-fold on average) than matched untreated cells which 
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migrated at an average of 13μm/hour (p=<0.001). The same pattern was observed in 
MDA-MB-231 cells, with all hydrogen peroxide treatments reducing migration from 
13.5μm/hour in untreated cells to 4.4μm/hour - a 2-3-fold reduction (p=<0.01) (Figure 
5-12). 
 
Figure 5-9. Metabolic activity of MCF-7 cells following stress. MCF-7 cells were treated with 
1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM 
hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours recovery. 
Untreated cells and cells in recovery periods received complete media. Media containing 
30μg/ml XTT was added at 0, 24, 48 and 72 hours post-treatment, the cells were then left to 
metabolise the XTT for 4 hours, and the optical density of the formazan dye metabolite was read 
at 450nm (corrected), as a direct correlation to cell proliferation. Statistical analysis was 
performed using a One Way ANOVA with Tukey’s post-test.  Data shown is combined from N=3 
experimental replicates, each with n=2 technical replicates. 
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Figure 5-10. Metabolic activity of MDA-MB-231 cells following stress. MDA-MB-231 cells 
were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, 
or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours 
recovery. Untreated cells and cells in recovery periods received complete media. Media 
containing 30μg/ml XTT was added at 0, 24, 48 and 72 hours post-treatment, the cells were then 
left to metabolise the XTT for 4 hours, and the optical density of the formazan dye metabolite 
was read at 450nm (corrected), as a direct correlation to cell proliferation. Statistical analysis 
was performed using a One Way ANOVA with Tukey’s post-test.  Data shown is combined from 
N=3 experimental replicates, each with n=2 technical replicates. 
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Figure 5-11. Migration of MCF-7 cells following stress. MCF-7 cells were treated with 1μg/ml 
lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM hydrogen 
peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours recovery. Untreated cells 
and cells in recovery periods received complete media. Following treatment cells were seeded 
into 2-well inserts (Ibidi®) in 24 well plates, with untreated cells on the left and treated cells on 
the right and grown for 24 hours before the insert was removed leaving a “wound” between the 
two cell fronts. Plates were imaged at 10x magnification once an hour for 20 hours in the Nikon 
BioStation. Migration distance per hour was calculated using Nikon NIS software and the 
average plotted. Example images shown were taken at T10 (10 hours), with red lines indicating 
the position of the cell front at T0 (start of imaging). Statistical analysis was performed using a 
One Way ANOVA with Tukey’s post-test.  Data shown is combined from N=3 experimental 
replicates, each with n=1 technical replicate. 
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Figure 5-12. Migration of MDA-MB-231 cells following stress. MDA-MB-231 cells were 
treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 
200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours 
recovery. Untreated cells and cells in recovery periods received complete media. Following 
treatment cells were seeded into 2-well inserts (Ibidi®) in 24 well plates, with untreated cells on 
the left and treated cells on the right and grown for 24 hours before the insert was removed 
leaving a “wound” between the two cell fronts. Plates were imaged at 10x magnification once an 
hour for 20 hours in the Nikon BioStation. Migration distance per hour was calculated using 
Nikon NIS software and the average plotted. Example images shown were taken at T10 (10 
hours), with red lines indicating the position of the cell front at T0 (start of imaging). Statistical 
analysis was performed using a One Way ANOVA with Tukey’s post-test.  Data shown is 
combined from N=3 experimental replicates, each with n=1 technical replicate. 
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5.3.4 Assessing the Potential for CXCL8 Nitration in a Breast Cancer Model 
Having established that wild type CXCL8 protein secretion by both MCF-7 and MDA-MB-
231 cells increases following oxidative stress but not bacterial or nitrative stress, I 
aimed to assess whether the CXCL8 produced was likely to be nitrated in any of these 
circumstances. Due to the development of an anti-nitrated CXCL8 antibody still being a 
work in progress, this was tested using double immunofluorescence to detect CXCL8 and 
3NT (co-localisation of which indicated nitrated CXCL8) in cells treated in chamber 
slides. 
Staining for these two markers in MCF-7 cells (Figure 5-13) suggests a low level 
expression of CXCL8 in untreated cells, which generally does not increase and remains 
consistent in response to LPS and peroxynitrite treatments. The intensity of CXCL8 
staining increases in response to hydrogen peroxide treatment, and remains constant 
over the acute, intermediate and chronic treatments. Little 3NT staining is detected, and 
this does not appear to increase in response to any of the treatments. While 3NT and 
CXCL8 staining can clearly be observed in the same cells, reliably identifying areas of co-
localisation between the two markers is difficult due to their different intensities of 
staining. The same pattern can be seen for MDA-MB-231 cells in Figure 5-14, however 
CXCL8 staining in these cells appears more intense than in MCF-7 cells, and an increase 
in CXCL8 staining can also be observed following 2 hours of peroxynitrite treatment in 
these cells. 
Untreated MCF-7 cells show a higher intensity of CXCL8 staining than untreated MDA-
MB-231 cells, and several different staining patterns of cells were observed in both cell 
lines both treated and untreated, and have been highlighted in the indented images 
within the figures. These show nuclear, perinuclear and cytoplasmic CXCL8 expression. 
These results suggest the potential presence of nitrated CXCL8 in both cell lines in 
response to oxidative stress, but this is not conclusive.  
In order to compare expression of CXCL8 and 3NT between clinical breast cancer 
samples and breast cancer cell lines, the staining was repeated using sections of biopsies 
from non-cancerous and cancerous regions within the breast tissue of a patient with 
confirmed invasive ductal carcinoma of non-specific type, as well as metastatic and non-
metastatic lymph nodes from the same patient (Figure 5-15). Non-metastatic lymph 
nodes showed uniform low expression of both CXCL8 and 3NT, which largely co-
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localised throughout the tissue indicating the potential presence of nitrated CXCL8. In 
the metastatic lymph node, a number of highly CXCL8+ cells with round morphology can 
be observed. These CXCL8+ cells show little co-localisation with 3NT (suggesting the 
CXCL8 detected is most likely wild type), and there is generally less 3NT staining 
throughout the whole tissue in this case.  
 A similar staining pattern is observed in the breast tissue, with non-cancerous tissue 
showing higher levels of 3NT, and low levels of CXCL8 staining, and the cancerous tissue 
again showing less 3NT expression but a high number of CXCL8+ cells.  
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Figure 5-13. CXCL8 and 3-nitrotyrosine (3NT) protein expression in MCF-7 cells following stress. MCF-7 cells were treated with 1μg/ml 
lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 
hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete media. Following treatment, slides were fixed in ice-cold 
methanol, and stained for both CXCL8 (AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary antibody (red) 
(GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 conjugated secondary antibody 
(green) (GtxMs-003-E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). No primary antibody control is 
shown indented (NP), as are close-up images of individual cells with different staining patterns. Images were taken at 20x magnification, and images 
shown are representative of 5 fields of view imaged per chamber.
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Figure 5-14. CXCL8 and 3-nitrotyrosine (3NT) protein expression in MDA-MB-231 cells following stress. MDA-MB-231 cells were treated with 
1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, 
or 2 hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete media. Following treatment, slides were fixed in ice-
cold methanol, and stained for both CXCL8 (AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary antibody 
(red) (GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 conjugated secondary 
antibody (green) (GtxMs-003-E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). No primary antibody 
control is shown indented (NP), as are close-up images of individual cells with different staining patterns. Images were taken at 20x magnification, 
and images shown are representative of 5 fields of view imaged per chamber.
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Figure 5-15. CXCL8 and 3-nitrotyrosine (3NT) protein expression in breast and lymph 
node. Sections of breast (n=2) and lymph node (n=2) tissue were stained for both CXCL8 
(AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary 
antibody (red) (GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected 
using an anti-mouse-DyLight488 conjugated secondary antibody (green) (GtxMs-003-
E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). 
No primary antibody controls are shown indented (NP), as are close-up images of individual 
CXCL8+ or CXCL8+ 3NT+ cells. Images were taken at 20x magnification, and images shown are 
representative of 5 fields of view imaged per section. 
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5.3.5 Determining How Stress Affects CXCL8 Production in a Cardiac Model  
The same treatments used to induce oxidative, bacterial and nitrative stress where then 
applied to AC10 cardiomyocyte cells and HMEC-1 endothelial cells to assess how stress 
affects these cells as different components of the cardiac environment. 
In AC10 cells, only chronic hydrogen peroxide treatment induced a significant increase 
in CXCL8 gene expression of ~7-fold (p=<0.001) (Figure 5-16E). This was mirrored in 
the protein secretion analysis by ELISA, whereby the general trend suggests an increase 
in CXCL8 secretion following chronic hydrogen peroxide treatment above the level 
secreted by matched untreated cells, however this did not reach statistical significance 
(Figure 5-16F). Neither LPS nor peroxynitrite treatment induced any significant change 
in CXCL8 gene or protein expression in these cells (Figure 5-16A-D). 
HMEC-1 cells showed a different response to stress, with bacterial stress induced by LPS 
treatment causing a significant upregulation in CXCL8 gene expression (Figure 5-17A). 
Acute LPS treatment induced a ~9-fold increase (P=<0.05), intermediate treatment 
induced a 10.3~fold increase (p=<0.01), and chronic treatment induced a ~7-fold 
increase which was not found to be statistically significant. All durations of LPS 
treatment did, however, result in a significant increase in CXCL8 protein secretion 
(p=<0.001) (Figure 5-17B). Acute treatment resulted in an average secretion of 
181pg/ml CXCL8, intermediate treatment 1.7ng/ml, and chronic treatment 2.4ng/ml in 
comparison to the 80pg/ml, 217pg/ml and 716pg/ml secreted by matched untreated 
cells. In this cell line neither hydrogen peroxide nor peroxynitrite treatment (for any 
duration) significantly affected CXCL8 gene or protein expression (Figure 5-17C-F).  
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Figure 5-16. CXCL8 gene and protein expression in AC10 cells following stress. AC10 cells 
were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, 
or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 hours 
recovery. Untreated cells and cells in recovery periods received complete media. Following 
treatment, A, C, E) CXCL8 gene expression (as fold change normalised to HPRT1) was assessed 
using RT-qPCR and B, D, F) CXCL8 protein expression in the supernatant was assessed using 
R&D’s Human CXCL8 Duoset ELISA kit. Statistical analysis was performed using a One Way 
ANOVA with Tukey’s post-test.  Data shown in A) and B) is combined from N=3 experimental 
replicates, each with n=2 technical replicates. 
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Figure 5-17. CXCL8 gene and protein expression in HMEC-1 cells following stress. HMEC-1 
cells were treated with 1μg/ml lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 
hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 hours + 14 
hours recovery. Untreated cells and cells in recovery periods received complete media. 
Following treatment, A, C, E) CXCL8 gene expression (as fold change normalised to HPRT1) was 
assessed using RT-qPCR and B, D, F) CXCL8 protein expression in the supernatant was assessed 
using R&D’s Human CXCL8 Duoset ELISA kit. Statistical analysis was performed using a One Way 
ANOVA with Tukey’s post-test.  Data shown in A) and B) is combined from N=3 experimental 
replicates, each with n=2 technical replicates. 
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5.3.6 Assessing the Potential for CXCL8 Nitration in a Cardiac Model 
As with breast cancer cell lines, immunofluorescence staining was also performed to 
detect CXCL8 surface expression and possible nitration. Results in Figure 5-18 show that 
untreated AC10 cells appear to express little to no CXCL8 and have almost no detectable 
3NT. Staining suggests there is a slight increase in CXCL8 expression in LPS treated cells, 
and in 3NT expression in peroxynitrite treated cells which both appear to be highest 
during acute treatment and decrease over intermediate and chronic treatment. As the 
intensity of these staining patterns are low, this likely corresponds to the lack of change 
in CXCL8 expression observed in ELISA assays. Hydrogen peroxide treatment appears to 
increase CXCL8 expression at all durations of treatment, which likely links to the trend 
towards an increase in CXCL8 protein secretion observed by ELISA assay, although the 
latter was only observed during chronic treatment whereas surface expression appears 
to increase during all treatment durations.  
HMEC-1 cells, when untreated, also showed almost no detectable CXCL8 or 3NT 
expression, and this was found to be unaltered by peroxynitrite treatment of any 
duration (Figure 5-19). LPS treatment, however, did appear to cause an increase in 
CXCL8 surface expression in these cells, which increases in intensity as the duration of 
treatment increases. This staining pattern is in agreement with the pattern of CXCL8 
protein secretion observed in ELISA assays. Hydrogen peroxide treatment also appears 
to cause some CXCL8 surface expression increase which is highest in intensity during 
acute treatment, but decreases as recovery time increases in through the intermediate 
and chronic treatments. This pattern is different than that observed in ELISA assays, 
which suggests that hydrogen peroxide does not increase CXCL8 gene expression or 
protein secretion, but could indicate that these cells are able to cope with and recover 
from this treatment.   
In this instance, I also had access to mouse heart tissue from an MI model generated by 
permanent ligation of the left anterior descending coronary artery (Dr Rachel Redgrave, 
Professor Helen Arthur). As mice do not express CXCL8, staining in hearts from 1, 3 and 
5 days post-MI single staining was performed to detect 3NT only, as a measure of 
general protein nitration in relation to ischaemic injury. This was compared to normal 
mouse heart tissue.  
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Figure 5-20 shows that 3NT staining of cardiomyocytes in the right ventricle (RV) (i.e. a 
site distant to the infarct zone) is low level, only clearly detectable 1 day after MI, and 
reduces gradually over 3 and 5 days post-MI. Closer to the injured region of the heart, 
low level 3NT staining can be seen in both the infarct zone (IZ) and border zone (BZ) 
post-MI, with a few highly 3NT+ cells present in the BZ. By day 3 post-MI (the peak 
inflammatory phase), staining has increased in both the IZ and BZ, as has the number of 
highly 3NT+ infiltrating cells. By 5 days post-MI, as healing moves towards the more pro-
fibrotic and anti-inflammatory phase, 3NT expression on cardiomyocytes has reduced to 
a similar level observed in the RV, with some 3NT+ infiltrating cells remaining within the 
IZ but not BZ. 
This suggests that during cardiac ischaemic injury, reactive species like peroxynitrite are 
rapidly produced following injury, leading to the nitration of proteins within the vicinity 
on both cardiomyocytes and infiltrating cells during the initial inflammatory phase post-
MI, as evidenced by 3NT staining.  
Staining for both CXCL8 and 3NT was also performed in clinical samples from patients 
who were undergoing ventricular assist device (VAD) implantation (as a non-transplant 
cardiac procedure for comparison), and in biopsy sections taken 1 month post –heart 
transplant in both in healthy patients and those with confirmed allograft rejection 
(Figure 5-21). CXCL8 and 3NT expression was shown to vary between samples, with 
VAD patient and non-rejecting transplant patient biopsies showing generally similar low 
level CXCL8 and 3NT staining mainly on cardiomyocytes. The greatest variability in 
staining pattern was observed between biopsy samples from transplant patients 
experiencing allograft rejection, although most showed small patches of increased 
CXCL8 expression. One biopsy section from this group showed higher levels of staining 
for both CXCL8 and 3NT than any other, and also showed a high degree of co-localisation 
between these markers, indicating the possible presence of nitrated CXCL8.
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Figure 5-18. CXCL8 and 3-nitrotyrosine (3NT) protein expression in AC10 cells following stress. AC10 cells were treated with 1μg/ml 
lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 
hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete media. Following treatment, slides were fixed in ice-cold 
methanol, and stained for both CXCL8 (AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary antibody (red) 
(GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 conjugated secondary antibody 
(green) (GtxMs-003-E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). No primary antibody control is 
shown indented (NP), as are close-up images of individual cells with different staining patterns. Images were taken at 20x magnification, and images 
shown are representative of 5 fields of view imaged per chamber.
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Figure 5-19. CXCL8 and 3-nitrotyrosine (3NT) protein expression in HMEC-1 cells following stress. HMEC-1 cells were treated with 1μg/ml 
lipopolysaccharide (LPS) or 600μM peroxynitrite for 2, 6 or 16 hours, or 200μM hydrogen peroxide for 2 hours, 2 hours + 4 hours recovery, or 2 
hours + 14 hours recovery. Untreated cells and cells in recovery periods received complete media. Following treatment, slides were fixed in ice-cold 
methanol, and stained for both CXCL8 (AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary antibody (red) 
(GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 conjugated secondary antibody 
(green) (GtxMs-003-E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). No primary antibody control is 
shown indented (NP), as are close-up images of individual cells with different staining patterns. Images were taken at 20x magnification, and images 
shown are representative of 5 fields of view imaged per chamber.
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Figure 5-20. Protein nitration within the heart following myocardial infarction (MI). Single 
immunofluorescent staining showing the expression of 3NT (06-284, Millipore) detected using 
an anti-rabbit-DyLight550 conjugated secondary antibody (red) (GtxRb-003-D550NHSX, 
Immunoreagents) in the right ventricle (RV), border zone (BZ) and infarct zone (IZ) of mouse 
hearts harvested at days 1, 3 and 5 post-myocardial infarction, and a normal mouse heart (n=2 
for each time-point). Myocardial infarction (MI) was generated by permanent ligation of the left 
anterior descending coronary artery. No primary antibody control is shown indented (NP), as 
are close-up images of individual 3NT+ cells. Images were taken at 20x magnification, and shown 
are representative of 5 fields of view imaged per chamber.  
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Figure 5-21. CXCL8 and 3-nitrotyrosine (3NT) protein expression in the heart. Sections of 
heart tissue from in patient biopsies taken at the time of VAD implantation (n=5), or one month 
post-heart transplant with (n=5)/without (n=4) rejection, were stained for both CXCL8 
(AHC0881, Life Technologies) detected using an anti-rabbit-DyLight550 conjugated secondary 
antibody (red) (GtxRb-003-D550NHSX, Immunoreagents) and 3NT (ab61392, Abcam) detected 
using an anti-mouse-DyLight488 conjugated secondary antibody (green) (GtxMs-003-
E488NHSX, Immunoreagents) to detect the potential presence of nitrated CXCL8 (NO2-CXCL8). 
No primary antibody control is shown indented (NP). Images were taken at 20x magnification, 
and images shown are representative of 5 fields of view imaged per section from 3 
representative samples from each group. 
5.3.7 CXCL8 and 3NT Expression in a Range of Tissues 
As varying staining patterns were observed for CXCL8 and 3NT in all the samples 
assessed by immunofluorescence, additional staining was performed on a range of 
tissue types shown in Figure 5-22. Large bowel, small intestine and tonsil expressed 
high levels of 3NT with little CXCL8 detected. Kidney showed a high intensity of CXCL8 
staining within the tubules, and placenta shows global low level CXCL8 expression. 
Tissue from lung and hepatocellular carcinoma showed the highest degree of co-
localisation of CXCL8 and 3NT, although in different staining patterns. Lung tissue shows 
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more global expression of 3NT with CXCL8 staining more localised to certain epithelial 
cells, whereas in hepatocellular carcinoma CXCL8 is more globally expressed with small 
areas of high intensity 3NT staining.  Some highly CXCL8+ cells were visible in the large 
bowel and liver, similar to the cells previously observed in the cancerous breast tissue 
and lymph node in Figure 5-15. These images depict the naturally varying levels of 
expression of both CXCL8 and 3NT within tissues, and highlight the need for a specific 
anti-nitrated CXCL8 antibody if the expression of nitrated CXCL8 is to be documented 
and confirmed. 
 
Figure 5-22.CXCL8 and 3-nitrotyrosine (3NT) protein expression in different tissues. 
Sections of heart tissue were stained for both CXCL8 (AHC0881, Life Technologies) detected 
using an anti-rabbit-DyLight550 conjugated secondary antibody (red) (GtxRb-003-D550NHSX, 
Immunoreagents) and 3NT (ab61392, Abcam) detected using an anti-mouse-DyLight488 
conjugated secondary antibody (green) (GtxMs-003-E488NHSX, Immunoreagents) to detect the 
potential presence of nitrated CXCL8 (NO2-CXCL8). No primary antibody controls are shown 
indented (NP). Images were taken at 20x magnification, and images shown are representative of 
5 fields of view imaged per section from 1 sample per tissue type.  
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5.4 DISCUSSION 
5.4.1 CXCL8 Production and Nitration in a Breast Cancer Model 
In both MCF-7 and MDA-MB-231 cells, only oxidative stress but not bacterial or nitrative 
stress induced an increase in CXCL8 gene and protein expression, as well as a reduction 
in proliferation and migratory capacity in both cell lines. 
The difference in baseline CXCL8 protein secretion between the two cell lines could be 
reflective of their different phenotypes, and has been previously documented 325. The 
higher CXCL8 secretion observed by MDA-MB-231 cells could be due to their more 
aggressive and metastatic nature which is well documented 271,272, in comparison to the 
less aggressive and non-metastatic MCF-7s. This is supported by documentation of 
higher CXCL8 expression being linked to metastasis and worse prognosis in clinical 
patient samples 308-311. Regardless of whether breast cancer cells produce naturally high 
(MDA-MB-231) or low (MCF-7) levels of CXCL8, oxidative stress mediated by hydrogen 
peroxide causes significant increases in both gene and protein expression above this 
level. This is supported by literature where hydrogen peroxide treatment has been 
reported to increase CXCL8 expression in squamous carcinoma cells 326. The reduction 
in proliferation and migration observed following acute, intermediate and chronic 
hydrogen peroxide could be due to the oxidative stress causing cells to become 
senescent 327,328, although further analysis would be needed to confirm this. 
The increase in CXCL8 expression without an increase in 3NT expression observed by 
immunofluorescence in treated cells correlates with the increase in wild type CXCL8 
observed in ELISA assays, suggesting surface expression of CXCL8 mirrors CXCL8 
secretion. While untreated MCF-7 cells showed higher CXCL8 expression as detected by 
immunofluorescence than untreated MDA-MB-231 cells, a greater increase in CXCL8 
staining in MDA-MB-231 cells than in MCF-7 cells observed in response to hydrogen 
peroxide treatment also reflects the higher amounts of CXCL8 secreted by these cells. 
Cancerous tissue appears to be associated with the presence of highly CXCL8+ cells, 
which are largely undetected in non-cancerous equivalent tissue. Lower 3NT expression 
in cancerous tissue compared to non-cancerous tissue suggests that the increased 
CXCL8 staining detected is likely to be wild type. These could be infiltrating leukocytes 
or breast cancer cells, although this is unconfirmed as no further characterisation was 
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performed, and no other patient samples were tested. Staining experiments would need 
to be repeated with greater sample numbers to confirm these trends. 
5.4.2 CXCL8 Production and Nitration in a Cardiac Model 
Analysis of CXCL8 gene and protein expression following stress in this model suggests 
that AC10 cardiomyocytes are most susceptible to oxidative stress, as only hydrogen 
peroxide treatment resulted in a significant upregulation in CXCL8 gene expression, and 
a trend towards an upregulation in protein expression, although this was not 
statistically significant.  
HMEC-1 cells were the only cell line to show little response to hydrogen peroxide – as 
acute, intermediate and chronic treatment with this stressor induced no changes in 
CXCL8 gene expression or protein secretion, although some surface expression of CXCL8 
was detected using immunofluorescence. This observation is supported by 
Lakshminarayanan, et al, who found that 800µM hydrogen peroxide treatment did not 
upregulate CXCL8 protein expression in HMEC-1 cells 329. These cells instead appeared 
to be more senstitive to bacterial-dervied stress, as all durations of treatment 
significantly upregulated CXCL8 gene expression and protein expression, with the latter 
increasing in conjunction with the length of treatment. HMEC-1 cells have been 
previously shown to respond to LPS treatment when administered at 100µg/ml, 
although this study suggests that these cells are sensitive to LPS even at concentrations 
of 1µg/ml 330,331. 
Strong 3NT staining in the initial inflammatory phase post-MI in mice, and in the AC10 
cells subjected to acute peroxynitrite treatment, suggests that production of radicals and 
subsequent protein nitration is likely to occur rapidly after ischaemic injury rather than 
during the fibrotic phase of wound healing. Staining for 3NT alone in mouse heart tissue 
and CXCL8 with 3NT in human heart tissue shows that both cardiomyocytes and 
infiltrating cells can be targets of protein nitration, and both cardiomyocytes98-101 and 
neutrophils/macrophages105,219,225,228-230,332 could be potential sources of the 
peroxynitrite mediating the nitration within this environment, although this is not 
confirmed. The production of CXCL8 and 3NT within the same vicinity (leading to their 
co-localisation), was observed in one case of cardiac allograft rejection, normal lung 
tissue, and in liver tisse from a hepatocellular carcionoma biopsy and indicates that 
nitrated CXCL8 is likely to be present in a range of tissues and disease states. Repeats of 
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these staining experiments, and those performed on the breast cancer model cell lines 
and tissue would need to be performed in order to confirm these observed patterns.  
5.4.3 Future Studies 
Due to time and resource constraints, functional assessments such as proliferation could 
not be completed for cells in the cardiac model as they were for the breast cancer model. 
Ideally, future work could involve testing the effects of the different stressors in primary 
cells for both models (e.g. isolated primary breast cancer cells or isolated primary 
cardiomyocytes, for example). Co-culture models could also be performed to mimic the 
complexity of the tumour microenvironment 333, and allow multiple components from 
the cardiac environment, such as endothelial cells and fibroblasts as well as 
cardiomyocytes 334, to be cultured in close proximity to enable cross-talk. These studies 
would be likely to yield results that are more reflective of how these cell types would 
behave in vivo.  
Future experiments could also involve assessing how the different cells used in this 
chapter respond to direct treatment with CXCL8 or nitrated CXCL8, as HMEC-1s 335, 
MCF-7s 336, MDA-MB-231s 336 are all documented to express CXCR1 and CXCR2. No data 
is available regarding AC10 expression of CXCR1/CXCR2, however primary 
cardiomyocytes are known to express CXCR2 337. 
One limitation of the studies conducted in both models is the concentrations of reagents 
used. While these had been optimized by a previous student, they may not have been 
optimal for the cell lines used in this study. As both MCF-7 and MDA-MB-231 cells both 
express TLR4, they should respond to LPS treatment, and a study by Yang et al (2014) 
found that treatment with 10μg/ml LPS increased invasiveness in MDA-MB-231 cells 
and increased migration in MCF-7 cells 338. The lack of response to LPS observed in this 
study could therefore be due to an inadequate treatment concentration. Peroxynitrite 
treatment showed no real effect on any of the parameters assessed in either model other 
than a slight increase in 3NT surface expression by AC10 cells following treatment, and 
this could be due to this unstable molecule reacting almost instantly when diluted into 
treatment media (peroxynitrite has a half-life of 10ms) 79, meaning that very little/none 
may have actually reached the cells. In future studies, a peroxynitrite donor molecule 
such as 3-morpholinosydnonimine (SIN-1) 339,340 could be used to ensure treatment 
reliability. The concentration of 200µM used for hydrogen peroxide treatments could 
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also be further optimized. Stone et al state that at applied concentrations of 0.1-10µM 
hydrogen peroxide acts as a signalling molecule and induces epithelial-to-mesenchymal 
transition, increased migration and proliferation, however between 10µM and 100µM it 
can induce oxidative stress and growth arrest 341. It is therefore likely that the 200µM 
used in these studies induced cellular senescence, and future studies could involve 
testing a range of hydrogen peroxide concentrations to fully span its range of possible 
effects.  
The development of a novel specific anti-nitrated CXCL8 antibody (possibly candidate 
49) would ideally be a key component in the future work for both disease models in this 
chapter. A specific and sensitive antibody would allow for the detection of nitrated 
CXCL8 in the supernatant from treated cells to complement the wild type CXCL8 
measurements collected as part of this project. The antibody could also possibly be used 
to detect nitrated CXCL8 on cell surfaces by immunofluorescence to confirm/build upon 
the staining performed using CXCL8 and 3NT together, however results in Chapter 3 
suggest that the nitrated chemokine has impaired GAG-binding ability, potentially 
meaning that nitrated CXCL8 is more likely to be present unbound in the supernatant 
rather than immobilized on cell surfaces. Work could also be expanded to detect wild 
type and nitrated CXCL8 in patient tissue and serum samples from, for example, 
different stages and gradings of breast cancer, pre and post-heart transplant, or post-
myocardial infarction. Ethical approval was attained for the collection of serum and 
tumour tissue samples from breast cancer patients as part of this project (study number 
NAHPB-136) but unfortunately none could be collected for testing during the time of 
this study, although such samples would be useful to continue this research. This testing 
could also be rolled out to other patient samples from different diseases with ischaemic 
components, and where CXCL8 plays a role, in order to fully characterize ratio of wild 
type to nitrated CXCL8 in relation to ischaemia-reperfusion injury/oxidative stress. 
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6 FINAL DISCUSSION 
6.1 SUMMARY OF AIMS AND OUTCOME 
6.1.1 Characterise the biological activity of chemokines and variants in vitro and 
in vivo  
Work in Chapter 3 has established that nitration of CXCL8 by peroxynitrite renders the 
chemokine almost completely non-functional, reducing its ability to recruit human 
neutrophils in vitro and murine neutrophils in vivo. This reduction in function is likely 
due to impaired receptor signalling as confirmed by calcium flux assays and detection of 
phosphorylated ERK in primary human neutrophils, and impaired GAG binding as 
confirmed by surface plasmon resonance assays and by an in vivo murine 
intraperitoneal recruitment model (although the latter encompasses both GPCR 
signalling and GAG binding as neutrophils cross the endothelium and extravasate into 
the peritoneum). The GPCR and ACKR binding capabilities of nitrated CXCL8 should also 
be assessed, using a method such as radio-ligand binding assays, for example. 
Mass spectrometry analysis confirmed that incubation with peroxynitrite results in the 
addition of one nitrate group to CXCL8, and that this occurs in the N-terminal half of the 
chemokine. As nitrated CXCL8 was detectable using an anti-3-NT antibody, this confirms 
that the nitrate group is added to tyrosine13 within CXCL8. Despite this finding, tyrosine 
cannot be the only amino acid that has the potential to be nitrated and affect chemokine 
function. A nitrated Y13F mutant variant of CXCL8 (which contains phenylalanine 
instead of tyrosine at position 13) and nitrated CXCL1 (which contains no tyrosine 
residues) also both showed impaired abilities to induce neutrophil migration in vitro.  
This means that the effect that nitration has on a chemokine cannot be predicted by the 
location and number of tyrosine residues, but that the effect that nitration has on each 
chemokine must be studied individually in a case-by-case manner. 
Studies also showed that nitrated CXCL8 cannot inhibit the function of wild type CXCL8 
when administered in equimolar concentrations as tested in calcium flux assays and 
chemotaxis assays in vitro, although the function of nitrated CXCL8 and its ability to 
inhibit wild type CXCL8 should be also explored using a greater range of concentrations 
than was used in these studies.  
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6.1.2 Develop a method to detect nitrated CXCL8  
Chapter 4 has highlighted the difficulties that surround antibody development, from 
using peptides versus full proteins to raise antibodies, to issues with cross-reactivity, 
specificity and sensitivity. My work involved the initial stages of antibody discovery and 
development, and resulted in the production of a novel antibody, candidate 49, which 
shows specificity for nitrated CXCL8 over wild type CXCL8, and has an approximate limit 
of detection between 1ng/ml and 10ng/ml in direct assays. This antibody does, 
however, also show cross-reactivity with other proteins present in serum, meaning that 
it would need to be used as part of a sandwich ELISA assay for the testing of any patient 
biological fluids. It is suitable however, for use in Western blot analysis, which although 
an unsuitable method for any clinical assay development, allowed me to analyse a small 
number of VAP patient BAL samples, and to detect the presence of naturally occurring 
nitrated CXCL8 in one of these samples. Sample RVI 1 contained a band around the 
correct weight for nitrated CXCL8, which was detectable with a CXCL8 polyclonal 
antibody (known to detect wild type and nitrated CXCL8), candidate 49, and a 3-NT 
antibody. This result is still preliminary due to detection only occurring in one sample, 
but could represent the first detection of naturally occurring nitrated CXCL8. Western 
blot analysis of greater numbers of patient samples from a range of diseases could be 
performed to corroborate this result, alongside the development of a sandwich ELISA 
assay, which would be more suitable for testing large numbers of patient samples 
simultaneously and in a more time-efficient manner. 
The incorporation of a suitable antibody such as candidate 49 into a novel ELISA assay 
will require further validation involving assessment of the limit of blank (highest 
“apparent” amount of analyte measured when testing blank samples containing no 
analyte), limit of detection (lowest analyte concentration that can be reliably 
distinguished from the limit of blank value), limit of quantitation (lowest analyte 
concentration that can be reliably distinguished from the limit of blank value, that also 
meets targets for bias and imprecision), and reproducibility measurements 342. Perhaps 
the optimum antibody pair for use in a sandwich assay to detect nitrated CXCL8 would 
be a capture antibody raised against the C-terminal end of the chemokine, which would 
therefore orientate the chemokine in the correct position for detection of the nitrated N-
terminal end by a detection antibody specific for nitrated CXCL8 (such as antibody 
candidate 49 that was assessed in this project). This antibody requires further 
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development work in order for it to be incorporated into a fully validated assay that 
could be used to detect nitrated CXCL8 reliably in large numbers of patient samples. 
Another method of detection that could be used to measure nitrated CXCL8 is mass 
spectrometry, as shown in Chapter 3. The experiments in this study were performed on 
pure samples of chemokine, and would not be suitable for analysis of a complex sample 
containing a mix of proteins such as serum. A pre-purification step would be necessary 
to isolate the chemokine from the sample in order for it to be analysed. This would most 
likely involve an antibody-based pull-down/purification technique, which would again 
require a high affinity antibody that would bind to both wild type and nitrated CXCL8, or 
specific antibodies for each of these chemokine variants individually. 
6.1.3 Determine how stress effects CXCL8 production and nitration 
Testing the effects of bacterial, nitrative and oxidative stress in metastatic MDA-MB-231 
and non-metastatic MCF-7 breast cancer cell lines in Chapter 5 suggests that only 
oxidative stress significantly increases upregulation of CXCL8 gene expression, protein 
expression, and protein secretion in both cell lines. Testing the same stressors in a 
cardiac model revealed that AC10 cardiomyocytes are most likely to upregulate CXCL8 
following oxidative stress, but that HMEC-1 endothelial cells are more responsive to 
bacterial-derived stress. In this study, the anti-nitrated CXCL8 antibody was not 
developed to a sufficient standard to allow the measurement of nitrated CXCL8 in these 
experimental models to be correlated with wild type CXCL8 concentrations. This data 
would be key to understanding when CXCL8 nitration is likely to occur, although 
assessing this in primary cell lines or co-culture models would likely be more 
representative of the inflammatory scenarios occurring in vivo. Using a wider range of 
concentrations of the stressing agents, as well as a more reliable nitrative stress-inducer 
such as SIN-1 would also likely improve upon the accuracy of results gathered. 
6.2 CONCLUSIONS AND IMPLICATIONS  
This project has emphasised the complexities of the chemokine system, which have 
perhaps been previously underestimated. Results presented show that post-
translational modifications can alter the functionality of chemokines, making their 
further study of great importance. As most studies to date, including this present one, 
have found that nitration decreases chemokine function 119,121-124,173, nitration of 
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chemokines could be a novel natural mechanism to dampen and resolve inflammation, 
preventing excessive leukocyte recruitment. This theory is shown diagrammatically in 
Figure 6-1, where injured cells produce wild type CXCL8 which is present at its highest 
concentration close to the site of injury in the form of a dynamic “cloud”, existing in an 
equilibrium of GAG and GPCR bound and unbound monomers and dimers. This CXCL8 
recruits neutrophils to the inflamed region where degranulation may occur. Within this 
inflammatory situation, the damaged endothelial cells, tissue cells and degranulating 
neutrophils upregulate production of enzymes such as iNOS, NADPH and XOD, which 
produce NO and O2- that will react together and form peroxynitrite. As well as its 
damaging effects previously discussed, peroxynitrite is also likely to nitrate any 
localised CXCL8, which will render it non-functional, preventing it from binding to GAGs 
and GPCRs. This will inhibit its ability to contribute to the CXCL8 gradient formation, as 
well as preventing it from recruiting further neutrophils, thus likely contributing to the 
resolution of inflammation. This could be supported by the increased inflammation 
observed in patients with chronic granulomatous disease, where a defect in the NADPH 
enzyme that inhibits phagocytosis and leads to recurrent infections is also likely to 
impair protein nitration (due to reduced superoxide anion production) 343.  This could 
also be supported by studies conducted on IL-10, where incubation with peroxynitrite 
has been shown to increase the cytokine’s anti-inflammatory activity 344,345, but the 
study of a wider range of both pro and anti-inflammatory chemokines/cytokines would 
be required to confirm this.  
The data presented in the second results chapter show that, at least in the case of CXCL8, 
most antibodies raised against the wild type chemokine cannot detect the nitrated 
chemokine, meaning that all current measurements of CXCL8 are only likely to be 
reflective of the amount of wild type chemokine present. This may provide an inaccurate 
picture of the overall inflammatory situation, and the ratio of wild type to nitrated 
chemokine may be a more complete and informative indicator of the type and severity 
of inflammation occurring. While the expression of wild type CXCL8 is well known to 
increase during inflammation, and nitration of CXCL8 is likely to occur during increased 
inflammation, this is not yet confirmed due to a lack of reliable detection methods. It is 
also unknown, therefore, whether the ratio of wild type to nitrated CXCL8 remains 
constant or also changes in relation to the severity of inflammation.  
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The results in the third results chapter highlight that different forms of stress (nitrative, 
oxidative and bacterial) can elicit a different response in terms of CXCL8 production in 
different cell lines.  While nitration of CXCL8 was not reliably detected in these 
experiments, they show that as CXCL8 production may vary depending upon the type of 
insult/injury, so may nitration. This further reinforces the need for a reliable anti-
nitrated CXCL8 antibody in order to determine if nitration is directly related to IRI and 
oxidative stress as hypothesised, possibly by measuring the amount of wild type and 
nitrated CXCL8 in donor organs perfused ex vivo before transplantation, or in serum 
samples from organ transplant patients post-surgery, where IRI is known to occur. If 
this theory is proven, then this could inform which disease types/patient samples are 
likely to contain nitrated CXCL8 and how its expression relates to disease severity. The 
ratio of wild type to nitrated CXCL8 could be indicative of the severity of IRI sustained 
during transplantation, for example, and could help stratify those patients at risk of graft 
dysfunction.  
In order to better understand the quantity and patterns in expression of nitrated and 
wild type chemokines and their relationships with disease states, there is a need to 
develop novel antibodies to enable the detection of nitrated chemokines separately from 
their wild type counterparts, which could be extrapolated out to other forms of modified 
chemokines, such as truncated and citrullinated variants. Teasing apart and quantifying 
the relative amounts of all chemokine forms, if the functionality and circumstances of 
production of each is understood, would allow for the most complete and accurate 
assessment of how post-translational modifications regulate chemokine function during 
inflammation. This knowledge could also help to improve the development of 
therapeutics targeting the chemokine system, and their use as clinical biomarkers which 
has been disappointing to date, through better understanding of natural chemokine 
regulation. 
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Figure 6-1.Proposed role for CXCL8 nitration in the resolution of inflammation during 
ischaemia-reperfusion injury (IRI). A CXCL8 gradient localised to the site of injury exists as an 
“equilibrated cloud” of bound and unbound chemokine monomers/dimers, likely transiently 
binding to glycosaminoglycans (GAGs) and G-protein-coupled receptors (GPCRs) 
(CXCR1/CXCR2) present on neutrophils. Neutrophils then adhere to the endothelium and 
extravasate into the tissue. At peak inflammation, degranulating neutrophils and 
tissue/endothelial cells damaged by IRI (grey) contribute to the production of peroxynitrite 
(ONOO-), which nitrates CXCL8. Nitration renders CXCL8 almost completely non-functional, 
inhibiting its ability to bind to GPCRs and GAGs, therefore preventing further neutrophil 
recruitment. CXCL8 nitration could therefore pose as a natural mechanism involved in the 
resolution of inflammation. 
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